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1. ABSTRACT 
 
 
Cancer is a complex and a multiple-genes involved disease; for this reason it can 
not be treated or cured with a single drug modulating the biological function of a 
single target. The innovation related to multi-targeted drugs, combining the 
activity of different cancer progression relevant targets, became a burgeoning 
research topic. Drugs that act on multiple targets can enhance efficacy and 
reduce chemo-resistance that causes disease relapse and metastasis and remains 
the main obstacle to cancer therapy. One of the main target nowadays are 
tyrosine kinases (TKs); since most protein kinases stimulate cell growth and 
proliferation, cell survival and migration, they can, if overexpressed, amplified or 
constitutively active, assume oncogenic properties. Other ideal biological targets 
are enzymes as histone deacetylases (HDAC) and mitochondrial functions. Herein 
we present the development and the preliminary evaluation of new Abl/HDAC 
inhibitors bearing the pyrido-pyrimidine main scaffold; the functionalization of 
the most active compounds with metal ions (i.e. Zn2+, Cu2+ and Fe3+); the 
development of novel multi-kinase inhibitors bearing the 4-anilinopyrimidine 
scaffold; the development of novel cKIT/wtRET/V804MRET inhibitors bearing the 4-
anilinopyridine scaffold. Besides, the development of multi-kinase inhibitors 
endowed with antifibrotic properties as well as novel topoisomerase inhibitors 
are reported. 
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The structures of the novel still unpublished compounds are reported in Figure 1. 
 
 
Figure 1. Structures of potential dual TK/HDAC inhibitors. 
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2. INTRODUCTION 
 
 
The anti-cancer drugs research is constantly moving from the study of drugs with 
a nonspecific mechanism of action to the so called targeted therapy. This novel 
approach relies on inhibiting specific biomolecules fundamental for cancer 
growth and for the maintenance of an adequate microenvironment for cell 
hyper-proliferation.1 Hence, most drugs have emerged from the current ‘one 
molecule - one target - one disease’ philosophy, and it will undoubtedly remain 
dominant in medicinal chemistry research for many years to come.2  
The aim of this strategy is to discover small molecules that are able to modulate 
the biological function of a single target that is fully responsible for a disease in 
order to reduce the risk of related side effects (off- target effects). However, the 
evidences that drugs designed to act on single molecular targets are usually 
insufficient for multigene diseases such as cancer are constantly increasing. 
Recent findings have highlighted the importance of a multi-target approach: the 
simultaneous blockade of different pathways involved in the cancer growth leads 
to a more effective therapy over the mono-therapies, with reduced drug 
resistance phenomena onset.3  
Multi-target therapeutics can be achieved through two different strategies, the 
combination of single targeted drugs or the administration of a multi-targeted 
agent. 
The co-administration of two or more drugs to target cancer-inducing or cell-
sustaining pathways is a fundamental principle of cancer therapy; certain cancers 
have been effectively treated with such combinatorial approach.4 Tyrosine 
kinases (TK) and the histone deacetylases (HDACs) are among the most 
interesting targets. Indeed, the co-administration of a TKI and of an HDACI is 
largely more effective than the administration of the single drug.5,6  
Nevertheless, the co-administration of multiple agents is often limited by drug-
drug interactions and dose limiting toxicities.  
Introduction 
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2.1 MULTIFUNCTIONAL ANTICANCER AGENTS 
 
The multi-target approach can be pursued also through a single agent endowed 
with multiple potency, i.e. a single compound able to simultaneously modulate 
the biological function of multiple targets. The multifunctional agent shows many 
advantages: 
 The avoidance of different bioavailabilities, pharmacokinetics and 
metabolism of each component within the combination regimen; 
 The lack of possible drug-drug interactions;  
 The dosing regimen would be greatly simplified to enhance compliance 
and therapeutic efficacy;  
 The cost of a single agent could be less than two separate agents; 
 The administration of multi-target compounds leads to higher potency 
and lower side effects compared to the action of a mono-targeted agent 
but also then the co-administration of different target-selective agents.7 
Positive clinical and preclinical data suggest that the multi-targeted agents are a 
burgeoning approach of treatments in cancer therapy.8,9 
However, the molecular basis of the enhanced potency for dual inhibitors is far 
to be fully investigated. 
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2.2 PROTEIN KINASES 
Protein kinases (PKs) are among the most investigated targets for cancer 
therapy, since they play a predominant regulatory role in almost every aspect of 
cell biology. PKs control metabolism, transcription, cell division and movement, 
programmed cell death and participate in the immune response and nervous 
system function.10  
This class of enzymes regulates all the cellular events by transferring the γ-
phosphate group of ATP to the target protein substrate that usually contain a 
tyrosine, a serine or a threonine residue.11  
Protein phosphorylation involves the balanced action of protein kinases and 
phosphoprotein phosphatases, making phosphorylation-dephosphorylation an 
overall reversible process. The protein kinase family is about the second largest 
enzyme family and the fifth largest gene family in humans. It was revealed by 
chromosomal mapping that nearly half of protein kinase genes are involved in 
typical genetic alteration in cancer. Considering that cancer develops through the 
alteration of multiple genes, gene amplification is an effective acceleration 
machinery to promote tumorigenesis.12 This result further emphasizes the 
importance of protein kinase inhibitors as potential drug targets. 
The human kinome comprises 518 members, grouped in families, subfamilies, 
and classes, according to structural and functional similarities. Based on the 
phosphorylated amino acid residue PKs can be classify in two main classes: 
tyrosine kinases (TKs) and serine-threonine kinases (STKs).13  
Protein kinases typically share a conserved arrangement of secondary structure 
elements that are arranged into 12 subdomains that fold into a bilobed catalytic 
core structure with ATP binding in a deep cleft located between the lobes (Figure 
2). 
Introduction 
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Figure 2. Main elements in kinase structure. 
 
The catalytic cleft is between the N-terminal lobe (N-lobe) and a larger C-
terminal lobe. The N-lobe mainly consists of 5 β-strands, which form the upper 
limit of the cleft, and one α-helix; differently, the C-lobe is mainly constituted of 
α-helixes. As shown in figure 3 the two lobes are connected with a linker 
including a hinge region and a convex-shaped motif (E0). The N-lobe contains a 
highly flexible glycine-rich loop (G-loop) that can adopt various conformations, 
depending on the conformational state of the PK and on the presence of a 
ligand.14 
 
 
Figure 3. Topological distribution of the binding pockets in the catalytic cleft with (A) a 
DFG-in conformation and (B) a DFG-out conformation. 
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The catalytic cleft consists of two regions: the front cleft and the back cleft. The 
front cleft contains predominantly the ATP-binding site and the back cleft 
comprises elements important for the kinase catalysis regulation. These two 
regions share the N-terminus of the activation segment (A-segment) including 
the DFG (Asp-Phe-Gly) motif and are divided by a gatekeeper residue. The 
gatekeeper controls the access of small molecules into the back cleft: a small 
amino acid (threonine or alanine) at this position allows the back cleft to be 
accessible; a bulky gatekeeper (phenylalanine, leucine, or methionine) blocks the 
entry. 
The A-segment in the C-lobe and α-helix in the N-lobe are two key elements for 
regulation of the kinase enzymatic activity. The A-segment consists of the DFG 
motif, the activation loop (A-loop), the P-loop, and other secondary structural 
elements. 
In a fully active state (DFG-in conformation) the A-segment adopts an open 
conformation in order to move away the A-loop from the catalytic center, 
allowing the substrate binding. In the DFG-in conformation the side chain of the 
DFG Asp is directed into the ATP binding site and the aromatic ring of the Phe is 
positioned in the back cleft. The Asp is required to chelate Mg 2+ and orient the 
ATP γ-phosphate for its transfer. Importantly, while the DFG-in conformation is 
required for the catalysis of an active protein kinase this motif can be present as 
well in inactive kinases. 
In the DFG-out conformation the side chains of Asp and Phe exchange their 
position so that Asp is directed far from the ATP binding site. In this 
conformation these amino acids are oriented in order to avoid the transfer of 
phosphate and the activation loop blocks the access of both ATP and substrate to 
the enzyme.  
The front cleft contains mainly the ATP binding site and relatively small non-ATP 
contact regions. The ATP binding site comprises the adenine (A), ribose (R), and 
phosphate (P) binding pockets. 
Introduction 
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The adenine binding pocket is highly hydrophobic, providing a major scaffold for 
ATP or inhibitor binding. 
The back cleft comprises elements important for regulation of kinase catalysis 
(ATP-contactless). There exists hydrophobic binding pockets: BP-I (this pocket 
has often been used in the design of inhibitors to gain selectivity for kinase 
targets with a small-sized gatekeeper) and BP-II. In DFG-out conformation the 
movement of the activation loop exposes an additional hydrophobic binding sites 
directly adjacent to the ATP binding cleft, BP-III and BP-IV. 
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2.2.1 TYROSINE KINASES 
 
The protein kinase family includes 385 serine/threonine kinases, 90 protein-
tyrosine kinases, and 43 tyrosine-kinase like proteins. Of the 90 protein-tyrosine 
kinases, 58 are receptors with extracellular, transmembrane, and intracellular 
domains and 32 are non-receptors occurring intracellularly. 
The family of TKs is of particular interest; their deregulation, through mutation or 
overexpression, is often related to cancer onset and progression.13  
In the last two decades, a number of ATP-mimic TK inhibitors (TKIs) have been 
developed. TKIs share some common pharmacophore features, like a nitrogen-
containing heterocycle (for the interaction with the kinase hinge region), a 
lipophilic moiety (for interaction with a hydrophobic region not exploited by ATP) 
and a bridge connecting the two. According to the bound kinase conformation, 
TKIs are classified as type I, I 1/2, II, III, IV, V and VI inhibitors.15 
Type I, I½, and type II inhibitors occupy part of the adenine binding pocket and 
form hydrogen bonds with the hinge region connecting the small and large lobes 
of the enzyme. Type III and IV inhibitors are allosteric in nature. 
In particular:  
 Type I binds the active kinase conformation (DFG-in). Type I inhibitors 
typically consist of a heterocyclic ring system that occupies the purine 
binding site, where it serves as a scaffold for side chains that occupy the 
adjacent hydrophobic regions I and II. 
 Type I½ inhibitors bind to a DFG-in inactive conformation. 
 Type II inhibitors bind to a DFG-out inactive kinase conformation, which 
bears a larger lipophilic cleft. Accordingly, type II inhibitors have a larger 
lipophilic moiety than type I inhibitors. 
 Type III inhibitors bind next to the ATP-binding pocket, they are not ATP 
competitors. 
 Type IV inhibitors do not bind to the ATP or peptide substrate binding 
sites.  
Introduction 
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 Type V inhibitors bind to two different regions of the protein kinase 
domain and are therefore bivalent inhibitors.  
 Type VI inhibitors bind covalently to their target enzyme, they are capable 
of forming an irreversible bond, usually, by reacting with a nucleophilic 
cysteine residue 
 
Receptor tyrosine kinases  
 
The receptor TKs (RTKs) are cell-surface receptors that are sensitive to 
extracellular levels of growth factors, such as epidermal growth factor (EGF), 
chemokines or other ligands including those belonging to the insulin. 
RTKs can be grouped into subfamilies according to their ligand affinity, amino 
acid sequences and structural homology. The RTK subfamilies include, among 
others, epidermal growth factor receptors (EGFRs), fibroblast growth factor 
receptors (FGFRs), insulin and insulin-like growth factor receptors (IR and IGFR), 
platelet-derived growth factor receptors (PDGFRs), vascular endothelial growth 
factor receptors (VEGFRs), hepatocyte growth factor receptors (HGFRs), and 
proto-oncogene c-KIT.16 
All RTKs possess a glycosylated extracellular ligand binding domain, a short 
transmembrane segment and a cytoplasmic region containing the kinase domain. 
 
 
Figure 4. Mechanism of RTK activation. 
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The intracellular signal transduction originates with RTKs ligand interaction, 
promoting receptor dimerization and tyrosine auto-phosphorylation within the 
RTK intracellular domains. 
RTK phosphorylation stimulates the association of effector proteins and adaptor 
proteins, including phospholipase C-γ, mitogen-activated protein kinases and 
phosphatidylinositol 3-kinase, propagating the signal transduction cascade 
(Figure 4). 
A hyperactivation of these downstream effector signaling networks promotes 
cellular growth, proliferation, migration, survival, metabolism, and other 
biological processes that are frequently associated with transformation and 
oncogenesis.17 
 
Cytoplasmic tyrosine kinases  
 
Cytoplasmic tyrosine kinases, or non-receptor tyrosine kinases (NRTK), mainly 
differ from the RTKs for the absence of the extracellular domain (Figure 5). 
 
 
Figure 5. Cytoplasmic TK structure. 
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The majority of NRTKs are in the cytoplasm, although few of them are linked to 
the cellular membrane. Some NRTKs are anchored to the cell membrane through 
myristoylated or palmytoylated amino terminus.18 
NRTKs are part of the signal cascade controlled by RTKs: upon interaction with 
activated RTKs, the NRTKs undergo a spatial rearrangement that leads to the 
active conformation (Figure 6). The active conformation is able to phosphorylate 
the protein substrate, thus causing the signal transduction.19  
 
 
Figure 6. TK activation mechanism 
 
NRTKs possess domains that mediate protein-protein, protein-lipid and protein-
DNA interactions. 
The most commonly protein-protein interaction domains are the Src homology 2 
(SH2) and 3 (SH3) domains. The SH2 domain is a compact domain of about 100 
residues that binds phosphotyrosine residues in a sequence-specific manner. The 
smaller SH3 domain (around 60 residues) binds sequences containing proline. 
Some NRTKs possess other interaction domains: for example Abl contains a F-
actin and a DNA binding domain in addition to SH2 and SH3.18, 20 
Usually, the activation of NRTKs is tightly regulated. However, a NRTKs 
deregulation can cause a hyper-stimulation of cell growth. One of the main NRTK 
example in clinical medicine is Abl (Abelson kinase). 
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2.3 DUAL TYROSINE KINASES-HDAC INHIBITORS 
 
2.3.1 Abl TYROSINE KINASE AND INHIBITORS 21-23 
 
ABL was discovered over 30 years ago as the oncogene in the Abelson murine 
leukemia virus and later identified as an oncogene associated with chromosome 
translocations in human leukemia. These ABL fusion genes encode constitutively 
activated forms of the Abl tyrosine kinase required for cellular transformation.21 
The Abl family of protein kinases connect several extracellular stimuli to signaling 
pathways causing cell growth, survival, invasion, adhesion, and migration. 
The SH2 and SH3 domains, the TK domain (containing the N-lobes and the C-
lobe) and the portion called N-cap containing a myristic acid residue structurally 
characterize Abl (Figure 7). 
 
 
Figure 7. Abl structure 
 
The interactions among the Abl domains are fundamental for the enzyme down-
regulation: mutations or deletions within the different domains lead, in fact, to 
an increase kinase activity.  
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Examples of Abl domains interactions: 
 The myristic acid binds to a hydrophobic region of the C-lobe, allowing the 
formation of hydrogen bonds between Tyr158 (of SH2 domain) and Tyr136 (of 
C-lobe) that hide the TK active site.  
 The Ser69 phosphorylated amino acid (in the N-cap) interacts with the linker 
between SH3 and SH2 domains, regulating the kinase inhibition. 
 The SH2 domain is able to modify its spatial orientation by interacting to the 
N-lobe stabilizing the kinase active form. 
 The C-lobe contributes to the kinase activity through the activation loop. The 
activation loop contains a Tyr residue that, once phosphorylated, establish 
electrostatic interactions with an Arg. These interactions stabilize the open 
active site conformation allowing the substrate peptide access. 
 
Chronic myeloid leukemia and imatinib 
 
Chronic myeloid leukemia (CML) results from a gene defect in hematological 
stem cell (HSCs). ABL gene moves from chromosome 9 to chromosome 22 under 
the BCR gene leading to the formation of Philadelphia chromosome (Figure 8). 
The obtained oncogene is called BCR-ABL (Breakpoint Cluster Region - Abelson 
Leukemia) and codifies for the Bcr-Abl protein that contains the Abl kinase 
domain.22 
In contrast to the tightly regulated c-Abl kinase, an auto-regulatory domain in the 
oncoprotein is truncated, leading to constitutive activation of the tyrosine kinase 
activity. The resulting unregulated phosphorylation of intracellular proteins in 
HSCs leads to the uncontrolled growth and survival of the leukemic cells.24 
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Figure 8. Philadelphia chromosome formation. 
 
Imatinib (Figure 9, e) inhibits Bcr-Abl protein and was the first FDA approved 
small molecule protein-kinase inhibitor. It was initially used for the treatment of 
CML.23 Imatinib is a type II multi-TK inhibitor: besides Bcr-Abl, it is active against 
PDGFRβ and c-KIT. The chemical precursor of imatinib was discovered by the 
time-consuming process of testing a large number of compounds for inhibition of 
Protein kinase C (PKC) in vitro. PKC is a serine/threonine kinase that participates 
in many cellular processes and is implicated in tumor formation. Calcium and 
diacylglycerol second messengers regulate PKC activity. 
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Figure 9. Imatinib optimization steps. 
 
The imatinib lead compound optimization (Figure 9) began from a 
phenylaminopyrimidine scaffold that inhibited serine/threonine protein kinases 
(compound a). The addition of a pyridine ring increased the PKC inhibitory 
potency (compound b), the addition of an amide group on the phenyl ring 
provided inhibitory activity against tyrosine kinases such as Bcr-Abl and PDGFR 
(compound c). A subsequent substitution at position 6 of the diaminophenyl ring 
abolished its PKC inhibitory activity (compound d). However, the first library of 
inhibitors based on d showed poor oral bioavailability and water solubility. The 
problem was solved through the additional attachment of a highly polar side 
chain (N-methylpiperazine) leading to imatinib (compound e).13, 25 
 
Imatinib resistance and nilotinib 
 
A rapid drug resistance onset often impairs the use of imatinib in therapy. The 
mechanisms of resistance can be described as Bcr-Abl dependent (amplification 
or overexpression of Bcr-Abl and point mutations in the Abl protein kinase 
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domain, including the gatekeeper T315I mutation) or independent (decreased 
drug uptake, increased drug efflux, upregulation of signaling pathways). 
Thus, new potent Bcr-Abl inhibitors have been developed as, for example, 
nilotinib (Figure xB), that is a Abl, c-Kit, PDGFR, MAPK, ZAK inhibitor.26 
 
 
Figure 10. Structures of imatinib (A) and nilotinib (B). 
 
Imatinib and nilotinib are structurally related as they share three common 
features: a pyridine-pyrimidine portion interacting to the TK hinge region; an 
aniline hydrophobic moiety; a hydrophilic moiety (Figure 10). 
Imatinib and  nilotinib show highly comparable binding modes (Figure 11). 
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Figure 11. Crystal structures of Abl-Imatinib (A) and Abl-Nilotinib (B) complexes. 
 
Nilotinib presents a reversed amidic function compared to imatinib, allowing for 
a better interaction with the amino acid of the catalytic pocket. Furthermore, the 
trifluoromethyl function increase the steric complementarity between the drug 
and the target. Nevertheless, also nilotinib can undergo to rapid onset of drug 
resistance phenomena.26  
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2.3.2 HISTONE DEACETYLASES AND INHIBITORS 
 
The DNA is contained in the cell nucleus in a high organized and compact 
structure, called chromatin.27 The structural entity of chromatin is the 
nucleosome, which is constituted by an octamer of histone proteins around 
which the double helix is enveloped (Figure 12). 
 
 
Figure 12. Chromatin structure. 
 
Histones are small basic proteins characterized by a central hydrophobic domain, 
with a globular structure, and by N-terminal and C-terminal regions containing a 
high amount of basic amino acids, such as lysine and arginine. The histone 
terminal residues are directed outside the nucleosome and are accessible to 
proteases, thus undergoing to post-translational modifications such as 
acetylation and de-acetylation. These modifications regulate the chromatin 
structure, regulating the gene transcription. Histone acetylation state is 
regulated by the activity of two families of enzymes:28 the histone 
acetyltransferases (HATs) and the histone deacetylases (HDACs). Usually, a highly 
acetylated histone core corresponds to a transcriptional activation, while a low 
acetylation causes a transcriptional repression. In fact, the positive charges of 
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low acetylated histones interact with the negatively charged DNA phosphate 
groups, maintaining a compact silent structure of chromatin (heterochromatin). 
The lysine acetylation neutralizes this histone positive charge, leading to a 
relaxed chromatin (euchromatin), which is accessible to the transcriptional 
factors and to the RNA polymerases (Figure 13).  
 
 
Figure 13. Heterochromatin/euchromatin regulation equilibria by HATs and HDACs. 
 
The HDACs are grouped in two different classes, on the basis of the catalytic 
mechanism:29 
1. Zinc dependent enzymes: 
 Class I: HDAC1, HDAC2, HDAC3, HDAC8; 
 Class II: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10; 
2.  NAD dependent enzymes. 
Class I and II HDACs are emerging therapeutic targets for cancer treatment. In 
vivo studies have demonstrated that HDACIs impair the cancer growth.  
Different HDAC isoforms have been crystallized, allowing for the tridimensional 
characterization of the enzymes (Figure 14).29 
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Figure 14. Example of HDAC structure. 
 
The catalytic pocket of zinc-dependent HDACs is constituted by a deep channel 
of about 11Å length, containing the zinc ion. Besides the metal ion, the bottom 
of the channel presents a further cavity for the acetate ion. The zinc ion is 
coordinated by two aspartates, one histidine and one water molecule. 
As previously mentioned, histone deacetylases remove the acetyl group from 
lysine side chains in histone proteins. Class I/II HDACs have homologous active 
sites and are thought to proceed through a catalytic mechanism in which the His-
Asp dyad work as a general acid-base catalytic pair. The proposed chemical 
mechanism is illustrated in figure 15. 
 
 
Figure 15. Proposed chemical mechanism of class I/II histone deacetylases (HDACs). 
 
The Zn2+ and Tyr306 polarize the carboxyl by coordinating to the acetyl oxygen. 
Asp178, His180 and Asp267 (numbering from HDAC8 taken as representative 
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example) and a molecule of water coordinates the metal ion. The metal ion, 
His142 and His143 activate the water molecule for the nucleophilic attack to the 
acetyl carboxyl carbon. Subsequently, the tetrahedral intermediate collapses to 
form acetate and release the positively charged lysine products.30 
HDACIs obstruct the substrate access directly binding the catalytic site, thus 
causing an accumulation of acetylated histone. 
These inhibitors show several biological effects that concern the differentiation, 
the growth arrest and the apoptosis of transformed cells thus resulting in 
inhibitory growth of the tumor mass. 
HDACIs can be grouped in hydroxamic acids, carboxylic acids, electrophilic 
ketones, orto-aminobenzamides and cyclic peptides, according to their chemical 
structures.29 The suberoyl anilide of hydroxamic acid (SAHA) is the first FDA-
approved HDACI to enter the clinic as a treatment for cutaneous T-cell 
lymphoma. Hydroxamic acids and orto-aminobenzamides (e.g. entinostat) are 
the most studied classes of HDACIs. 
 
 
Figure 16. Structures of SAHA (A) and entinostat (B) complexed with HDAC8. 
 
In figure 16 are described the structures of the complexes of SAHA (A) and 
entinostat (B) with HDAC8 and it is visible that the alkyl chain and the pyridine-
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carbamate extend out of the lipophilic channel similarly to the side chain of a 
lysine residue.31 
All the HDACIs share three common features: a zinc-chelating motif; an enzyme 
surface recognition portion; a linker between the first two portions (Figure 17). 
 
 
Figure 17. Structural features of SAHA (A) entinostat (B). 
 
Recent studies have shown that the association of Abl and HDAC inhibitors 
increases the efficacy of the anticancer therapy when compared to single agent 
treatment.5 Moreover, the use of chimeric molecules bearing erlotinib and SAHA 
substructures have shown higher therapeutic efficacy when compared to the 
association therapy with the same drugs.32 It is well known that the inhibition of 
HDAC influences the activity of different proteins (including TKs). However, it is 
not still clear why chimeric compounds lead to higher activity than the 
association of the same parent inhibitors. Therefore, these experimental 
evidences suggest the importance to identify new dual inhibitors of TK/HDAC 
and to study the mechanism of action.  
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2.3.3 METAL COMPLEXES 
 
In the past, metal-based compounds were widely used in the treatment of 
disease conditions, but the lack of clear distinction between the therapeutic and 
toxic doses was a major challenge.  
The milestone of metal-based anticancer therapy is cisplatin, that was discovered 
in 1960 by Barnett Rosenberg and founded the modern era of the metal-drugs.33 
However, platinum drugs can reveal many limitations such as severe side effects, 
toxicity and inherent and acquired resistance. Nowadays there is a growing 
interest in bio-metals (like copper, zinc and iron) as they are biocompatible and 
less toxic compared to non-endogenous heavy metals. Furthermore, metal 
complexes has gained much attention as their high anti-proliferative potency and 
their ability to preferentially accumulate in cancer cells.34 
In nature, many biological systems make extensive use of metal ions, such as zinc 
and copper, which play critical roles in the normal functioning of organisms. 
Transition metals such as copper, iron, and manganese, among others, are 
involved in multiple biological processes, from electron transfer to catalysis to 
structural roles, and are frequently associated with active sites of proteins and 
enzymes. A dysregulation of some of these essential metals during normal 
biochemical processing can be implicated in the development of various 
pathological disorders, such as cancer. Therapeutic potential of metal complexes 
in cancer therapy has attracted a lot of interest mainly because metals exhibit 
unique characteristics, such as redox activity, variable coordination modes and 
reactivity toward the organic substrate.  
Most metal ion complexes interfere with the DNA double helix differently than 
an uncoordinated drug. Complexes can bind to the nucleic acid structure in a 
covalent or noncovalent way and/or can function as a source of ROS which in 
turn causes DNA degradation.35 
A large spectrum of transition metal complexes have been used as anticancer 
agents, although for many intercalation is not required for activity. For example: 
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 Zinc is an indispensable element that plays a critical role in cell 
proliferation, differentiation, and defense against free radicals. Zinc acts 
as a key structural component in many proteins and enzymes, including 
transcription factors, cellular signaling proteins, and DNA repair enzymes. 
Zinc is interesting in medicinal chemistry as DNA nucleases due to its 
natural abundance in humans and important roles in cellular functions.36 
 Copper is an essential cellular element necessary for many biological 
pathways and it is a cofactor in enzyme catalytic processes. Copper 
complexes are known to mimic superoxide dismutase (SOD), an 
important antioxidant enzyme that protects cells from harmful radical 
superoxide through its dismutation to non-toxic molecules. Copper can 
undergo redox activity and competitively bind to the site that could 
otherwise be occupied by other metals.33 
 Iron has been exploited in the development of anticancer agents as it is 
an essential component of various biological processes including 
erythropoiesis, electron transport and DNA synthesis. Additionally, iron 
most commonly exists in two oxidation states Fe(II) and Fe(III), which 
allows it to participate at important redox reactions.36 
The huge variety of transition metal properties and ligand combinations has 
produced an extremely broad spectrum of metal-based compounds, each with a 
unique mechanism of action.  
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3. OBJECTIVE 
 
 
The present project relies on the synthesis and the biological evaluation of novel 
anticancer multi-target compounds able to inhibit: 1) at least one tyrosine kinase 
and 2) another biomolecular target such as one of the HDAC.  
Overall, the project aims at: 
1. developing prototypes of novel potential anticancer agents, merging different 
molecular scaffolds endowed with known pharmacological properties; 
2. characterizing the biological profile of the most interesting synthesized 
compounds, determining as much as possible the mechanism of action at 
molecular level. 
The cytotoxicity of all the synthesized compounds will be determined on a panel 
of human cancer cell lines over-expressing and not-expressing the TKs of 
interest. The ability to inhibit the kinase activity of a panel of TKs (EGFR, CSF1-R, 
KIT, FLT3, PDGFRβ, VEGFR-2, RET, Abl and Src) will be assessed. Then, depending 
on the molecular structure of the compounds, the inhibitory activity against 
HDACs is also measured. Overall, the screening of the compounds will furnish a 
set of molecules on which more detailed biological assays will be performed. The 
selected compounds will be also evaluated on cell lines resistant to TKIs, HDACIs 
in order to investigate whether the dual inhibitors overcome the drug resistance 
phenomena. The molecular structure of the selected compounds will constitute 
the template for the design of novel and more active compounds that will be in 
turn synthesized and submitted to biological evaluation.  
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Figure 18. Structures of reference compounds. 
 
With the aim to develop novel potential dual HDAC/TK inhibitors, a set of 
imatinib (Figure 18A) and nilotinib (Figure 18B) analogues, bearing either a 
hydroxamic moiety (Figure 18C, SAHA) or an o-aminobenzamide moiety (Figure 
18D, entinostat), have been designed. 
The compounds of the library showing the most interesting activity will be 
subsequently functionalized with metal ions, as Zn2+, Cu2+ and Fe3+. The purpose 
of the functionalization is to investigate whether a metal could increase the 
cytotoxicity of these compounds by altering the redox cellular equilibrium and 
whether it could modulate the interaction with the cellular targets and the 
cellular uptake. 
 
The main goal of the present PhD project is to synthesized and evaluate novel 
compounds endowed with multi-target properties. In particular, the research is 
focused on: 
 Quinazolinone derivatives inhibiting EGFR and VEGFR2; 
 Benzoquinoline derivatives as novel topoisomerase inhibitors; 
 N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives inhibiting 
class III RTKs (CSF1R, FLT3, c-KIT, PDGFRα and PDGFRβ); 
 N-(2-fluoro-5-trifluoromethylphenyl)-N’-[4-(pyrimidin-4-
ylamino)phenyl]urea derivatives inhibiting c-KIT/ wtRET/ V804MRET; 
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 Pyrido-pyrimidine derivatives bearing either hydroxamate or 
aminobenzamide functions able to inhibit Abl kinase and HDAC; 
 Metal complexes of pyrido-pyrimidine derivatives bearing hydroxamate 
function able to additionally modulate the redox balance. 
 
The general structures of designed compounds are reported in Figure 19. 
 
 
Figure 19. General structures of A) Quinazolinone derivatives; B) Benzoquinoline 
derivatives; C) N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives; D) N-(2-
fluoro-5-trifluoromethylphenyl)-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives; E) 
Pyrido-pyrimidine derivatives; F) Metal complexes of pyrido-pyrimidine derivatives. 
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4. RESULTS AND DISCUSSION 
 
 
4.1 SYNTHESIS OF DUAL TK-HDAC INHIBITORS 
 
4.1.1 SYNTHESIS OF [4I-(PYRIDIN-3II-YL)PYRIMIDIN-2I-YL]ANILINE 
MOIETIES 
 
The synthesis of imatinib (20) and nilotinib (21) scaffolds (i.e. the portion of 
compound deputed to the interaction with the kinase hinge region; Scheme 1), 
started from 3-acetylpyridine (24) heated to reflux with N,N-dimethylformamide 
dimethyl acetal obtaining 25 with a good yield. At the same time, the two 
guanidine derivatives, N-(2-methyl-5-nitrophenyl)guanidine (23) and methyl 3-
guanidino-4-methylbenzoate nitrate (28), were synthesized by reaction of the 
proper aniline derivative with cyanamide.  
To obtain the imatinib scaffold 3-(N,N-dimethylamine)-1-(pyridin-3I-yl)propen-1-
one (25) was firstly condensed with 23 by microwave irradiation, affording the 
cyclization of the pyrimidine ring; the nitro group was subsequently reduced to 
amine 20. Differently, nilotinib scaffold 21 was synthesized by classic heating, in 
the presence of sodium hydroxide, permitting both the cyclization of the 
pyrimidine ring and the hydrolysis of the methyl ester to obtain the acid 
function. 
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Scheme 1. Synthesis of intermediates 20 and 21. Reagents and conditions: 
a. 1) NH2CN, HNO3 15 M, EtOH, H2O, reflux, 16 h; 2) NaOH, H2O, RT, 1 h, 70% 
yield; 
b. DMF-DMA, xylene, reflux, 16 h, 90% yield;  
c. isopropanol, MW, 130°C, 10 min, 75% yield; 
d. SnCl2 ٠2H2O, reflux, 1 h, 80% yield; 
e. NH2CN, HNO3 15 M, EtOH, H2O, reflux, 16 h, 75% yield; 
f. EtOH, NaOH 2 M, reflux, 16 h, 54% yield. 
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4.1.2 SYNTHESIS OF m- OR p-VINYLBENZOIC ACID MOIETIES 
 
The active function protection was required to synthesize the zinc chelating 
motif (both the o-aminobenzamide and the hydroxamic acid derivatives); in the 
first case the o-phenylenediamine (33) was mono-protected as tert-
butoxycarbonyl amine (34; Scheme 2), stable under neutral or even basic 
conditions. Conversely, the protected hydroxylamine is commercially available as 
O-(tetrahydro-2H-pyran-2-yl)hydroxylamine. 
 
 
Scheme 2. Synthesis of intermediates 29-32. Reagents and conditions: 
A) a. Boc2O, THF, RT, 4 h, 69% yield; 
B) a. 1) H2SO4 18 M, EtOH, reflux, 3.5 h; 2) I2, acetone; RT, 5 min, quantitative 
yields;  
  b. malonic acid, piperidine, pyridine, reflux, 2.5 h, 63-70% yields; 
  c. protected amine derivative, BOP, TEA, DMF, RT, 16 h, 53-92% yields; 
  d. NaOH, H2O, THF, RT, 16 h, 77-86% yields. 
 
The synthesis of the meta- and para- vinylbenzoic acid moieties started from the 
esterification of the acid function of the proper formylbenzoic acid with ethanol 
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in the presence of sulfuric acid, to afford 37 and 38. The subsequent step was the 
mixed aldol condensation between the aldehyde derivative and malonic acid in a 
basic medium to obtain the cinnamic acids (39 and 40). Then, the acid function 
was activated through the BOP method to afford the amide derivatives (41-44). 
The final step was the hydrolysis of the ester in alkaline medium. 
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4.1.3 SYNTHESIS OF m/p-{2IV-CARBAMOYL-VINYL}-N-{4I-METHYL-3I-
[4II-(PYRIDIN-3III-YL)PYRIMIDIN-2II-YL]AMINOPHENYL}BENZAMIDE 
DERIVATIVES 
 
The first library of compounds was synthesized through a convergent strategy by 
the condensation of the zinc-chelating moiety to the TKI scaffold, accordingly to 
scheme 3. The condensation of meta- and para-vinylbenzoic acids with imatinib 
scaffold 20 was carried out by BOP strategy. Finally the o-aminobenzamide was 
deprotected in trifluoroacetic acid and the hydroxamic acid in hydrochloric acid 
to obtain respectively compounds 1, 2 and 3, 4. 
 
 
Scheme 3. Synthesis of compounds 1–4. Reagents and conditions: 
a. acid derivative, BOP, TEA, DMF, RT, 16 h, 40-100% yields; 
b. TFA, RT, 2 h, 72-100% yields; 
c. HCl 1M, MeOH, RT, 1.5 h, 33-55% yields. 
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4.1.4 SYNTHESIS OF PHTHALAMIC ACID MOIETIES 
 
The first library of compounds included also the phthalamide derivatives 
synthesized starting from the terephthalic acid (53) or isophthalic acid (54) 
condensed to the protected o-phenylenediamine (34) and hydroxylamine 
through the BOP strategy and the subsequent hydrolysis to afford the 
phthalamic acid moiety (Scheme 4). 
 
 
Scheme 4. Synthesis of intermediates 50-52. Reagents and conditions: 
a. protected amine derivative, BOP, TEA, DMF, RT, 16 h, 80-100% yields; 
b. NaOH, H2O, THF, RT, 4 h, 58-76% yields. 
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4.1.5 SYNTHESIS OF N-{4I-METHYL-3I-[4II-(PYRIDIN-3III-
YL)PYRIMIDIN-2II-YL]AMINOPHENYL}PHTHALAMIDE DERIVATIVES 
 
 
Scheme 5. Synthesis of compounds 5–7. Reagents and conditions: 
a. acid derivative, BOP, TEA, DMF, RT, 16 h, 95-100% yields; 
b. TFA, RT, 2 h, 72-100% yields; 
c. HCl 1M, MeOH, RT, 1.5 h, 20% yield. 
 
The imatinib scaffold 20 was condensed to the proper phthalamic acid moiety 
activated through the BOP method to afford the amide derivatives (58-60) and 
finally the o-aminobenzamide and hydroxamic acid protection groups were 
treated with hydrochloric acid to release the final product active functions. 
(Scheme 5). 
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4.1.6 SYNTHESIS OF 3-{2IV-CARBAMOYL-VINYL}-5-
TRIFLUOROMETHYL-N-{4I-METHYL-3I-[4II-(PYRIDIN-3III-
YL)PYRIMIDIN-2II-YL]AMINOPHENYL}BENZAMIDE DERIVATIVES 
 
Compounds in the second library of potential dual TK/HDAC inhibitors bear a 
trifluoromethyl and/or an imidazole function, while maintaining the m-
vinylbenzamide and the isophthalamide moieties. Compounds 8 and 9 were 
synthesized accordingly to scheme 6 starting from the bromination of 3-
trifluoromethylbenzoic acid (61) with N-bromosuccinimide.  
 
 
Scheme 6. Synthesis of compounds 8 and 9. Reagents and conditions: 
a. N-bromosuccinimide, H2SO4 18 M, TFA, 40°C, 24 h, 91% yield; 
b. ethyl acrylate, Pd(OAc)2, TPP, TEA, 100°C (sealed tube), 16 h, 62% yield; 
c. imatinib scaffold, BOP, TEA, DMF, RT, 16 h, quantitative yield; 
d. NaOH, H2O, THF, RT, 4 h, 92% yield; 
e. protected amine derivative, BOP, TEA, DMF, RT, 16 h, quantitative yields; 
f. TFA, RT, 2 h, 88% yield; 
g. HCl 1M, MeOH, RT, 16 h, 75% yield. 
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The second step was the Heck’s reaction between 3-bromo-5-
trifluoromethylbenzoic acid (62) and ethyl acrylate, catalysed by palladium (II) 
acetate. 
Compound 63 was condensed with imatinib scaffold 20 through BOP strategy 
and then was hydrolyzed to release the acid function (65). The acid was 
subsequently condensed to the (tert-butoxycarbonylamino)aniline (34) and the 
O-(tetrahydro-2H-pyran-2-yl)hydroxylamine; compound 66 was deprotected in 
trifluoroacetic acid, while compound 67 in methanol with hydrochloric acid. 
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4.1.7 SYNTHESIS OF 3-{4IV-[(2V-HYDROXYLAMINO)CARBONYL-
VINYL]IMIDAZOL-1IV-YL}-5-TRIFLUOROMETHYLBENZAMIDE 
DERIVATIVES  
 
For the synthesis of compounds 68 and 69 two different strategies were applied, 
both starting with the esterification of urocanic acid (70) in ethanol (Scheme 7, 
A). 
 
 
Scheme 7. Synthesis of intermediates 68 and 69. Reagents and conditions: 
A) a. H2SO4 18 M, EtOH, reflux, 3 h, quantitative yield; 
B) a. imatinib scaffold, BOP, TEA, DMF, RT, 24 h, quantitative yield;  
  b. ethyl urocanate, K2CO3, DMF; 120°C (sealed tube), 10 h, 86% yield; 
C) a. N-bromosuccinimide, H2SO4 18 M, 60°C, 2h, 87% yield; 
  b. ethyl urocanate, CuI, 8-OH-quinoline, K2CO3, DMSO, 100°C (sealed tube), 
35% yield; 
  c. SnCl2 x 2 H2O, EtOH, 60°C, 1 h, 97% yield;  
  d. nilotinib scaffold, SOCl2, NMP, 60°C, 1 h, 45% yield. 
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Compound 68 was synthesized trough a linear method, consisting 1) in the 
condensation of 20 with 3-fluoro-5-trifluoromethylbenzoic acid activated 
through BOP strategy, and 2) condensation of the so obtained 73 with ethyl 
urocanate (Scheme 7, B). Differently, compound 69 was synthesized starting 
from the bromination of 3-nitrobenzotrifluoride (74) with N-bromosuccinimide.  
Then compound 75 was condensed with ethyl urocanate trough an optimized 
Aza-Ullmann coupling. The nitro group of 76 was then reduced in ethanol with 
tin(II) chloride and condensed with compound 21 previously activated as acyl 
chloride (Scheme 7, C). 
 
As aforementioned, the aza-Ullmann condensation needed optimization. Indeed, 
the generally accepted mechanism for this reaction involves the coordination of 
the nucleophile to the metal center, which then reacts with an aryl halide 
through oxidative addition, furnishing the final product after reductive 
elimination.37 
The reaction mechanism is described in Figure 20. 
 
 
Figure 20. Aza-Ullman reaction mechanism. 
 
With this methodology catalytic amounts of copper (generally Cu(I)) can be used, 
but conversely a stoichiometric (or greater) amount of base is required.38  
A mixture of ethyl urocanate (71) and 3-bromo-5-trifluoromethylnitrobenzene 
(75), in DMSO, employing copper iodide as catalyst and 8-hydroxyquinoline as 
ligand increasing the copper solubility and potassium carbonate as base was 
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initially heated at 120°C in a sealed tube under Ar2 for 29 hours. Adopting this 
method the yield was very poor. Indeed, many products formed, prompting us to 
test other conditions.  
Then ethylenediamine was used as ligand and N,N-dimethylformamide as 
solvent  but also in this case it was not possible to obtain the conversion of 
starting materials.  
We then performed a systematic search for the best reaction conditions, starting 
from the heating method in sealed tube, according to table 1. 
 
Run 
Solvent 
(5 ml x 
mmol Ar-Br) 
Coordinating 
agent Temp time CuI ratio 
Yield 
(%) 
1 DMSO 8-OH-quinoline 100°C 16h 10mol% 24 
2 DMSO 8-OH-quinoline 100°C 16h 20mol% 35 
Table 1. Tested conditions (sealed tube). 
 
In both the cases, a double molar amount of both ethyl urocanate and base 
(potassium bicarbonate) was used. 
 
The optimization through microwave assisted organic chemistry was also 
attempted as stated in table 2.  
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Run 
Solvent  
(5 ml x mmol 
Ar-Br) 
Coordinating 
agent Temp time NOTE 
Yield 
(%) 
1 MeCN 8-OH-quinoline 100°C 10’ - - 
2 Dioxane 8-OH-quinoline 100°C 10’ - - 
3 MeCN 8-OH-quinoline 130°C 10’ - 25 
4 Dioxane 8-OH-quinoline 130°C 10’ - 15 
5 MeCN Proline 130°C 10’ - 18 
6 MeCN Proline 130°C 10’ 
Ar-
Br/imidazole 
ratio (1:1.5) 
21 
7 DMSO Proline 130°C 10’ - 12 
8 DMSO Proline 120°C 10’ Complex mixture - 
9 DMSO Proline 110°C 20’ Complex mixture - 
10 DMSO Proline 100°C 20’ Complex mixture - 
Table 2. Tested conditions (MW). 
In all the cases, a five times molar amount of ethyl urocanate and a double 
amount of base (potassium bicarbonate) were used. Remarkably, microwave 
irradiation did not improve the yield of the product.  
 
The best reaction conditions are finally by heating in sealed tube with 20%mol of 
CuI. 
 
Compounds 68 and 69 were then submitted to the same sequences of reaction 
to obtain 10 and 11 respectively (Scheme 8), i.e.: 
1. ester hydrolysis in alkaline medium; 
2. activation of acid function with BOP; 
3. condensation with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine; 
4. de-protection in hydrochloric acid to release the hydroxamic acid (scheme xx). 
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Scheme 8. Synthesis of compounds 10 and 11. Reagents and conditions: 
a. NaOH, H2O, THF, RT, 16 h, 47-55 yields; 
b. O-(tetrahydro-2H-pyran-2-yl)hydroxylamine, BOP, TEA, DMF, RT, 16 h, 55% 
yields; 
c. HCl 1 M, MeOH, RT, 16 h, 30% yields. 
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4.1.8 SYNTHESIS OF NI-[5IV-(IMIDAZOL-1V-YL)-2IV-AMINOPHENYL]-N-
{4I-METHYL-3I-[4II-(PYRIDIN-3III-YL)PYRIMIDIN-2II-
YL]AMINOPHENYL}ISOPHTALAMIDE DERIVATIVES 
 
Compounds 12 and 13 were synthesized through the same method (Scheme 9), 
starting from the aza-Ullmann coupling between 2-nitro-4-bromoaniline (82) and 
imidazole (83) or methylimidazole (84). The amino function was then protected 
with Boc2O in a strong alkaline medium to give the N-boc derivatives 85 and 86.  
 
 
Scheme 9. Synthesis of compounds 12 and 13. Reagents and conditions: 
a. imidazole derivative, CuI, 8-OH-quinoline, K2CO3, DMSO; 130°C, 48 h, 31-66% 
yields; 
b. Boc2O, KOtBu, DMSO, RT, 2 h, 45-73% yields; 
c. FeCl3, hydrazine, MeOH, reflux, 1.5 h, 50-70% yields; 
d. mono-ethyl isophtalate , BOP, TEA, DMF, RT, 16 h, 50-75% yields; 
e. NaOH, H2O, THF, RT, 4 h, 22-31% yields; 
f. imatinib scaffold, BOP, TEA, DMF, RT, 16 h, 56-65% yields; 
g. TFA, RT, 2 h, 63-94% yields. 
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The nitro group was reduced with iron(III)chloride and hydrazine, and the amino 
derivatives were condensed with mono-ethyl isophtalate through the BOP 
method.  
The esters 89 and 90 were dissolved in THF and hydrolyzed with aqueous sodium 
hydroxide to give the corresponding acids 91 and 92. These intermediates were 
activated with BOP and condensed with compound 20; finally the o-
aminobenzamide moieties were deprotected by treatment with trifluoroacetic 
acid. 
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4.2 SYNTHESIS OF DUAL TYROSINE KINASES-HDAC 
INHIBITORS FUNCTIONALIZED 
 
 
Figure 21. Structures of the zinc (II), copper (II) and iron(III) complexes. 
 
All the complexes (Figure 21) were synthesized following the same method: 
starting compounds (4, 9) were dissolved in methanol and the solution was made 
alkaline with aqueous KOH 10% to allow the hydroxamate function to complex 
the respective metal. Then, an appropriate solution of the metal was added and 
the mixture was stirred overnight at room temperature.  
Complexes 14-15, 16-17 were synthesized using the half amount of zinc acetate 
and copper chloride with respect to the starting compounds 4 and 9. 
To obtain compounds 18 and 19 one third molar amount of iron chloride was 
used. 
The complexes were characterized by FT-IR spectrometry, elemental analysis and 
mass spectrometry. The Zinc derivatives were also analyzed by NMR (1H and 13C). 
The one week stability of the complexes was determined through NMR (only for 
the zinc derivatives) and subsequently the one month stability of frozen sample 
tubes in DMSO. 
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The HPLC stability analysis required that all the samples (compounds 4; 9 and 14) 
were diluted in ACN/Water solution (1:1) with 2 mM HEPES buffer at pH=7 to 
obtain a final concentration of 1 mM.  
The mobile phase consisting of acetonitrile/water (80/20) + 2% TFA, at 0.75 
ml/min flow rate was optimized which gave one sharp, well resolved peak with 
minimum tailing factor for each chromatogram. As described in table 3 the 
retention times were almost 3.4 minutes for all the eight samples but the 
presence of metals reduces the absorbance compared to the ligands. 
Compounds 4, 9 and all the functionalized complexes shown to be stable in 
solution for at least five days. 
 
Compound Day 
Retention 
time 
(min) 
Area 
(µV*sec)  Compound Day 
Retention 
time 
(min) 
Area 
(µV*sec) 
Ligand 4 1 3.37 29508706  Ligand 9 1 3.48 13758077 
 3 3.39 32122122   3 3.45 13183865 
 5 3.36 30876055   5 3.49 15466319 
14 1 3.38 1852581  15 1 3.50 4360167 
 3 3.39 2064780   3 3.40 4497950 
 5 3.38 2504862   5 3.51 4551947 
16 1 3.38 2481464  17 1 3.50 8147221 
 2 3.38 2956040   3 3.41 8726998 
 6 3.38 2768632   5 3.52 7781849 
 8 3.38 2922741  19 1 3.57 3552027 
 10 3.38 2928927   2 3.57 3313327 
18 1 3.40 686289   6 3.57 3539605 
 3 3.40 587372   8 3.57 3551614 
 5 3.41 718379   10 3.57 3522518 
Table 3. HPLC stability test results of ligands 4, 9 and their complexes. 
These compounds will be soon evaluated on isolated targets and against K562 
cell line in collaboration with Prof. Soellner, Michigan University, and Dr. Gandin, 
University of Padua; the results will be compared to the metal-free compounds. 
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4.3 BIOLOGICAL RESULTS 
 
Synthesized compounds were tested against isolated targets (i.e. Abl kinase and 
HDAC1). Besides, their ability to impair the viability of K562 cells (sensitive to 
HDACIs and TKIs) was measured. 
 
The first set of compounds (1-7) showed high activity against isolated targets 
(Table 4). 
 
Compound 
Ki Abl WT 
(nM) 
KiHDAC1 
(nM) 
GI50 
(nM) 
1 60 ± 20 >12400 >10000 
2 6.1 ± 0.9 280 ± 40 5400 
3 770 ± 90 15 ± 2 >10000 
4 11.4 ± 0.2 5.4 ± 0.6 6800 
5 230 ± 70 42 ± 10 >10000 
6 60 ± 20 220 ± 50 >10000 
7 1300 ± 200 55 ± 8 >10000 
Imatinib 14 ± 4 / 650 
Entinostat / 60 ± 20 4300 
Table 4. Results of biological evaluation for compounds 1-7. 
 
Almost all the compounds showed nanomolar affinity towards at least one 
target. In particular, compound 2 had higher affinity than imatinib vs Abl, while 
compound 4 showed the best inhibitory activity against both the targets with 
inhibition constants lower than those of the reference compounds. Nevertheless, 
all the compounds showed poor cytotoxicity, probably as consequence of low 
cell permeability. Therefore, novel analogs of 2 and 4 were synthesized and 
submitted to biological evaluation (Table 5). Indeed, the second library of 
compounds (8-13) is characterized by the presence of a trifluoromethyl and/or 
an imidazole functions to improve the pharmacokinetic profile. 
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Compound 
Ki Abl WT 
(nM) 
KiHDAC1 
(nM) 
GI50 
(nM) 
8 <0.6 355 ± 75 19.4 
9 2.6 ± 0.3 22 ± 1 28.2 
10 <0.6 2400 ± 510 28.8 
11 1.9 ± 0.6 420 ± 13 9.6 
12 26 ± 14 30 ± 3 4000 
13 7.5 ± 3.3 62 ± 25 3000 
Imatinib 14 ± 4 / 650 
Entinostat / 60 ± 20 4300 
Table 5. Results of biological evaluation for compounds 8-13. 
 
Compounds 9, 12 and 13 resulted as dual inhibitors of Abl and HDAC1 being 
almost equipotent against the two targets, whereas compounds 8, 10 and 11 
were certainly more active against the kinase. As expected, the trifluoromethyl 
group increased the affinity vs Abl. Indeed nilotinib was originally designed as an 
improved analog of imatinib: the CF3 function was introduced to enhance the 
steric complementarity with the target.  
All the compounds in the 2nd set showed a more interesting cytotoxicity than 
compounds in the 1st set. Taking together, the results indicated compound 9 as 
the most promising derivative, being a dual inhibitor endowed with nanomolar 
cytotoxicity.  
 
The 2nd set of compounds was subsequently profiled against Ba/F3 cells (a 
murine interleukin-3 dependent pro-B cell lines) overexpressing the Bcr-Abl 
protein or the T315I Bcr-Abl mutant and against the parental line, to asses both 
the potency and downstream signaling of kinase oncogenes drawing the cell 
viability profile (Table 6). 
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Compound 
WT Abl Ba/F3 
GI50 (nM) 
Parental Ba/F3 
GI50 (nM) 
T315I Abl Ba/F3 
GI50 (nM) 
8 2.5 >10000 4200 
9 5.6 2500 4400 
10 8.5 >10000 5200 
11 29 >10000 17500 
12 6700 4700 5700 
13 885 24700 10400 
Table 6. Compounds 8-13 cell viability assays. 
 
Accordingly to the other biochemical and biological tests, compounds 8, 9 and 10 
showed promising growth inhibitory potency against the cell line overexpressing 
wild-type Abl.  
The overall SARs against isolated targets are summarized in figure 22. 
 
 
Figure 22. SARs of synthesized compounds 1-13. 
Briefly:  
- Compounds 4, 9, 12 and 13 resulted dual inhibitors of Abl and HDAC1; 
- Compounds 2, 8, 10 and 11 showed a better activity against the kinase; 
- Compounds 8, 9 and 10 showed a great growth inhibition against the cell line 
expressing wild-type Abl; 
- All the compounds in the 2nd set showed a more interesting cytotoxicity; 
- Accordingly to all the results compound 9 is the most promising derivative, 
being a dual inhibitor with nanomolar cytotoxicity.  
Results and Discussion 
52 
 
 
53 
 
5. EXPERIMENTAL PROCEDURES 
 
 
5.1 MATERIALS 
 
All commercial chemicals and solvents used (Sigma Aldrich, Alfa Aesar and Carlo 
Erba) were analytical grade and were used without further purifications. 
Deuterated solvents for NMR analysis (Aldrich) show at least isotopic purity of 
99.5%. 
The thin layer chromatography was performed on pre-coated plates of silica gel 
60 with fluorescent indicator UV254 (0.2 mm, Macherey-Nagel).  
Flash chromatography was performed on a Biotage Isolera One using SNAP KP-Sil 
cartridges, eluting with the solvent specified for individual compounds. 
Column chromatography was done with silica gel 60 (0.063-0.100 mm, Merck) 
each time by solvents elution. 
An YMC-Pack Pro C18 column (5 µm particle size with a pore diameter of 120 Å, 
25 cm length, 4.6 mm internal diameter) was used for stability analysis. 
 
5.2 INSTRUMENTATION 
 
Melting points were determined on open capillary, using the melting point 
apparatus Gallenkamp MFB-595-010M. 
The 1H-NMR spectra were recorded on a Bruker 300-AMX, 400-AMX and 500-
AMX spectrometers with TMS as an internal standard. Coupling constants are 
given in Hz, and the relative area peaks agreed with all assignments. 
Elemental analyses were performed on a Perkin-Elmer 2400 analyzer. 
Mass spectra were performed on an Applied Biosystem Mariner System 5220 
with direct injection of the sample. 
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IR spectra were recorded as KBr discs (4000-400 cm-1) on a Perkin Elmer precisely 
Spectrum100 FT-IR spectrometer. 
Microwave assisted reactions were performed on a CEM Discover® monomode 
reactor with the temperature monitored by a built-in infrared sensor and 
automatic control of power; all reactions were performed in closed devices with 
pressure control. 
HPLC stability analysis were performed on a Waters Alliance 2695 separations 
module, with a detector at 254 nm (model W2487).  
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5.3 METHODS 
 
5.3.1 SYNTHESIS OF DUAL TK-HDAC INHIBITORS 
 
5.3.1.1 GENERAL METHODS 
 
A) General method for the amide coupling reactions with BOP 
(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
(4.5 mmol), TEA (9.0 mmol) and the amino derivative (4.5 mmol) were in 
sequence added to a solution of acid derivative (4 mmol) in DMF (8 ml). The 
mixture was stirred at room temperature for 24 hours and then, drop to drop, 
poured into a saturated solution of NH4Cl in H2O (40 ml). The obtained 
precipitate was collected by filtration and washed with abundant H2O to afford 
the amide derivative. 
 
B) General method for the ester derivatives hydrolysis with NaOH 
A solution of NaOH (0.1 g, 2.0 mmol) in H2O (10 ml) was added to a solution of 
ester derivative (1 mmol) in MeOH or THF (10 ml). The mixture was heated at 
45°C overnight. After cooling, the organic solvent was evaporated under vacuum 
and then the mixture was acidified with HCl 0.5M until complete precipitation of 
a solid. The solid precipitate was collected by filtration to obtain the acid 
derivative. 
 
C) General method for the o-aminobenzamide derivatives deprotection 
A solution of [(tert-butoxycarbonyl)aminophen-2-yl]benzamide derivative (0.5 
mmol) in TFA (5 ml) was stirred at room temperature for 2 hours. The mixture 
was subsequently diluted with H2O (100 ml) and alkalinized with NH4OH 33% 
until complete precipitation of an insoluble residue. The precipitate was 
collected by filtration and washed with water to afford the o-aminobenzamide 
derivative. 
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D) General method for the hydroxamic acid derivatives deprotection 
Starting from the [O-(tetrahydro-pyran-2-yl)hydroxylamino]carbonyl derivative 
(0.5 mmol) dissolved in MeOH (20 ml), HCl 1M (3.5 ml) was added. The mixture 
was stirred at room temperature for 2 hours and then part of the solvent was 
evaporated under vacuum. The solid precipitate was collected by filtration and 
was washed with water to give the hydroxamic acid derivative. 
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5.3.1.2 SYNTHESIS OF [4I-(PYRIDIN-3II-YL)PYRIMIDIN-2I-YL]ANILINE MOIETIES 
 
Synthesis of N-(2-methyl-5-nitrophenyl)guanidine  
 
 
 
A solution of cianamide (1.3 g, 30.0 mmol) in water (3 ml) and HNO3 65% (1.4 
mL) were added to a suspension of 2-methyl-5-nitroaniline (3.0 g, 20.0 mmol) in 
EtOH (15 ml). The reaction mixture was refluxed for 16 hours (TLC: CHCl3/MeOH 
9/1). After cooling, a solution of cianamide (1.3 g, 30.0 mmol) in water (3 ml) and 
HNO3 65% (1.4 ml) were again added to the mixture. The reaction mixture was 
refluxed for 16 hours. After cooling, diethyl ether (200 ml) was added to the 
mixture under stirring. The solid precipitate was collected by filtration and 
dissolved in H2O (1 L). The solution was alkalized with NaOH (pH = 12). The 
mixture was stirred one hour in cooled bath to obtain a yellow precipitate. The 
solid residue was filtered to give N-(2-methyl-5-nitrophenyl)guanidine (2.7 g, 
70% yield); mp 225°C. 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 7.59 (dd, J=8.3, J=2.5, 1H, 4-H); 7.50 (d, J=2.5, 
1H, 6-H); 7.32 (d, J=8.3, 1H, 3-H); 5.28 (broad s, 4H, 2 x NH, NH2); 2.15 (s, 3H, 
CH3). 
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Synthesis of 3-(N,N-dimethylamine)-1-(pyridin-3I-yl)propen-1-one  
 
 
 
DMF-DMA (4.0 mL, 30.0 mmol) was added to a solution of 3-acetylpyridine (1.8 
ml, 15.0 mmol) in xylene (6 ml). The mixture was heated at reflux for 16 hours 
(TLC: CHCl3/MeOH 9/1). After cooling, the methanol formed was evaporated 
under reduced pressure. The oil residue was diluted with n-exane (3 ml) and 
stirred at room temperature. The resulting solid precipitate was collected by 
filtration to give 3-(N,N-dimethylamine)-1-(pyridin-3I-yl)propen-1-one (2.4 g, 
90% yield); mp: 82°C. 
 
 
1H-NMR (300 MHz, CDCl3-d): δ 9.08 (dd, J=2.0, J=0.8, 1H, 2I-H); 8.67 (dd, J=4.9, 
J=2.0, 1H, 6I-H); 8.19 (dt, J=8.0, J=2.0, 1H, 4I-H); 7.86 (d, J=12.2, 1H, 2-H); 7.35 
(ddd, J=8.0, J=4.9, J=0.8, 1H, 5I-H); 5.68 (d; J=12.2, 1H, 3-H); 3.18 (s, 3H, CH3), 
2.95 (s, 3H, CH3). 
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Synthesis of NI-(2-methyl-5-nitrophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-
yl]amine  
 
 
 
N-(2-methyl-5-nitrophenyl)guanidine (1.9 g, 10.0 mmol) was added to a solution 
of 3-(N,N-dimethylamine)-1-(pyridin-3I-yl)propen-1-one (1.5 mg, 8.2 mmol) in 
isopropanol (16 ml). The mixture was microwave irradiated at 100°C for one 
minute (power set point 100W), subsequently at 130°C for 10 minutes (power 
set point 130W) and at 140°C for 10 minutes (power set point 150W), (TLC: 
CHCl3/MeOH 9/1). After cooling the mixture was stirred at room temperature 
and n-hexane (20 ml) was added. The solid precipitate formed was collected by 
filtration to give NI-(2-methyl-5-nitrophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-
yl]amine (2.3 g, 75% yield); mp: 209°C. 
 
 
1H-NMR (300 MHz, CDCl3-d): δ 9.50 (d, J=2.2, 1H, 6-H); 9.30 (dd, J=2.4, J=0.8, 1H, 
2II-H); 8.78 (dd, J=4.9, J=1.7, 1H, 6II-H); 8.62 (d, J=5.20, 1H, 6I-H); 8.57 (ddd, J=8.0, 
J=2.4, J=1.7, 1H, 4II-H); 7.90 (dd, J=8.3, J=2.2, 1H, 4-H); 7.53 (d, J=8.3, 1H, 3-H); 
7.35 (ddd, J=8.0, J=4.9, J=0.8, 1H, 5II-H); 7.35 (d, J=5.2, 1H, 5I-H); 2.48 (s, 3H, CH3). 
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Synthesis of NI-(2-methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-
yl]amine  
 
 
 
Tin(II) chloride dihydrate (6.2 g, 27.0 mmol) was added to a suspension of NI-(2-
methyl-5-nitrophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (1.4 g, 4.5 mmol) 
in MeOH (45 ml). The mixture was heated at reflux for 1 hour (TLC: CHCl3/MeOH 
9/1). After cooling, the methanol was evaporated under vacuum. The residue 
mixture was diluted in water (200 ml) and gently neutralized with NaHCO3, the 
aqueous solution was extracted with EtOAc (3 x 40 ml). The organic phase was 
dried with Na2SO4 and concentrated to obtain compound NI-(2-methyl-5-
aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (1.0 g, 80% yield); mp: 
135°C.  
 
 
1H-NMR (300 MHz, CDCl3-d): δ 9.27 (dd, J=2.0, J=0.8, 1H, 2II-H); 8.72 (dd, J=4.8, 
J=2.0, 1H, 6II-H); 8.60 (d, J=5.20, 1H, 6I-H); 8.35 (dt, J=8.0, J=2.0, 1H, 4II-H); 7.62 
(d, J=2.4, 1H, 6-H); 7.43 (ddd, J=8.0, J=4.8, J=0.8, 1H, 5II-H); 7.16 (d, J=5.2, 1H, 5I-
H); 7.02 (d, J=8.1, 1H, 3-H); 6.94 (broad s, 1H, NH); 6.43 (dd, J=8.1, J=2.4, 1H, 4-
H); 3.63 (broad s, 2H, NH2); 2.25 (s, 3H, CH3). 
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Synthesis of methyl 3-guanidino-4-methylbenzoate nitrate  
 
 
 
A solution of cianamide (0.9 g, 22.5 mmol) in H2O (4.5 ml) and HNO3 65% (1.0 ml, 
14.3 mmol) were added to a suspension of 3-amino-4methylbeanzoate (2.5 g, 
15.0 mmol) in Ethanol. The mixture was heated at reflux for 6 hours (TLC: 
CHCl3/MeOH 9/1). After cooling, a solution of cianamide (0.9 g, 22.5 mmol) in 
H2O (4.5 ml) and HNO3 65% (1.0 ml, 14.3 mmol) were added again to the 
mixture. The mixture was heated at reflux for 16 hours. After cooling, the 
mixture was chilled in ice bath, diluted with diethyl ether (150 ml) and stirred to 
obtain a precipitate. The solid precipitate was collected by filtration to obtain 
methyl 3-guanidino-4-methylbenzoate nitrate (2.6 g, 75% yield), m.p. 206°C. 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 7.86 (dd, J=1.7, J=7.9, 1H, 6-H); 7.74 (d, 1H, 
J=1.7, 2-H); 7.50 (d, J=7.9, 1H, 5-H); 7.27 (broad s, 4H, 2 x NH, NH2); 3.85 (s, 3H, 
CH3); 2.27 (s, 3H, CH3). 
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Synthesis of 4-methyl-3-{[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzoic acid  
 
 
 
Methyl 3-guanidino-4-methylbenzoate nitrate (1.8 g, 6.5 mmol) was added to a 
solution of 3-(N,N-dimethylamine)-1-(pyridin-3I-yl)propen-1-one (1.3 g, 7.2 
mmols) and NaOH (0.2 g, 6.3 mmol) in EtOH (20 ml). The mixture was heated to 
reflux for 16 hours (TLC: CHCl3/MeOH 9/1). The solvent was subsequently 
evaporated and the obtained residue diluted with H2O (150 ml) and extracted 
with EtOAc (3 x 60 ml). The organic phase was dried with anhydrous sodium 
sulphate and evaporated to obtain a solid residue. The residue was suspended in 
EtOH (20 ml) and H2O (20 ml) and a NaOH 2M water solution (9 ml) was 
subsequently added. The mixture was heated to 45°C for 24 hours. After cooling, 
the mixture was acidified by addiction of HCl 1M until the formation of a 
precipitate. The precipitate was collected by filtration to give 4-methyl-3-{[4I-
(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzoic acid (1.1 g, 54% yield), m.p. 279°C. 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 9.27 (dd, J=2.0, J=0.7, 1H, 2II-H); 9.06 (broad s, 
1H, NH); 8.69 (dd, J=4.9, J=2.0, 1H, 6II-H); 8.54 (d, J=5.2, 1H, 6IH); 8.45 (dt, J=7.9, 
J=2.0, 1H, 4II-H); 8.29 (d, J=1.7, 1H, 2-H); 7.63 (dd, J=7.9, J=1.7, 1H, 6-H); 7.53 
(ddd, J=7.9, J=4.9, J=0.7, 1H, 5II-H); 7.48 (d, J=5.2, 1H, 5I-H); 7.36 (d, J=7.9, 1H, 5-
H); 2.33 (s, 3H, CH3). 
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5.3.1.3 SYNTHESIS OF o/p-VINYLBENZOIC ACID MOIETIES 
 
Synthesis of 2-(tert-butoxycarbonyl)aminoaniline  
 
 
 
A solution of di Boc2O (2.2 g, 10.0 mmol) in THF (3 ml) was added to a solution of 
o-phenylenediamine (1.1 g, 10 mmol) in THF (10 ml). The mixture was stirred at 
room temperature for 3 hours (TLC: CHCl3/MeOH 9/1). The solvent was 
evaporated under vacuum and the solid residue was dissolved in EtOAc (1 ml) 
and precipitated by addition of petrol ether (4 ml). The solid obtained was 
collected by filtration obtaining 2-(tert-butyloxycarbonylamino)aniline (1.4 g, 
69% yield), m.p. 114 °C. 
 
 
1H-NMR (300 MHz, CDCl3-d): δ 7.29-7.27 (m, 1H, 4-H); 6.99-6.97 (m, 2H, 3-H and 
5-H); 6.88 (dd, J=6.4, J=1.8, 1H, 6-H); 4.50 (broad s, 2H, NH2); 1.49 (s, 9H, CH3).  
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Synthesis of 4-(ethoxycarbonyl)benzaldehyde  
 
 
 
A solution of 4-formylbenzoic acid (5.5 g, 36.6 mmol) in EtOH (160 ml) and H2SO4 
96% (0.9 ml) was heated at reflux for 16 hours (TLC: CHCl3/MeOH 9/1). After 
cooling, the solvent was evaporated under vacuum obtaining a solid residue. The 
residue was dissolved in EtOAc (100 ml) and was washed with a NaHCO3 water 
solution (3 x 50 ml). The organic phase was dried over anhydrous sodium sulfate 
and was then evaporated under vacuum. The obtained solid was dissolved in 
acetone (140 ml) and I2 (0.9 g, 3.5 mmol) was added to the solution. The mixture 
was stirred at room temperature for 5 minutes; it was subsequently diluted with 
a water solution of sodium thiosulfate (150 ml). Acetone was removed under 
vacuum and the mixture extracted with EtOAc (3 x 50 ml). The organic phase was 
dried over anhydrous sodium sulfate and then evaporated under vacuum to 
afford 4-(ethoxycarbonyl)benzaldehyde (6.5 g, quantitative yield), m.p. 158°C. 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.11 (s, 1H, CHO); 8.15 (d, J=8.4, 2H, 3-H and 5-
H); 8.04 (d, J=8.4, 2H, 2-H and 6-H); 4.36 (q, J=7.0, 2H, CH2CH3); 1.34 (t, J=7.0, 3H, 
CH2CH3). 
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Synthesis of 3-(ethoxycarbonyl)benzaldehyde  
 
 
 
Compound 38 was obtained starting from 3-formylbenzoic acid (0.5 g, 3.0 mmol) 
with the same procedure as for compound 37 (0.5 g, quantitative yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.10 (s, 1H, CHO); 8.45 (t, J=1.8, 1H, 2-H); 8.25 
(dt, J=7.8, J=1.4, 1H, 4-H); 8.17 (dt, J=7.8, J=1.4, 1H, 6-H); 7.76 (t, J=7.8, 1H, 5-H); 
4.37 (q, J=7.1, 2H, CH2CH3); 1.35 (t, J=7.1, 3H, CH2CH3). 
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Synthesis of 4-(ethoxycarbonyl)cinnamic acid  
 
 
 
A mixture of 4-(ethoxycarbonyl)benzaldehyde (3.0 g, 16.8 mmol), malonic acid 
(3.5 g, 33.7 mmol) and pyridine (0.3 g, 3.4 mmol) in piperidine (8.4 ml) was 
heated to reflux for 2.5 hours (TLC: CHCl3/MeOH 9/1). After cooling, the mixture 
was slowly poured into H2O (70 ml) under stirring. The obtained precipitate was 
collected by filtration and purified by crystallization in EtOH to obtain 4-
(ethoxycarbonyl)cinnamic acid (2.3 g, 63% yield), m.p. 220°C. 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 12.56 (s, 1H, OH); 7.97 (d, J=8.3, 2H, 3-H and 5-
H); 7.83 (d, J=8.3, 2H, 2-H and 6-H); 7.63 (d, J=16.0, 1H, 1I-H); 6.66 (d, J=16.0, 1H, 
2I-H); 4.32 (q, J=7.1, 2H, CH2CH3); 1.32 (t, J=7.1, 3H, CH2CH3). 
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Synthesis of 3-(ethoxycarbonyl)cinnamic acid  
 
 
 
Compound 40 was obtained starting from 3-(ethoxycarbonyl)benzaldehyde (0.5 
g, 3.0 mmol), with the same procedure as for compound 39 (0.5 g, 70% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 12.51 (s, 1H, OH); 8.18 (t, J=1.8, 1H, 2-H); 8.01-
7.95 (m, 2H, 4-H and 6-H); 7.66 (d, J=16.2, 1H, 1I-H); 7.57 (t, J=7.7, 1H, 5-H); 6.61 
(d, J=16.2, 1H, 2I-H); 4.34 (q, J=7.1, 2H, CH2CH3); 1.34 (t, J=7.1, 3H, CH2CH3). 
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Synthesis of Ethyl-4-{2I-[(tert-butoxycarbonyl)aminophen-2II-yl]carbamoyl-
vinyl}benzoate  
 
 
 
Compound 41 was obtained starting from 4-(ethoxycarbonyl)cinnamic acid (0.2 
g, 0.7 mmol) and 2-(tert-butoxycarbonyl)aminoaniline (0.2 g, 0.8 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, 76% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 9.76 (s, 1H, NH); 8.49 (s, 1H, NH); 8.02 (d, J=8.4, 
2H, 2-H and 6-H); 7.78 (d, J=8.4, 2H, 3-H and 5-H); 7.65 (d, J=16.0, 1H, 1I-H); 7.62-
7.43 (m, 2H, 3II-H and 6II-H); 7.19-7.09 (m, 2H, 4II-H and 5II-H); 7.05 (d, J=16.0, 1H, 
2I-H); 4.33 (q, J=7.2, 2H, CH2CH3); 1.46 (s, 9H, 3 x CH3), 1.34 (t, J=7.2, 3H, CH2CH3). 
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Synthesis of Ethyl-3-{2I-[(tert-butoxycarbonyl)aminophen-2II-yl]carbamoyl-
vinyl}benzoate 
 
 
 
Compound 42 was obtained starting from 3-(ethoxycarbonyl)cinnamic acid (0.3 
g, 1.5 mmol) and 2-(tert-butoxycarbonyl)aminoaniline (0.3 g, 1.6 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1), (0.6 g, 92% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 9.74 (broad s, 1H, NH); 8.51 (broad s, 1H, NH); 
8.24 (s, 1H, 2-H); 7.98 (d, J=8.0, 1H, 6-H); 7.91 (d, J=8.0, 1H, 4-H); 7.71-7.54 (m, 
4H, 5-H, 1I-H, 3II-H and 6II-H); 7.20-7.08 (m, 2H, 4II-H and 5II-H); 7.05 (d, J=16.3, 
1H, 2I-H); 4.36 (q, J=7.0, 2H, CH2CH3); 1.46 (s, 9H, 3 x CH3); 1.35 (t, J=7.0, 3H, 
CH2CH3). 
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Synthesis of Ethyl-4-{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-
vinyl}benzoate  
 
 
 
A mixture of 4-(ethoxycarbonyl)cinnamic acid (0.9 g, 4.1 mmol), O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine (0.5 g, 4.5 mmol), BOP (2.0 g, 4.5 mmol) and TEA 
(1.2 ml, 9.0 mmol) was stirred at room temperature for 24 hours (TLC: 
CHCl3/MeOH 9/1 + vanillin). The mixture was diluted with a saturated water 
solution of NH4Cl (50 mL) and extracted with EtOAc (3 x 20 ml). The organic 
phase was dried over sodium sulfate, filtered and the solvent evaporated under 
vacuum. The solid residue was purified by flash chromatography (eluted with 
CE/EtOAc 4/6) to give Ethyl-4-{2I-[O-(tetrahydro-pyran-2II-
yl)hydroxylamino]carbonyl-vinyl}benzoate (0.8 g, yield 53%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.31 (broad s, 1H, NH); 7.98 (d, J=8.4, 2H, 2-H 
and 6-H); 7.72 (d. J=8.4, 2H, 3-H and 5-H); 7.54 (d, J=16.1, 1H, 1I-H); 6.63 (d, 
J=16.1, 1H, 2I-H); 4.92 (broad s, 1H, 2II-H); 4.32 (q, J=7.1, 2H, CH2CH3); 4.00-3.91 
(m, 1H, tetrahydropyran CH2); 3.58-3.50 (m, 1H, tetrahydropyran CH2); 1.76-1.66 
(m, 3H, tetrahydropyran CH2); 1.61-1.48 (m, 3H, tetrahydropyran CH2); 1.33 (t, 
J=7.1, 3H, CH2CH3). 
 
  
Experimental Procedures  
 
71 
 
Synthesis of Ethyl-3-{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-
vinyl}benzoate  
 
 
 
Compound 44 was obtained starting from 4-(ethoxycarbonyl)cinnamic acid (0.5 
g, 2.1 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.3 g, 2.3 mmol) 
with the same procedure as for compound 43 (0.5 g, yield 68%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.26 (s, 1H, NH); 8.14 (s, 1H, 2-H); 7.95 (d. 
J=7.7, 1H, 6-H); 7.85 (d, J=7.7, 1H, 4-H); 7.58 (t, J=7.7, 1H, 5-H); 7.56 (d, J=15.8, 
1H); 6.62 (d, J=15.8, 1H, 2I-H); 4.92 (broad s, 1H, 2II-H); 4.34 (q, J=6.9, 2H, 
CH2CH3); 4.00-3.91 (m, 1H, tetrahydropyran CH2); 3.58-3.51 (m, 1H, 
tetrahydropyran CH2); 1.76-1.64 (m, 3H, tetrahydropyran CH2); 1.61-1.50 (m, 3H, 
tetrahydropyran CH2); 1.34 (t, J=6.9, 3H, CH2CH3). 
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Synthesis of 4-{2I-[(tert-butoxycarbonyl)aminophen-2II-yl]carbamoyl-
vinyl}benzoic acid  
 
 
 
Compound 29 was obtained starting from Ethyl-4-{2I-[(tert-
butoxycarbonyl)aminophen-2II-yl]carbamoyl-vinyl}benzoate (0.2 g, 0.4 mmol) in 
THF with general method B (TLC: CHCl3/MeOH 9/1), (0.1 g, yield 77%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 9.78 (s, 1H, NH); 8.46 (s, 1H, NH); 8.15 (d, J=8.4, 
2H, 2-H and 6-H); 7.95 (d, J=8.4, 2H, 3-H and 5-H); 7.68 (d, J=16.0, 1H, 1I-H); 7.63-
7.43 (m, 2H, 3II-H and 6II-H); 7.19-7.07 (m, 2H, 4II-H and 5II-H); 7.10 (d, J=16.0, 1H, 
2I-H); 1.43 (s, 9H, 3 x CH3). 
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Synthesis of 3-{2I-[(tert-butoxycarbonyl)aminophen-2II-yl]carbamoyl-
vinyl}benzoic acid  
 
 
 
Compound 30 was obtained starting from Ethyl-3-{2I-[(tert-
butoxycarbonyl)aminophen-2II-yl]carbamoyl-vinyl}benzoate (0.5 g, 1.3 mmol) in 
THF with general method B (TLC: CHCl3/MeOH 9/1), (0.4 g, yield 81%). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 9.72 (broad s, 1H, NH); 8.51 (broad s, 1H, NH); 
8.24 (s, 1H, 2-H); 7.96 (d, J=7.7, 1H, 6-H); 7.86 (d, J=7.7, 1H, 4-H); 7.70-7.53 (m, 
4H, 5-H, 1I-H, 3II-H and 6II-H); 7.19-7.10 (m, 2H, 4II-H and 5II-H); 7.06 (d, J=15.5, 
1H, 2I-H); 1.46 (s, 9H, 3 x CH3). 
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Synthesis of 4-{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-
vinyl}benzoic acid  
 
 
 
A solution of NaOH (0.1 g, 2 mmol) in H2O (10 ml) was poured to a solution of 
Ethyl-4-{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-vinyl}benzoate 
(0.3 g, 0.9 mmol) in MeOH (10 ml). The mixture was heated at 70°C for 16 hours 
(TLC: CHCl3/MeOH 9/1 + vanillin). After cooling, the organic solvent was 
evaporated and the aqueous mixture was acidified with HCl 0.1M (pH = 6). The 
mixture was extracted with Et2O (3 x 5 ml), the organic phase was dried over 
sodium sulfate, filtered and the solvent evaporated under vacuum to afford 4-
{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-vinyl}benzoic acid (0.2 
g, yield 78%). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 11.34 (broad s, 1H, NH); 7.95 (d, J=8.5, 2H, 2-H 
and 6-H); 7.67 (d. J=8.5, 2H, 3-H and 5-H); 7.53 (d, J=15.9, 1H, 2I-H); 6.63 (d, 
J=15.9, 1H, 1I-H); 4.92 (broad s, 1H, 2II-H); 4.001-3.90 (m, 1H, tetrahydropyran 
CH2); 3.59-3.50 (m, 1H, tetrahydropyran CH2); 1.77-1.62 (m, 3H, tetrahydropyran 
CH2); 1.60-1.48 (m, 3H, tetrahydropyran CH2). 
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Synthesis of 3-{2I-[O-(tetrahydro-pyran-2II-yl)hydroxylamino]carbonyl-
vinyl}benzoic acid  
 
 
 
Compound 32 was obtained starting from Ethyl-3-{2I-[O-(tetrahydro-pyran-2II-
yl)hydroxylamino]carbonyl-vinyl}benzoate (0.5 g, 1.4 mmol) with the same 
procedure as for compound 31 (0.2 g, yield 86%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.23 (s, 1H, NH); 8.13 (s, 1H, 2-H); 7.94 (d. 
J=7.7, 1H, 6-H); 7.82 (d, J=7.7, 1H, 4-H); 7.58-7.51 (m, 2H, 5-H and 1I-H); 6.62 (d, 
J=16.0, 1H, 2I-H); 4.92 (broad s, 1H, 2II-H); 4.00-3.91 (m, 1H, tetrahydropyran 
CH2); 3.58-3.51 (m, 1H, tetrahydropyran CH2); 1.76-1.64 (m, 3H, tetrahydropyran 
CH2); 1.61-1.50 (m, 3H, tetrahydropyran CH2). 
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5.3.1.4 SYNTHESIS OF m/p-{2IV-CARBAMOYL-VINYL}-N-{4I-METHYL-3I-[4II-
(PYRIDIN-3III-YL)PYRIMIDIN-2II-YL]AMINOPHENYL}BENZAMIDE DERIVATIVES 
 
Synthesis of 4-{2IV-[(tert-butoxycarbonyl)aminophen-2V-yl]carbamoyl-vinyl}-N-
{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 45 was obtained starting from 4-{2I-[(tert-
butoxycarbonyl)aminophen-2II-yl]carbamoyl-vinyl}benzoic acid (0.1 g, 0.2 mmol) 
and NI-(2-methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.1 
g, 0.3 mmol) with general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, quantitative 
yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.27 (broad s, 1H, NH); 9.75 (broad s, 1H, NH); 
9.28 (dd, J=2.3, J=0.7, 1H, 2III-H); 8.98 (s, 1H, NH); 8.69 (dd, J=4.9, J=1.7, 1H, 6III-
H); 8.52 (d, J=5.3, 1H, 6II-H); 8.49 (broad s, 1H, NH); 8.47 (ddd, J=8.1, J=2.3, J=1.7, 
1H, 4III-H); 8.10 (d, J=2.1, 1H, 2I-H); 8.03 (d, J=8.4, 2H, 2-H and 6-H); 7.79 (d, J=8.4, 
2H, 3-H and 5-H); 7.67 (d, J=15.8, 1H, 1IV-H); 7.62-7.56 (m, 2H, 3V-H and 6V-H); 
7.52 (ddd, J=8.1, J=4.9, J=0.7, 1H, 5III-H); 7.50 (dd, J=8.0, J=2.1, 1H, 6I-H); 7.43 (d, 
J=5.3, 1H, 5II-H); 7.22 (d, J=8.0, 1H, 5I-H); 7.19-7.09 (m, 2H, 4V-H and 5V-H); 7.04 
(d, J=15.8, 1H, 2IV-H); 2.23 (s, 3H, CH3); 1.46 (s, 9H, 3 x CH3). 
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Synthesis of 3-{2IV-[(tert-butoxycarbonyl)aminophen-2V-yl]carbamoyl-vinyl}-N-
{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 46 was obtained starting from 3-{2I-[(tert-
butoxycarbonyl)aminophen-2II-yl]carbamoyl-vinyl}benzoic acid (0.2 g, 0.4 mmol) 
and NI-(2-methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.1 
g, 0.4 mmol) with general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, quantitative 
yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.30 (broad s, 1H, NH); 9.73 (broad s, 1H, NH); 
9.28 (d, J=2.1, 1H, 2III-H); 8.97 (s, 1H, NH); 8.69 (dd, J=4.6, J=1.6, 1H, 6III-H); 8.52 
(d, J=5.1, 1H, 6II-H); 8.50-8.44 (m, 2H, NH and 4III-H); 8.23 (t, J=1.6, 1H, 2-H); 8.08 
(d, J=2.1, 1H, 2I-H); 7.97 (d, J=7.8, 1H, 6-H); 7.84 (d, J=7.8, 1H, 4-H); 7.74-7.65 (m, 
2H, 1IV-H and 5III-H); 7.52-7.49 (m, 4H, 5-H, 6I-H, 3V-H and 6V-H); 7.43 (d, J=5.1, 
1H, 5II-H); 7.23 (d, J=8.5, 1H, 5I-H); 7.19-7.09 (m, 2H, 4V-H and 5V-H); 7.04 (d, 
J=16.1, 1H, 2IV-H); 2.23 (s, 3H, CH3); 1.46 (s, 9H, 3 x CH3). 
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Synthesis of 4-{2IV-[O-(tetrahydro-pyran-2V-yl)hydroxylamino]carbonyl-vinyl}-N-
{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 47 was obtained starting from 4-{2I-[O-(tetrahydro-pyran-2II-
yl)hydroxylamino]carbonyl-vinyl}benzoic acid (0.2 g, 0.7 mmol) and NI-(2-methyl-
5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.2 g, 0.8 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1 + vanillin), (0.2 g, yield 52%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.30 (broad s, 1H, NH); 10.24 (s, 1H, NH); 9.28 
(dd, J=2.2, J=0.6, 1H, 2III-H); 8.96 (s, 1H, NH); 8.68 (dd, J=4.8, J=1.7, 1H, 6III-H); 
8.51 (d, J=5.1, 1H, 6II-H);8.48 (ddd, J=8.0, J=2.2, J=1.7, 1H-4III-H); 8.09 (d, J=2.0, 
1H, 2I-H); 7.99 (d, J=8.4, 2H,2-H and 6-H); 7.72 (d, J=8.4, 2H, 3-H and 5-H); 7.59-
7.47 (m, 3H, 1IV-H, 5III-H and 6I-H); 7.43 (d, J=5.1, 1H, 5II-H); 7.21 (d, J=8.3, 1H, 5I-
H); 6.63 (d, J=16.0, 1H, 2IV-H); 4.93 (broad s, 1H, 2V-H); 4.01-3.92 (m, 1H, 
tetrahydropyran CH2); 3.58-3.51 (m, 1H, tetrahydropyran CH2); 2.23 (s, 3H, CH3); 
1.76-1.64 (m, 3H, tetrahydropyran CH2); 1.62-1.49 (m, 3H, tetrahydropyran CH2). 
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Synthesis of 3-{2IV-[O-(tetrahydro-pyran-2V-yl)hydroxylamino]carbonyl-vinyl}-N-
{4I-methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 48 was obtained starting from 3-{2I-[O-(tetrahydro-pyran-2II-
yl)hydroxylamino]carbonyl-vinyl}benzoic acid (0.2 g, 0.8 mmol) and NI-(2-methyl-
5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.3 g, 0.9 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1 + vanillin), (0.2 g, yield 40%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.27 (broad s, 1H, NH); 10.27 (s, 1H, NH); 9.28 
(dd, J=2.2, J=0.7, 1H, 2III-H); 8.97 (s, 1H, NH); 8.69 (dd, J=4.8, J=1.8, 1H, 6III-H); 
8.52 (d, J=5.3, 1H, 6II-H);8.47 (ddd, J=8.0, J=2.2, J=1.8, 1H-4III-H); 8.15 (t, J=1.4, 1H, 
2-H); 8.09 (d, J=2.1, 1H, 2I-H); 7.94 (dt, J=7.9, J=1.4, 1H, 6-H); 7.78 (dt, J=7.9, 
J=1.4, 1H, 4-H); 7.57 (t, J=7.9, 1H, 5-H); 7.56 (d, J=16.1, 1H, 1IV-H); 7.52 (ddd, 
J=8.0, J=4.8, J=0.7, 1H, 5III-H); 7.49 (dd, J=8.3, J=2.1, 1H, 6I-H);7.43 (d, J=5.3, 1H, 
5II-H); 7.22 (d, J=8.3, 1H, 5I-H); 6.63 (d, J=16.1, 1H, 2IV-H); 4.93 (broad s, 1H, 2V-H); 
3.99-3.92 (m, 1H, tetrahydropyran CH2); 3.57-3.50 (m, 1H, tetrahydropyran CH2); 
2.24 (s, 3H, CH3); 1.73-1.66 (m, 3H, tetrahydropyran CH2); 1.60-1.48 (m, 3H, 
tetrahydropyran CH2). 
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Synthesis of 4-[2Iv-(aminophen-2V-yl)carbamoyl-vinyl]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 1 was obtained starting from 4-{2IV-[(tert-
butoxycarbonyl)aminophen-2V-yl]carbamoyl-vinyl}-N-{4I-methyl-3I-[4II-(pyridin-
3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.2 g, 0.3 mmol) accordingly to 
the general method C (TLC: CHCl3/MeOH 9/1), (0.1 g, yield 72%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H, NH); 9.75 (broad s, 1H, NH); 9.28 
(dd, J=2.2, J=0.7, 1H, 2III-H); 8.98 (s, 1H, NH); 8.69 (dd, J=4.7, J=1.7, 1H, 6III-H); 
8.52 (d, J=5.0, 1H, 6II-H); 8.48 (ddd, J=8.0, J=2.2, J=1.7, 1H, 4III-H); 8.10 (d, J=2.0, 
1H, 2I-H); 8.03 (d, J=8.5, 2H, 2-H and 6-H); 7.79 (d, J=8.5, 2H, 3-H and 5-H); 7.67 
(d, J=15.6, 1H, 1IV-H); 7.62-7.56 (m, 2H, 3V-H and 6V-H); 7.53 (ddd, J=8.0, J=4.7, 
J=0.7, 1H, 5III-H); 7.50 (dd, J=8.1, J=2.0, 1H, 6I-H); 7.43 (d, J=5.0, 1H, 5II-H); 7.22 (d, 
J=8.1, 1H, 5I-H); 7.17 (td, J=7.7, J=1.7, 1H, 4v-H); 7.12 (td, J=7.7, J=1.7, 1H, 5V-H); 
7.04 (d, J=15.8, 1H, 2IV-H); 2.23 (s, 3H, CH3). 
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Synthesis of 3-[2IV-(aminophen-2V-yl)carbamoyl-vinyl]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 2 was obtained starting from 3-{2Iv-[(tert-butoxycarbonyl)aminophen-
2v-yl]carbamoyl-vinyl}-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (0.3 g, 0.4 mmol) accordingly to the general method 
C (TLC: CHCl3/MeOH 9/1), (0.2 g, quantitative yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.32 (s, 1H, NH); 9.45 (s, 1H, NH); 9.28 (d, J=1.5, 
1H, 2III-H); 9.00 (s, 1H, NH); 8.69 (dd, J=4.8, J=1.5, 1H, 6III-H); 8.52 (d, J=5.3, 1H, 
6II-H); 8.48 (dt, J=7.9, J=1.5, 1H, 4III-H); 8.20 (s, 1H, 2-H); 8.09 (d, J=1.5, 1H, 2I-H); 
7.96 (d, J=7.7, 1H, 6-H); 7.82 (d, J=7.7, 1H, 4-H); 7.64 (d, J=15.9, 1H, 1IV-H); 7.62-
7.48 (m, 3H, 5-H, 6I-H and 5III-H); 7.43 (d, J=5.3, 1H, 5II-H); 7.36 (dd, J=7.9, J=1.4, 
1H, 6V-H); 7.23 (d, J=7.9, 1H, 5I-H); 7.03 (d, J=15.9, 1H, 2IV-H); 6.93 (td, J=7.9, 
J=1.4, 1H, 4V-H); 6.75 (dd, J=7.9, J=1.4, 1H, 3V-H); 6.59 (td, J=7.9, J=1.4, 1H, 5V-H); 
4.97 (broad s, 1H, NH); 2.23 (s, 3H, CH3). 
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Synthesis of 4-[2IV-(hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-[4II-(pyridin-
3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 3 was obtained starting from 4-{2Iv-[O-(tetrahydro-pyran-2v-
yl)hydroxylamino]carbonyl-vinyl}-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (0.2 g, 0.4 mmol) accordingly to the general method 
D (TLC: CHCl3/MeOH 9/1 + vanillin), (55 mg, yield 33%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H, NH); 9.38 (d, J=1.7, 1H, 2III-H); 9.08 
(s, 1H, NH); 8.82 (dd, J=5.2, J=1.7, 1H, 6III-H); 8.79 (dt, J=8.0, J=1.7, 1H, 4III-H);8.58 
(d, J=5.0, , 1H-6II-H); 8.13 (d, J=1.9, 1H, 2I-H); 8.00 (d, J=8.2, 2H,2-H and 6-H); 7.79 
(dd, J=8.0, J=5.2, 1H, 5III-H); 7.70 (d, J=8.2, 2H, 3-H and 5-H); 7.55-7.49 (m, H, 1IV-
H and 5II-H); 7.47 (dd, J=8.2, J=1.9, 1H, 6I-H); 7.22 (d, J=8.2, 1H, 5I-H); 6.59 (d, 
J=15.9, 1H, 2IV-H); 2.23 (s, 3H, CH3). 
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 4 was obtained starting from 3-{2Iv-[O-(tetrahydro-pyran-2v-
yl)hydroxylamino]carbonyl-vinyl}-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (0.2 g, 0.3 mmol) accordingly to the general method 
D (TLC: CHCl3/MeOH 9/1 + vanillin), (0.1 g, yield 55%). 
 
1H-NMR (500 MHz, DMSO-d6): δ 10.37 (s, 1H, NH); 9.52 (d, J=1.4, 1H, 2III-H); 9.26 
(s, 1H, NH); 9.12 (dt, J= 8.0, J=1.4, 1H, 4III-H); 8.98 (d, J=5.0, 1H, 6III-H); 8.64 (d, 
J=5.2, 1H, 6II-H); 8.17 (d, J=2.2, 1H, 2I-H); 8.15 (t, J=1.6, 1H, 2-H); 8.07 (dd, J=8.0, 
J=5.0, 1H, 5III-H); 7.96 (dt, J=8.2, J=1.6, 1H, 6-H); 7.76 (dt, J=8.2, J=1.6, 1H, 4-H); 
7.61 (d, J=5.2, 1H, 5II-H); 7.56 (t, J=8.2, 1H, 5-H); 7.53 (d, J=16.0, 1H, 1IV-H); 7.46 
(dd, J=8.3, J=2.2, 1H, 6I-H); 7.23 (d, J=8.3, 1H, 5I-H); 6.62 (d, J=16.0, 1H, 2IV-H); 
2.24 (s, 3H, CH3). 
 
13C-NMR (500 MHz, DMSO-d6): δ 165.12; 162.43; 160.75; 159.81; 159.31; 145.05; 
142.38; 141.45; 137.52; 137.34; 137.12; 135.70; 135.01; 134.85; 130.43; 130.24; 
129.08; 128.64; 127.65; 126.62; 126.52; 120.31; 117.21; 117.03; 107.97; 17.64. 
 
IR νmax/cm-1: 3423 (hydroxamic acid N-H); 3233 (hydroxamic acid O-H); 1654 
(benzamide C=O); 1581 (hydroxamic acid C=O); 1552 (hydroxamic acid C-N).  
 
Elemental analysis for C26H22N6O3 :  
Calcd: C 66.94%; H 4.75%; N 18.02%. Found: C 65.80%; H 4.05%; N 16.98%. 
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5.3.1.5 SYNTHESIS OF PHTHALAMIC ACID MOIETIES 
 
 
Synthesis of Methyl-N-[2I-(tert-butoxycarbonyl)aminophenyl]terephthalamate  
 
 
 
Compound 55 was obtained starting from mono-methyl terephthalate (0.3 g, 1.5 
mmol) and 2-(tert-butoxycarbonyl)aminoaniline (0.3 g, 1.6 mmol) with general 
method A (TLC: CHCl3/MeOH 9/1), (0.6 g, quantitative yield), m.p. 145°C. 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 9.97 (broad s, 1H, NH); 8.69 (broad s, 1H, NH); 
8.13-8.06 (m, 4H, 2-H, 3-H, 5-H and 6-H); 7.58-7.51 (m, 2H, 3I-H and 6I-H); 7.24-
7.12 (m, 2H, 4I-H and 5IH); 3.90 (s, 3H, CH3); 1.44 (s, 9H, 3 x CH3). 
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Synthesis of Methyl-N-[2I-(tert-butoxycarbonyl)aminophenyl]isophthalamate  
 
 
 
Compound 56 was obtained starting from mono-methyl isophthalate (0.2 g, 1.0 
mmol) and 2-(tert-butoxycarbonyl)aminoaniline (0.2 g, 1.1 mmol) with general 
method A (TLC: CHCl3/MeOH 9/1), (0.3 g, yield 80%), m.p.130°C. 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.02 (broad s, 1H, NH); 8.70 (broad s, 1H, NH); 
8.54 (t, J=1.6, 1H, 2-H); 8.23 (dt, J=7.7, J=1.6, 1H, 6-H); 8.18 (dt, J=7.7, J=1.6, 1H, 
4-H); 7.71 (t, J=7.7, 1H, 5-H)); 7.59-7.49 (m, 2H, 3I-H and 6I-H); 7.25-7.12 (m, 2H, 
4I-H and 5IH); 3.91 (s, 3H, CH3); 1.43 (s, 9H, 3 x CH3). 
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Synthesis of Methyl-N-[O-(tetrahydro-pyran-2I-yl)hydroxy]terephthalamate  
 
 
 
Compound 57 was obtained starting from mono-methyl terephthalate (0.1 g, 0.7 
mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.1 g, 0.8 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, yield 86%), m.p. 79°C. 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.04 (d, J=8.3, 2H,2-H and 6-H); 7.88 (d, J=8.3, 
2H, 3-H and 5-H); 5.02 (broad s, 1H, 2I-H); 4.10-4.00 (m, 1H, tetrahydropyran 
CH2); 3.88 (s, 3H, CH3); 3.57-3.49 (m, 1H, tetrahydropyran CH2); 1.77-1.66 (m, 3H, 
tetrahydropyran CH2); 1.62-1.50 (m, 3H, tetrahydropyran CH2). 
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Synthesis of N-[2I-(tert-butoxycarbonyl)aminophenyl]terephthalamic acid  
 
 
 
Compound 50 was obtained starting from Methyl-N-[2I-(tert-
butoxycarbonyl)aminophenyl]terephthalamate (0.6 g, 1.5 mmol) in MeOH with 
general method B (TLC: CHCl3/MeOH 9/1), (0.3 g, yield 58%), m.p. 190°C. 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 9.93 (broad s, 1H, NH); 8.69 (broad s, 1H, NH); 
8.09-8.00 (m, 4H, 2-H, 3-H, 5-H and 6-H); 7.57-7.52 (m, 2H, 3I-H and 6I-H); 7.24-
7.13 (m, 2H, 4I-H and 5IH); 1.44 (s, 9H, 3 x CH3). 
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Synthesis of N-[2I-(tert-butoxycarbonyl)aminophenyl]isophthalamic acid  
 
 
 
Compound 51 was obtained starting from Methyl-N-[2I-(tert-
butoxycarbonyl)aminophenyl]isophthalamate (0.3 g, 0.8 mmol) in MeOH with 
general method B (TLC: CHCl3/MeOH 9/1), (0.2 g, yield 76%). 
 
 
1H-NMR (400 MHz, Acetone-d6): δ 9.85 (broad s, 1H, NH); 8.68 (t, J=1.7, 1H, 2-H); 
8.29-8.23 (m, 2H, 4-H and 6-H); 7.79-7.67 (m, 2H, 5-H and 3I-H or 6I-H); 7.62 (dd, 
J=7.7, J=1.7, 1H, 3I-H or 6I-H); 7.26-7.17 (m, 2H, 4I-H and 5I-H); 1.47 (s, 9H, 3 x 
CH3). 
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Synthesis of N-[O-(tetrahydro-pyran-2I-yl)hydroxy]terephthalamic acid  
 
 
 
Compound 52 was obtained starting from Methyl-4-{[O-(tetrahydro-pyran-2I-
yl)hydroxylamino]carbonyl}benzoate (0.2 g, 0.6 mmol) in THF with general 
method B (TLC: CHCl3/MeOH 9/1), (0.1 g, yield 74%), m.p. 180°C. 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.79 (s, 1H, NH); 8.01 (d, J=8.4, 2H,2-H and 6-
H); 7.85 (d, J=8.4, 2H, 3-H and 5-H); 5.01 (broad s, 1H, 2I-H); 4.10-4.00 (m, 1H, 
tetrahydropyran CH2); 3.57-3.49 (m, 1H, tetrahydropyran CH2); 1.77-1.66 (m, 3H, 
tetrahydropyran CH2); 1.62-1.50 (m, 3H, tetrahydropyran CH2). 
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5.3.1.6 SYNTHESIS OF N-{4I-METHYL-3I-[4II-(PYRIDIN-3III-YL)PYRIMIDIN-2II-
YL]AMINOPHENYL}PHTHALAMIDE DERIVATIVES 
 
Synthesis of NI-[(tert-butoxycarbonyl)aminophen-2IV-yl]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}terephthalamide  
 
 
 
Compound 58 was obtained starting from N-[2I-(tert-
butoxycarbonyl)aminophenyl]terephthalamic acid (0.1 g, 0.2 mmol) and NI-(2-
methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.1 g, 0.3 
mmol) with general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, quantitative yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.35 (broad s, 1H, NH); 9.95 (broad s, 1H, NH); 
9.28 (dd, J=2.2, J=0.8, 1H, 2III-H); 8.97 (broad s, 1H, NH); 8.70 (broad s, 1H, NH); 
8.69 (dd, J=4.9, J=1.7, 1H, 6III-H); 8.52 (d, J=5.1, 1H, 6II-H); 8.48 (ddd, J=8.0, J=2.2, 
J=1.7, 1H, 4III-H); 8.13-8.06 (m, 5H, 5 x Ar-H); 7.56 (dd, J=8.1, J=1.5, 1H, 6I-H); 
7.54-7.49 (m, 3H, 3 x Ar-H); 7.44 (d, J=5.1, 1H, 5II-H); 7.26-7.14 (m, 3H, 3 x Ar-H); 
2.24 (s, 3H, CH3); 1.45 (s, 9H, 3 x CH3). 
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Synthesis of NI-[(tert-butoxycarbonyl)aminophen-2IV-yl]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}isophthalamide  
 
 
 
Compound 59 was obtained starting from N-[2I-(tert-
butoxycarbonyl)aminophenyl]isophthalamic acid (0.2 g, 0.4 mmol) and NI-(2-
methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.1 g, 0.4 
mmol) with general method A (TLC: CHCl3/MeOH 9/1), (0.2 g, yield 95%). 
 
 
1H-NMR (400 MHz, Acetone-d6): δ 9.89 (broad s, 1H, NH); 9.86 (broad s, 1H, NH); 
9.33 (dd, J=2.0, J=0.9, 1H, 2III-H); 8.68-5.56 (m, 4H, NH and 3 x Ar-H); 8.53 (dd, 
J=5.1, J=1.7, 1H, 6II-H); 8.25-8.17 (m, 2H, 4-H and 6-H); 8.01 (broad s, 1H, NH); 
7.74-7.67 (m, 2H, 5-H and 3IV-H or 6IV-H); 7.65 (dd, J=8.0, J=1.5, 1H, 6I-H); 7.60 (d, 
J=8.2,1H, 3IV-H or 6IV-H); 7.49 (dd, J=8.1, J=5.1, 1H, 5III-H); 7.42 (d, J=5.1, 1H, 5II-
H);7.27-7.23 (m, 2H, 4IV-H and 5IV-H); 7.22 (m, 2H, 2 x Ar-H); 2.37 (s, 3H, CH3); 
1.45 (s, 9H, 3 x CH3). 
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Synthesis of NI-[O-(tetrahydro-pyran-2IV-yl)hydroxy]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}therephthalamide  
 
 
 
Compound 60 was obtained starting from N-[O-(tetrahydro-pyran-2Iv-
yl)hydroxy]terephthalamic acid (0.1 g, 0.4 mmol) and NI-(2-methyl-5-
aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.1 g, 0.5 mmol) with 
general method A (TLC: CHCl3/MeOH 9/1 + vanillin), (0.2 g, quantitative yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.79 (s, 1H, NH); 10.31 (broad s, 1H, NH); 9.28 
(dd, J=2.0, J=0.6, 1H, 2III-H); 8.96 (broad s, 1H, NH); 8.68 (dd, J=4.7, J=2.0, 1H, 6III-
H); 8.52 (d, J=5.2, 1H, 6II-H);8.48 (dt, J=7.9, J=2.0, 1H, 4III-H); 8.10 (d, J=1.9, 1H, 2I-
H); 8.04 (d, J=8.3, 2H, 2-H and 6-H); 7.89 (d, J=8.4, 2H, 3-H and 5-H); 7.52 (ddd, 
J=7.9, J=4.7, J=0.6, 1H, 5III-H); 7.49 (dd, J=8.3, J=1.9, 1H, 6I-H); 7.43 (d, J=5.2, 1H, 
5II-H); 7.22 (d, J=8.3, 1H, 5I-H); 5.03 (s, 1H, 2IV-H); 4.12-4.03 (m, 1H, 
tetrahydropyran CH2); 3.59-3.50 (m, 1H, tetrahydropyran CH2); 2.23 (s, 3H, CH3); 
1.79-1.67 (m, 3H, tetrahydropyran CH2); 1.63-1.49 (m, 3H, tetrahydropyran CH2). 
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Synthesis of NI-(aminophen-2IV-yl)-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-
2II-yl]aminophenyl}terephthalamide  
 
 
 
Compound 5 was obtained starting from NI-[(tert-butoxycarbonyl)aminophen-
2IV-yl]-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}terephthalamide (0.3 g, 0.5 mmol) with general method C (TLC: 
CHCl3/MeOH 9/1), (0.2 g, yield 72%). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.33 (broad s, 1H, NH); 9.79 (broad s, 1H, NH); 
9.28 (dd, J=2.0, 1H, 2III-H); 8.97 (broad s, 1H, NH); 8.69 (dd, J=5.0, J=1.5, 1H, 6III-
H); 8.52 (d, J=5.1, 1H, 6II-H); 8.48 (dd, J=8.0, J=2.0, 1H, 4III-H); 8.15-8.06 (m, 5H, 5 
x Ar-H); 7.55-7.49 (m, 2H, 2 x Ar); 7.44 (d, J=5.1, 1H, 5II-H); 7.23 (d, J=8.3, 1H, 5I-
H); 7.19 (dd, J=7.5, J=1.5, 1H, 6IV-H); 6.99 (td, J=7.5, J=1.5, 1H, 4IV-H); 6.79 (d, 
J=7.5, J=1.5, 1H, 3IV-H); 6.61 (d, J=7.5, J=1.5, 1H, 5IV-H); 4.94 (s, 2H, NH2); 2.24 (s, 
3H, CH3). 
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Synthesis of NI-(aminophen-2IV-yl)-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-
2II-yl]aminophenyl}isophthalamide  
 
 
 
Compound 6 was obtained starting from NI-[(tert-butoxycarbonyl)aminophen-
2IV-yl]-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}isophthalamide (0.4 g, 0.6 mmol) with general method C (TLC: 
CHCl3/MeOH 9/1), (0.4 g, quantitative yield). 
 
 
1H-NMR (400 MHz, Acetone-d6): δ 9.78 (broad s, 1H, NH); 9.33 (dd, J=2.0, 1H, 2III-
H); 8.66 (dd, J=4.8, J=2.0, 1H, 6III-H); 8.63-8.56 (m, 2H, 2I-H and 4III-H); 8.53 (d, 
J=5.1, 1H, 6II-H); 8.48 (t, J=1.5, 1H, 2-H); 8.22 (dt, J=7.8, J=1.4, 1H, 4-H or 6-H); 
8.08 (dt, J=7.8, J=1.4, 1H, 4-H or 6-H); 7.69 (t, J=7.8, 1H, 5-H); 7.56 (dt, J=8.3, 
J=2.1, 1H, 6I-H); 7.50 (dd, J=8.0, J=4.8, 1H, 5III-H); 7.43 (d, J=5.1, 1H, 5II-H); 7.26 (d, 
J=8.1, 1H, 5I-H);7.17-7.08 (m, 2H, 4IV-H and 5IV-H); 6.81-6.77 (m, 2H, 3IV-H and 6IV-
H);2.37 (s, 3H, CH3). 
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Synthesis of NI-hydroxy-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}therephthalamide  
 
 
 
Compound 7 was obtained starting from NI-[O-(tetrahydro-pyran-2Iv-yl)hydroxy]-
N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}therephthalamide 
(0.2 g, 0.4 mmol) with general method D (TLC: CHCl3/MeOH 9/1), (40 mg, 20% 
yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.37 (broad s, 1H, NH); 10.31 (s, 1H, NH); 9.36 
(d, J=1.5, 1H, 2III-H); 9.06 (broad s, 1H, NH); 8.79 (dd, J=5.0, J=1.5, 1H, 6III-H); 
8.72(dt, J=8.3, J=1.5, 1H, 4III-H); 8.56 (d, J=5.2, 1H, 6II-H); 8.13 (d, J=1.9, 1H, 2I-H); 
8.02 (d, J=8.3, 2H, 2-H and 6-H); 7.88 (d, J=8.4, 2H, 3-H and 5-H); 7.73 (dd, J=8.3, 
J=5.0, 1H, 5III-H); 7.49 (d, J=5.2, 1H, 5II-H); 7.47 (d, J=8.0, J=1.9, 1H, 6I-H); 7.22 (d, 
J=8.0, 1H, 5I-H); 2.23 (s, 3H, CH3). 
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5.3.1.7 SYNTHESIS OF 3-{2IV-CARBAMOYL-VINYL}-5-TRIFLUOROMETHYL-N-{4I-
METHYL-3I-[4II-(PYRIDIN-3III-YL)PYRIMIDIN-2II-YL]AMINOPHENYL} BENZAMIDE 
DERIVATIVES 
 
Synthesis of 3-Bromo-5-trifluoromethylbenzoic acid  
 
 
 
N-Bromosuccinimide (1.3 g, 7.5 mmol) and sulphuric acid 18M (0.7 ml) were 
added to a solution of 3-trifluoromethylbenzoic acid (1.0 g, 5.0 mmol) in 
trifluoroacetic acid (2.5 ml). The mixture was stirred 5 hours at 60°C (TLC: 
CHCl3/MeOH 9/1). After cooling the mixture was poured into water and ice (30 
ml) and the obtained precipitate was collected by filtration to give 3-Bromo-5-
trifluoromethylbenzoic acid (1.2 g, 91% yield), mp: 134°C.  
 
 
1H-NMR (400 MHz, CDCl3-d): δ 8.38 (t, J=1.6, 1H, 2-H); 8.23 (t, J=1.6, 1H, 6-H); 
8.09 (t, J=1.6, 1H, 4-H). 
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Synthesis of 3-(2I-ethoxycarbonyl-vinyl)-5-trifluoromethylbenzoic acid  
 
 
 
A mixture of 3-bromo-5-trifluoromethylbenzoic acid (1.1 g, 4.0 mmol), ethyl 
acrylate (0.5 ml, 5.0 mmol), tetrakis(triphenilphosphine)palladium(0) (9 mg, 0.04 
mmol) and TEA (0.7 ml, 5.0 mmol) was sealed into a vial. The mixture was heated 
at 100°C for 16 hours ((TLC: CE/EtOAc 2/8). After cooling the mixture was added 
to HCl 0.1M (40 ml) and the precipitate collected by filtration and washed with n-
hexane to give the 3-(2I-ethoxycarbonyl-vinyl)-5-trifluoromethylbenzoic acid 
(0.7 g, 62% yield). 
 
 
1H-NMR (400 MHz, MeOD-d4): δ 8.46 (broad s, 1H, 2-H); 8.27 (broad s, 1H, 6-H); 
8.13 (broad s, 1H, 4-H); 7.79(d, J=16.1, 1H, 1I-H); 6.71 (d, J=16.1, 1H, 2I-H); 4.27 
(q, J=7.3, 2H, CH2CH3); 1.34 (t, J=7.3, 3H, CH2CH3). 
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Synthesis of 3-(2IV-ethoxycarbonyl-vinyl)-5-trifluoromethyl-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 64 was obtained starting from 3-(2I-ethoxycarbonyl-vinyl)-5-
trifluoromethylbenzoic acid (0.6 g, 2.0 mmol) and NI-(2-methyl-5-aminophenyl)-
N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (0.6 g, 2.2 mmol) with condensation 
method A (TLC: CHCl3/MeOH 9/1), (1.2 g, quantitative yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.45 (s, 1H, NH); 9.30 (dd, J=2.2, J=0.8, 1H, 2III-
H); 9.0 (s, 1H, NH); 8.69 (dd, J=4.8, J=1.7, 1H, 6III-H);8.60 (broad s, 1H, 2-H); 8.52 
(d, J=5.1, 1H, 6II-H); 8.48 (ddd, J=8.0, J=2.2, J=1.7, 1H-4III-H); 8.35 (broad s, 1H, 6-
H); 8.26 (broad s, 1H, 4-H); 8.11 (d, J=1.9, 1H, 2I-H); 7.84 (d, J=16.1, 1H, 1IV-H); 
7.53 (ddd, J=8.0, J=4.8, J=0.8, 1H, 5III-H); 7.49 (dd, J=8.2, J=1.9, 1H, 6I-H); 7.45 (d, 
J=5.1, 1H, 5II-H); 7.25 (d, J=8.2, 1H, 5I-H); 6.97 (d, J=16.1, 1H, 2IV-H); 4.22 (q, J=7.2, 
2H, CH2CH3); 2.24 (s, 3H, CH3); 1.27 (t, J=7.2, 3H, CH2CH3). 
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Synthesis of 3-(2IV-hydroxycarbonyl-vinyl)-5-trifluoromethyl-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 65 was obtained starting from 3-(2IV-ethoxycarbonyl-vinyl)-5-
trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (1.1 g, 2.0 mmol) in THF with general method B (TLC: 
CHCl3/MeOH 9/1), (1.0 g, 92% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 12.65 (broad s, 1H, OH); 10.46 (s, 1H, NH); 9.31 
(dd, J=2.2, J=0.7, 1H, 2III-H); 9.02 (s, 1H, NH); 8.71 (dd, J=4.8, J=1.6, 1H, 6III-H); 
8.58 (t, J=1.7, 1H, 2-H); 8.53 (d, J=5.2, 1H, 6II-H); 8.52 (ddd, J=8.0, J=2.2, J=1.6, 1H, 
4III-H); 8.30 (t, J=1.7, 1H, 6-H); 8.25 (t, J=1.7, 1H, 4-H); 8.11 (d, J=2.1, 1H, 2I-H); 
7.77 (d, J=16.0, 1H, 1IV-H); 7.56 (ddd, J=8.0, J=4.8, J=0.7, 1H, 5III-H); 7.49 (dd, 
J=8.2, J=2.1, 1H, 6I-H); 7.46 (d, J=5.2, 1H, 5II-H); 7.25 (d, J=8.2, 1H, 5I-H); 6.85 (d, 
J=16.1, 1H, 2IV-H); 2.24 (s, 3H, CH3). 
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Synthesis of 3-{2IV-[2V-(tert-butoxycarbonyl)aminophenyl]carbamoyl-vinyl}-5-
trifluoromethyl-N-{4I-methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide  
 
 
 
Compound 66 was obtained starting from 3-(2IV-hydroxycarbonyl-vinyl)-5-
trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (0.3 g, 0.5 mmol) and 2-(tert-
butoxycarbonyl)aminoaniline (0.1 g, 0.6 mmol) accordingly to the general 
method B (TLC: CHCl3/MeOH 9/1), (0.4 g, quantitative yield). 
 
 
1H-NMR (300 MHz, Acetone-d6): δ 9.88 (s broad, 1H, NH); 9.42 (s broad, 1H, NH); 
9.37 (d, J=1.6, 1H, 2III-H); 8.70 (dd, J=5.1, J=1.6, 1H, 6III-H); 8.61-8.52 (m, 4H, 2I-H, 
6II-H, 4III-H and NH); 8.33 (s, 1H, 2-H); 8.18 (s, 1H, 6-H); 8.03 (s, 1H, 4-H); 7.87 (d, 
J=16.0, 1H, 1IV-H); 7.71 (d, J=8.1, 1H, 6V-H); 7.63-7.54 (m, 2H, 6I-H and 3V-H); 7.52 
(dd, J=8.0, J=5.1, 1H, 5III-H); 7.44 (d, J=5.1, 1H, 5II-H); 7.30-7.23 (m, 4H, 5I-H, 2IV-H, 
4V-H and 5V-H); 2.38 (s, 3H, CH3); 1.47 (s, 9H, 3 x CH3). 
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Synthesis of 3-{2IV-[O-(tetrahydro-pyran-2V-yl)hydroxylamino]carbonyl-vinyl}-5-
trifluoromethyl-N-{4I-methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide  
 
 
 
Compound 67 was obtained starting from 3-(2IV-hydroxycarbonyl-vinyl)-5-
trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide (0.3 g, 0.5 mmol) and O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine (64 mg, 0.6 mmol) with general method A (TLC: CHCl3/MeOH 
9/1 + vanillin), (0.3 g, quantitative yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 11.34 (s broad, 1H, NH); 10.49 (s, 1H, NH); 9.29 
(d, J=1.6, 1H, 2III-H); 9.01 (s, 1H, NH); 8.69 (dd, J= 4.7, J=1.4, 1H, 6III-H); 8.52 (d, 
J=5.4, 1H, 6II-H); 8.50-8.42 (m, 2H, 2I-H and 4III-H); 8.26 (s, 1H, 2-H); 8.17 (s, 1H, 6-
H); 8.08 (s, 1H, 4-H); 7.67 (d, J=16.1, 1H,1IV-H); 7.52 (dd, J=7.5, J=4.7, 1H, 5III-H); 
7.49 (dd, J=8.5, J=2.3, 1H, 6I-H); 7.44 (d, J=5.4, 1H, 5II-H); 7.25 (d, J=8.5, 1H, 5I-H); 
6.77 (d, J=16.1, 1H, 2IV-H); 4.93 (broad s, 1H, 2V-H); 4.01-3.89 (m, 2H, 
tetrahydropyran CH2); 2.24 (s, 3H, CH3); 1.76-1.67 (m, 3H, tetrahydropyran CH2); 
1.58-1.50 (m, 3H, tetrahydropyran CH2). 
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Synthesis of 3-[2IV-(aminophen-2V-yl)carbamoyl-vinyl]-5-trifluoromethyl-N-{4I-
methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 8 was obtained starting from 3-{2IV-[2V-(tert-
butoxycarbonyl)aminophenyl]carbamoyl-vinyl}-5-trifluoromethyl-N-{4I-methyl-3I-
N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.4 g, 0.5 mmol) 
with general method C (TLC: CHCl3/MeOH 9/1), (0.3 g, 88% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.51 (s broad, 1H, NH); 9.42 (s broad, 1H, NH); 
9.29 (d, J=1.7, 1H, 2III-H); 9.01 (s broad, 1H, NH); 8.69 (dd, J=4.7, J=1.7, 1H, 6III-H); 
8.52 (d, J=5.2, 1H, 6II-H ); 8.50-8.46 (m, 2H, 2I-H and 4III-H); 8.29 (s, 1H, 2-H); 8.20 
(s, 1H, 6-H); 8.09 (s, 1H, 4-H); 7.73 (d, J=15.8, 1H, 1IV-H); 7.55 (m, 2H, 6I-H and 5III-
H); 7.44 (d, J=5.2, 1H, 5II-H); 7.40 (dd, J=8.2, J=1.2, 1H, 3V-H); 7.25 (d, J=8.4, 1H, 5I-
H); 7.16 (d, J=15.8, 1H, 2IV-H); 6.93 (td, J=8.2, J=1.2, 1H, 5V-H); 6.76 (dd, J=8.2, 1.2, 
1H, 6V-H); 6.58 (td, J=8.2, J=1.2, 1H, 4V-H); 2.24 (s, 3H, CH3). 
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-5-trifluoromethyl-N-{4I-
methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 9 was obtained starting From 3-{2IV-[O-(tetrahydro-pyran-2V-
yl)hydroxylamino]carbonyl-vinyl}-5-trifluoromethyl-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide with general method D 
(TLC: CHCl3/MeOH 9/1 + vanillin), (0.2 g, 75% yield). 
 
1H-NMR (500 MHz, DMSO-d6): δ 10.57 (s, 1H, NH); 9.49 (d, J=1.7, 1H, 2III-H); 9.22 
(s, 1H, NH); 9.02 (dt, J= 8.1, J=1.7, 1H, 4III-H); 8.95 (d, J=5.5, 1H, 6III-H); 8.63 (d, 
J=5.2, 1H, 6II-H); 8.46 (t, J=1.5, 1H, 2-H); 8.26 (t, J=1.5, 1H, 6-H); 8.17-8.13 (m, 2H, 
4-H and 2I-H); 8.0 (dd, J=8.1, J=5.5, 1H, 5III-H); 7.63 (d,  J=16.2, 1H, 1IV-H); 7.59 (d, 
J=5.2, 1H, 5II-H); 7.47 (dd, J=8.4, J=2.0, 1H, 6I-H); 7.26 (d, J=8.4, 1H, 5I-H); 6.75 (d, 
J=16.2, 1H, 2IV-H); 2.24 (s, 3H, CH3). 
 
13C-NMR (500 MHz, DMSO-d6): δ 163.54; 161.64; 161.16; 159.49; 151.41; 148.21; 
148.23; 146.25; 137.93; 136.69; 136.61; 136.54; 135.95; 134.41; 132.18; 130.18; 
129.86; 128.06; 126.95; 124.66; 123.78; 122.41; 117.27; 116.80; 107.62; 90.36; 
17.66. 
 
IR νmax/cm-1: 3428 (hydroxamic acid N-H); 3240 (hydroxamic acid O-H); 1663 
(benzamide C=O); 1583 (hydroxamic acid C=O); 1552 (hydroxamic acid C-N).  
 
Elemental analysis for C27H21F3N6O3 :  
Calcd: C 60.67%; H 3.96%; N 15.72%. Found: C 61.47%; H 3.93%; N 15.39%. 
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5.3.1.8 SYNTHESIS OF 3-{4IV-[(2V-HYDROXYLAMINO)CARBONYL-
VINYL]IMIDAZOL-1IV-YL}-5-TRIFLUOROMETHYLBENZAMIDE DERIVATIVES  
 
Synthesis of Ethyl urocanate  
 
 
 
A mixture of SOCl2 (1.1 ml, 15.0 mmol) and urocanic acid (1.4 g, 10.0 mmol) 
suspended in EtOH (50 ml) was heated to reflux for 3 hours (TLC: CHCl3/MeOH 
9/1 + 1% Formic acid). After cooling the solvent was evaporated under vacuum 
and then the mixture was diluted with H2O (50 ml) and was neutralized with 
NaHCO3. The water solution was extracted with EtOAc (3 x 25 ml); the organic 
phase was dried over anhydrous sodium sulfate and evaporated to give ethyl 
urocanate (1.7 g, quantitative yield). 
 
 
 1H-NMR (300 MHz, DMSO-d6): δ 12.46 (broad s, 1H, NH); 7.77 (s, 1H, 2-H); 7.54 
(s, 1H, 5-H); 7.52 (d, J=16.0, 1H, 1I-H); 6.32 (d, J=16.0, 1H, 2I-H); 4.14 (q, J=7.2, 2H, 
CH2CH3); 1.23 (t, J=7.2, 3H, CH2CH3). 
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Synthesis of 3-Fluoro-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide) 
 
 
 
Compound 73 was obtained starting from 3-Fluoro-5-trifluoromethylbenzoic acid 
(0.1 g, 0.5 mmol) and NI-(2-methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-
2I-yl]amine (0.2 g, 0.6 mmol) with the general method A (TLC: CHCl3/MeOH 9/1), 
(0.2 g, quantitative yield). 
 
 
1H-NMR (400 MHz, Acetone-d6): δ 9.83 (s, 1H, NH); 9.34 (dd, J=2.2, J=0.9, 1H, 2III-
H); 8.68 (dd, J=4.9, J=1.9, 1H; 6III-H); 8.58 (ddd, J=7.7, J=4.9, J=1.6, 1H, 4III-H); 8.54 
(d, J=5.1, 1H, 6II-H); 8.53 (s, 1H, NH); 8.20 (s, 1H, 2I-H); 8.10 (dt, J=8.5, J=1.5, 1H, 
2-H); 8.02 (s, 1H, 6-H); 7.76 (dt, J=8.5, J=1.5, 1H, 4-H); 7.53-7.47 (m, 2H, 6I-H and 
5III-H); 7.43 (d, J=5.1, 1H, 5II-H); 7.26 (d, J=8.2, 1H, 5I-H); 2.37 (s, 3H, CH3). 
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Synthesis of 3-[4IV-(2V-ethoxycarbonyl-vinyl)imidazol-1IV-yl]-5-trifluoromethyl-
N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
A mixture of 3-Fluoro-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.3 g, 0.6 mmol), ethyl urocanate 
(0.5 g, 3.0 mmol) and K2CO3 (0.8 g, 6.0 mmol) in DMF (6 ml) was sealed in a tube 
under nitrogen atmosphere. The mixture was heated to 120°C for 10 hours (TLC: 
CHCl3/MeOH 9/1). After cooling, the mixture was diluted with a saturated 
solution of NH4Cl in H2O (60 ml), the solid precipitate was collected by filtration 
and washed with abundant water to give 3-[4IV-(2V-ethoxycarbonyl-
vinyl)imidazol-1IV-yl]-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.3 g, 86 % yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.55 (s, 1H, NH); 9.29 (d, J=2.1, 1H, 2III-H); 9.02 
(s, 1H, NH); 8.68 (dd, J=5.0, J=1.5, 1H, 6III-H); 8.64 (s, 1H, 2IV-H); 8.56-8.43 (m, 4H, 
6-H, 6II-H, 4III-H and 5IV-H); 8.32 (s, 1H, 2-H); 8.25 (s, 1H, 4-H); 8.10 (d, J=1.4, 1H, 
2I-H); 7.59-7.49 (m, 3H, 6I-H, 5III-H and 1V-H); 7.45 (d, J=5.1, 1H, 5II-H); 7.26 (d, 
J=8.0, 1H, 5I-H); 6.48 (d, J=15.5, 1H, 2V-H); 4.17 (q, J=7.0, 2H, CH2CH3); 2.25 (s, 3H, 
CH3); 1.25 (t, J=7.0, 3H, CH2CH3). 
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Synthesis of 3-bromo-5-trifluoromethylnitrobenzene  
 
 
 
A solution of 3-nitrobenzotrifluoride (1.9 g, 10.0 mmol) in H2SO4 conc. (10 ml) 
was warmed to 60°C and then N-Br-succinimide (2.1 g, 12.0 mmol) was added to 
the mixture. The mixture was stirred at 60°C for 2 hours (TLC: CHCl3/CE 1/1). 
After cooling the mixture was poured into H2O (200 ml) and extracted with 
CH2Cl2 (3 x 70 ml), the organic phase was subsequently dried over anhydrous 
sodium sulfate and evaporated to give 3-bromo-5-trifluoromethylnitrobenzene 
(2.3 g, 87% yield). 
 
 
1H-NMR (300 MHz, CDCl3-d): δ 8.57 (t, J=1.7, 1H, 2-H); 8.44 (t, J=1.7, 1H, 6-H); 
8.10 (t, J=1.7, 1H, 4-H). 
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Synthesis of 3-[4I-(2II-ethoxycarbonyl-vinyl)imidazol-1I-yl]-5-trifluoromethyl-
nitrobenzene 
 
 
 
A mixture of 3-bromo-5-trifluoromethylnitrobenzene (1.6 g, 6.0 mmol), CuI (0.2 
g, 1.2 mmol), 8-hydroxyquinoline (0.2 g, 1.2 mmol), ethyl urocanate (2.0 g, 12.0 
mmol) and K2CO3 (1.7 g, 12.0 mmol) in DMSO (30 ml) was sealed in a tube under 
nitrogen atm. The mixture was heated to 100°C for 24 hours (TLC: CHCl3/MeOH 
9/1). After cooling, the mixture was poured into a saturated water solution of 
NH4Cl (500 ml) and was extracted with EtOAc (3 x 150 ml). The organic phase was 
dried over anhydrous sodium sulfate and evaporated to give 3-[4I-(2II-
ethoxycarbonyl-vinyl)imidazol-1I-yl]-5-trifluoromethyl-nitrobenzene (0.7 g, 35% 
yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.84 (t, J=1.8, 1H, 2-H); 8.72 (d, J=0.8, 1H, 2I-H); 
8.60 (t, J=1.8, 1H, 6-H); 8.54 (d, J=0.8, 1H, 5I-H); 8.47 (t, J=1.8, 1H, 4-H); 7.53 (d, 
J=15.7, 1H, 1II-H); 6.49 (d, J=15.7, 1H, 2II-H); 4.18 (q, J=7.0, 2H, CH2CH3); 1.26 (t, 
J=7.0, 3H, CH2CH3). 
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Synthesis of 3-{4I-(2II-ethoxycarbonyl-vinyl)imidazol-1I-yl}-5-
trifluoromethylaniline  
 
 
 
A mixture of 3-[4I-(2II-ethoxycarbonyl-vinyl)imidazol-1I-yl]-5-trifluoromethyl-
nitrobenzene (0.4 g, 1.0 mmol) and SnCl2*2H2O (1.3 g, 6.0 mmol) in EtOH (10 ml) 
was heated at 60°C for 1 hour (TLC: CHCl3/MeOH 9/1). After cooling, the solvent 
was evaporated under vacuum and an aqueous solution of saturated NaHCO3 
(100 ml) was added to the solid residue. The mixture was extracted with Et2O (3 
x 40 ml), the organic phase was dried over anhydrous sodium sulphate and 
evaporated to give 3-{4I-(2II-ethoxycarbonyl-vinyl)imidazol-1I-yl}-5-
trifluoromethylaniline (0.3 g, 97% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.31 (d, J=0.8, 1H, 2I-H); 8.14 (d, J=0.8, 1H, 5I-H); 
7.54 (d, J=15.5, 1H, 1II-H); 7.04 (t, J=1.9, 1H, 4-H); 6.97 (t, J=1.9, 1H, 2-H); 6.88 (t, 
J=1.9, 1H, 6-H); 6.44 (d, J=15.5, 1H, 2II-H); 4.17 (q, J=7.2, 2H, CH2CH3); 1.25 (t, 
J=7.2, 3H, CH2CH3). 
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Synthesis of 4-methyl-N-{3III-[4IV-(2V-ethoxycarbonyl-vinyl)imidazol-1IV-yl]-5III-
trifluoromethyl-phenyl}-3-{[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzamide  
 
 
 
A solution of 4-methyl-3-{[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzoic acid 
(0.1 g, 0.3 mmol), 3-{4I-(2II-ethoxycarbonyl-vinyl)imidazol-1I-yl}-5-
trifluoromethylaniline (0.1 g, 0.3 mmol) and SOCl2 (0.1 ml, 1.2 mmol) in NMP (0.5 
ml) was heated at 90°C for 16 hours (TLC: CHCl3/MeOH 9/1). After cooling, the 
mixture was poured into a saturated solution of NaHCO3 in H2O (20 ml). The solid 
precipitate was collected by filtration. The residue was purified by flash 
chromatography (EtOAc/n-ex 95/5), to give 4-methyl-N-{3III-[4Iv-(2v-
ethoxycarbonyl-vinyl)imidazol-1Iv-yl]-5III-trifluoromethyl-phenyl}-3-{[4I-
(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzamide (0.1 g, 45% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.68 (s, 1H, NH); 9.28 (dd, J=2.1, J=0.7, 1H, 2II-
H); 9.15 (s, 1H, NH); 8.68 (dd, J=4.8, J=1.5, 1H, 6II-H); 8.55 (d, J=5.0, 1H, 6I-H); 8.44 
(ddd, J=8.0, J=2.1, J=1.5, 1H, 4II-H); 8.43 (d, J=1.0, 1H, 2Iv-H); 8.38 (t, J=1.8, 1H, 2III-
H); 8.33 (d, J=1.7, 1H, 2-H); 8.24 (d, J=1.0, 1H, 5Iv-H); 8.21 (t, J=1.8, 1H, 6III-H); 
7.80 (t, J=1.8, 1H, 4III-H); 7.77 (dd, J=8.2, J=1.7, 1H, 6-H); 7.57 (d, J=15.8, 1H, 1v-
H); 7.51 (ddd, J=8.0, J=4.8, J=0.7, 1H, 5II-H); 7.48 (d, J=5.0, 1H, 5I-H); 7.46 (d, 
J=8.2, 1H, 5-H); 6.47 (d, J=15.8, 1H, 2v-H); 4.18 (q, J=7.2, 2H, CH2CH3); 2.33 (s, 3H, 
CH3); 1.25 (t, J=7.2, 3H, CH2CH3). 
  
Experimental Procedures  
 
111 
 
Synthesis of 3-[4IV-(2V-hydroxycarbonyl-vinyl)imidazol-1IV-yl]-5-trifluoromethyl-
N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 78 was obtained starting from 3-[4Iv-(2v-ethoxycarbonyl-
vinyl)imidazol-1Iv-yl]-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.3 g, 0.5 mmol) in THF with the 
general method B (TLC: CHCl3/MeOH 9/1), (0.1 g, 47% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.52 (s, 1H, NH); 9.32 (d, J=2.1, 1H, 2III-H); 9.02 
(s, 1H, NH); 8.72 (dd, J=4.8, J=1.7, 1H, 6III-H); 8.65 (s, 1H, 2IV-H); 8.59-8.52 (m, 3H, 
6-H, 6II-H and 4III-H); 8.42 (s, 1H, 5IV-H); 8.33 (s, 1H, 2-H); 8.26 (s, 1H, 4-H); 8.11 (d, 
J=1.8, 1H, 2I-H); 7.60 (dd, J=8.0, J=4.8, 1H, 5III-H); 7.54-7.45 (m, 3H, 6I-H, 5II-H and 
1V-H); 7.27 (d, J=8.4, 1H, 5I-H); 6.48 (d, J=16.0, 1H, 2V-H); 2.25 (s, 3H, CH3). 
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Synthesis of 4-methyl-N-{3III-[4IV-(2V-hydroxycarbonyl-vinyl)imidazol-1IV-yl]-5III-
trifluoromethyl-phenyl}-3-{[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzamide  
 
 
 
Compound 79 was obtained starting from 4-methyl-N-{3III-[4Iv-(2v-
ethoxycarbonyl-vinyl)imidazol-1Iv-yl]-5III-trifluoromethyl-phenyl}-3-{[4I-(pyridin-
3II-yl)pyrimidin-2I-yl]amino}benzamide (0.1 g, 0.1 mmol) in THF with the 
hydrolysis general method B (TLC: CHCl3/MeOH 9/1), (42 mg, 55% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 12.22 (broad s, 1H, OH); 10.67 (s, 1H, NH); 9.28 
(d, J=1.8, 1H, 2II-H); 9.15 (s, 1H, NH); 8.68 (dd, J=4.7, J=1.8, 1H, 6II-H); 8.55 (d, 
J=5.1, 1H, 6I-H); 8.44 (dt, J=8.1, J=1.8, 1H, 4II-H); 8.42 (s, 1H, 2Iv-H); 8.37 (s, 1H, 2III-
H); 8.33 (d, J=1.6, 1H, 2-H); 8.23-8.19 (m, 2H, 6III-H and 5Iv-H); 7.81 (s, 1H, 4III-H); 
7.77 (dd, J=8.0, J=1.6, 1H, 6-H); 7.54-7.44 (m, 4H, 5-H, 5I-H, 5II-H and 1v-H); 6.42 
(d, J=15.5, 1H, 2v-H); 2.36 (s, 3H, CH3). 
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Synthesis of 3-(4IV-{2V-[O-(tetrahydro-pyran-2VI-yl)hydroxylamino]carbonyl-
vinyl}imidazol-1IV-yl)-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide  
 
 
 
Compound 80 was obtained starting from 3-[4IV-(2V-hydroxycarbonyl-
vinyl)imidazol-1IV-yl]-5-trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.1 g, 0.2 mmol) and O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine (31.0 mg, 0.3 mmol) with general method A (TLC: 
CHCl3/MeOH 9/1 + vanillin), (0.1 g, 55% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.21 (broad s, 1H,NH); 10.49 (s, 1H, NH); 9.29 
(dd, J=2.0, J=0.6, 1H, 2III-H); 8.98 (s, 1H, NH); 8.68 (dd, J=4.6, J=2.0, 1H, 6III-H); 
8.59 (s, 1H, 2IV-H);8.52 (d, J=5.2, 1H, 6II-H); 8.51 (s, 1H, 6-H); 8.48 (dt, J=8.0, J=2.0, 
1H, 4III-H); 8.33-8.28 (m, 2H, 2-H and 5IV-H); 8.23 (s, 1H, 4-H); 8.10 (d, J=2.0, 1H, 
2I-H); 7.55-7.49 (m, 2H, 6I-H and 5III-H); 7.44 (d, J=5.1, 1H, 5II-H); 7.40 (d, J=15.6, 
1H, 1V-H); 7.27 (d, J=8.4, 1H, 5I-H); 6.58 (d, J=15.6, 1H, 2V-H); 4.91 (s, 1H, 2VI-H); 
4.00-3.92 (m, 1H, tetrahydropyran CH2); 3.57-3.49 (m, 1H, tetrahydropyran CH2); 
2.25 (s, 3H, CH3); 1.74-1.64 (m, 3H, tetrahydropyran CH2); 1.60-1.47 (m, 3H, 
tetrahydropyran CH2). 
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Synthesis of 4-methyl-N-[3III-(4IV-{2V-[O-(tetrahydro-pyran-2VI-
yl)hydroxylamino]carbonyl-vinyl}imidazol-1IV-yl)-5III-trifluoromethyl-phenyl]-3-
{[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amino}benzamide  
 
 
 
Compound 81 was obtained starting from 4-methyl-N-{3III-[4Iv-(2v-
hydroxycarbonyl-vinyl)imidazol-1Iv-yl]-5III-trifluoromethyl-phenyl}-3-{[4I-(pyridin-
3II-yl)pyrimidin-2I-yl]amino}benzamide (41 mg, 0.1 mmol) and O-(tetrahydro-2H-
pyran-2-yl)hydroxylamine (10 mg, 0.1 mmol) with general method A (TLC: 
CHCl3/MeOH 9/1 + vanillin), (34 mg, 55% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 11.21 (broad s, 1H, NH); 10.66 (s, 1H, NH); 9.28 
(d, J=1.9, 1H, 2II-H); 9.15 (s, 1H, NH); 8.68 (dd, J=4.8, J=1.9, 1H, 6II-H); 8.55 (d, 
J=5.1, 1H, 6I-H); 8.44 (dt, J=7.9, J=1.9, 1H, 4II-H); 8.40 (s, 1H, 2Iv-H); 8.36 (s, 1H, 2III-
H); 8.33 (d, J=1.6, 1H, 2-H); 8.21 (s, 1H, 6III-H); 8.09 (s, 1H, 5Iv-H); 7.80 (s, 1H, 4III-
H); 7.77 (dd, J=8.0, J=1.6, 1H, 6-H); 7.51 (dd, J=7.9, J=4.8, 1H, 5II-H); 7.48 (d, J=5.1, 
1H, 5I-H); 7.46 (d, J=8.0, 1H, 5-H); 7.41 (d, J=15.5, 1H, 1v-H); 6.57 (d, J=15.5, 1H, 
2v-H); 4.91 (s, 1H, 2vI-H); 4.01-3.91 (m, 1H, tetrahydropyran CH2); 3.58-3.49 (m, 
1H, tetrahydropyran CH2); 2.36 (s, 3H, CH3); 1.76-1.64 (m, 3H, tetrahydropyran 
CH2); 1.60-1.48 (m, 3H, tetrahydropyran CH2). 
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Synthesis of 3-{4IV-[(2V-hydroxylamino)carbonyl-vinyl]imidazol-1IV-yl}-5-
trifluoromethyl-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}benzamide  
 
 
 
Compound 10 was obtained starting from 3-(4IV-{2V-[O-(tetrahydro-pyran-2VI-
yl)hydroxylamino]carbonyl-vinyl}imidazol-1IV-yl)-5-trifluoromethyl-N-{4I-methyl-
3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide (0.1 g, 0.1 mmol) 
with general method D (TLC: CHCl3/MeOH 9/1 + vanillin), (24 mg, 31% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.49 (s, 1H, NH); 9.30 (d, J=1.5, 1H, 2III-H); 8.98 
(s, 1H, NH); 8.69 (dd, J=4.7, J=1.5, 1H, 6III-H); 8.57-8.50 (m, 3H, 6-H, 6II-H and 2IV-
H); 8.48 (dt, J=7.8, J=1.5, 1H, 4III-H); 8.30 (s, 1H, 2-H); 8.21 (s, 1H, 5IV-H); 8.19 (s, 
1H, 4-H); 8.10 (d, J=1.7, 1H, 2I-H); 7.56-7.49 (m, 2H, 6I-H and 5III-H); 7.44 (d, J=5.4, 
1H, 5II-H); 7.26 (d, J=8.5, 1H, 5I-H);7.20 (d, J=15.6, 1H, 1V-H); 6.54 (d, J=15.6, 1H, 
2V-H); 2.25 (s, 3H, CH3). 
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Synthesis of 4-methyl-N-(3III-{4IV-[(2V-hydroxylamino)carbonyl-vinyl]imidazol-
1IV-yl)-5III-trifluoromethyl-phenyl]-3-{[4I-(pyridin-3II-yl)pyrimidin-2I-
yl]amino}benzamide  
 
 
 
Compound 11 was obtained starting from 4-methyl-N-[3III-(4IV-{2V-[O-
(tetrahydro-pyran-2VI-yl)hydroxylamino] carbonyl-vinyl}imidazol-1IV-yl)-5III-
trifluoromethyl-phenyl]-3-{[4I-(pyridin-3II-yl) pyrimidin-2I-yl]amino}benzamide 
(34 mg, 50 µm), with general method C (TLC: CHCl3/MeOH 9/1 + vanillin), (8 mg, 
30% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.67 (s, 1H, NH); 9.28 (dd, J=1.9, J=0.7, 1H, 2II-
H); 9.17 (s, 1H, NH); 8.68 (dd, J=4.9, J=1.9, 1H, 6II-H); 8.55 (d, J=5.3, 1H, 6I-H); 8.44 
(dt, J=8.1, J=1.9, 1H, 4II-H); 8.39 (s, 1H, 2Iv-H); 8.35 (s, 1H, 2III-H); 8.33 (d, J=1.8, 
1H, 2-H); 8.21 (s, 1H, 6III-H); 8.06 (s, 1H, 5Iv-H); 7.80 (s, 1H, 4III-H); 7.77 (dd, J=8.0, 
J=1.8, 1H, 6-H); 7.51 (ddd, J=8.1, J=4.9, J=0.7, 1H, 5II-H); 7.48 (d, J=5.3, 1H, 5I-H); 
7.46 (d, J=8.0, 1H, 5-H); 7.41 (d, J=15.7, 1H, 1v-H); 6.53 (d, J=15.7, 1H, 2v-H); 2.36 
(s, 3H, CH3). 
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5.3.1.9 SYNTHESIS OF NI-[5IV-(IMIDAZOL-1V-YL)-2IV-AMINOPHENYL]-N-{4I-
METHYL-3I-[4II-(PYRIDIN-3III-YL)PYRIMIDIN-2II-
YL]AMINOPHENYL}ISOPHTALAMIDE DERIVATIVES 
 
Synthesis of 4-(imidazol-1I-yl)-2-nitroaniline  
 
 
 
A mixture of 4-bromo-2-nitroaniline (0.5 g, 2.5 mmol), imidazole (0.7 g, 10.0 
mmol), CuI (0.1 mg, 0.5 mmol), 8-hydroxyquinoline (0.1 g, 0.5 mmol) and K2CO3 
(1.4 g, 10.0 mmol) in DMSO (13 ml) was sealed in a tube under nitrogen atm. The 
mixture was heated at 130°C for 16 hours (TLC: CH2Cl2/MeOH 95/5). After 
cooling, the mixture was diluted with a saturated solution of NH4Cl in H2O (500 
ml) and extracted with EtOAc (3 x 150 ml). The organic phase was dried over 
anhydrous sodium sulphate and was concentrated under vacuum. The residue 
was purified by flash chromatography (CH2Cl2/MeOH 95:5) to afford 4-(imidazol-
1I-yl)-2-nitroaniline (0.3 g, 31% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.15 (t, J=1.2, 1H, 2I-H); 8.12 (d, J=3.0, 1H, 3-H); 
7.72 (dd, J=9.0, J=3.0, 1H, 5-H); 7.67 (t, J=1.2, 1H, 5I-H); 7.56 (broad s, 1H, NH2); 
7.16 (d, J=9.0, 1H, 6-H); 7.07 (t, J=1.2, 1H, 4I-H). 
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Synthesis of 4-(4I-methylimidazol-1I-yl)-2-nitroaniline  
 
 
 
Compound 84 was obtained starting from 4-bromo-2-nitroaniline (0.5 g, 2.5 
mmol) and 4-methylimidazole (0.3 g, 4.0 mmol) with the same procedure as for 
compound 83 (0.1 g, 66% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 8.05 (d, J=2.6, 1H, 3-H); 8.02 (d, J=1.0, 1H, 2I-H); 
7.68 (dd, J=9.2, J=2.6, 5-H); 7.56 (broad s, 2H, NH2); 7.36 (d, J=1.0, 1H, 5I-H); 7.13 
(d, J=9.2, 1H, 6-H); 2.14 (s, 3H, CH3). 
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Synthesis of 4-(imidazol-1I-yl)-2-nitro-(tert-butoxycarbonyl)aniline  
 
 
 
Potassium tert-butoxide (0.1 g, 1.2 mmol) was slowly added to solution of 4-
(imidazol-1I-yl)-2-nitroaniline (0.2 g, 1.0 mmol) in DMSO (3 ml) stirred at 5°C. The 
mixture was left over stirring for 30 minutes at 5°C. A solution of Boc2O (0.3 g, 
1.2 mmol) in DMSO (1 ml) was poured into the mixture. The mixture was stirred 
at room temperature for 2 hours (TLC: CH2Cl2/MeOH 95/5); it was subsequently 
diluted with a saturated solution of NH4Cl in H2O (50 ml) and extracted with 
EtOAc (3 x 20 ml). The organic phase was dried over anhydrous sodium sulfate 
and concentrated under vacuum to give 4-(imidazol-1I-yl)-2-nitro-(tert-
butoxycarbonyl)aniline (0.2 g, 73% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H, NH); 8.34 (t, J=1.2, 1H, 2I-H); 8.23 (d, 
J=2.6, 1H, 3-H); 7.97 (dd, J=9.1, J=2.6, 1H, 5-H); 7.83 (t, J=1.2, 1H, 5I-H); 7.71 (d, 
J=9.1, 1H, 6-H); 7.13 (t, J=1.2, 1H, 4I-H); 1.45 (s, 9H, 3 x CH3). 
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Synthesis of 4-(4I-methylimidazol-1I-yl)-2-nitro-(tert-butoxycarbonyl)aniline  
 
 
 
Compound 86 was obtained starting from 4-(4I-methylimidazol-1I-yl)-2-
nitroaniline (0.2 g, 1.0 mmol) with the same procedure as for compound 85 (0.1 
g, 45% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.21 (d, J=1.2, 1H, 2I-H); 8.17 (d, J=2.6, 1H, 3-H); 
7.92 (dd, J=8.9, J=2.6, 5-H); 7.68 (d, J=8.9, 1H, 6-H); 7.52 (d, J=1.2, 1H, 5I-H); 2.16 
(s, 3H, CH3); 1.43 (s, 9H, 3 x CH3). 
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Synthesis of 4-(imidazol-1I-yl)-2-amino-(tert-butoxycarbonyl)aniline  
 
 
 
Hydrazine monohydrate (2.0 g, 40.0 mmol) and FeCl3 (6 mg, 40 µmol) were 
added to a solution of 4-(imidazol-1I-yl)-2-nitro-(tert-butoxycarbonyl)aniline (0.2 
g, 0.8 mmol) in MeOH (4 ml). The mixture was heated at reflux for 2 hours (TLC: 
CHCl3/MeOH 9/1). After cooling, the mixture was diluted with MeOH (50 ml), 
was filtered on celite and was concentrated under vacuum to obtain a residue. A 
saturated solution of NH4Cl in H2O (50 ml) was added to the residue and stirred 
at room temperature for 1 hour, the precipitate was collected by filtration to 
afford 4-(imidazol-1I-yl)-2-amino-(tert-butoxycarbonyl)aniline (0.1 g, 50% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.37 (broad s, 1H, NH); 8.01 (s, 1H, 2I-H); 7.51 (s, 
1H, 5I-H); 7.31 (d, J=9.0, 1H, 6-H); 7.06 (s, 1H, 4I-H); 6.86 (d, J=2.3, 1H, 3-H); 6.74 
(dd, J=9.0, J=2.3, 1H, 5-H); 5.14 (s, 2H, NH2); 1.45 (s, 9H, 3 x CH3). 
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Synthesis of 4-(4I-methylimidazol-1I-yl)-2-amino-(tert-butoxycarbonyl)aniline  
 
 
 
Compound 88 was obtained starting from 4-(4I-methylimidazol-1I-yl)-2-nitro-
(tert-butoxycarbonyl)aniline (0.2 g, 0.5 mmol) with the same procedure as for 
compound 87 (0.1 g, 70% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 8.37 (broad s, 1H, NH); 7.88 (d, J=1.2, 1H, 2I-H); 
7.27 (d, J=8.5, 1H, 6-H); 7.21 (d, J=1.2, 5I-H); 6.81 (d, J=2.5, 1H, 3-H); 6.68 (dd, 
J=8.5, J=2.5, 1H, 5-H); 5.12 (s, 2H, NH2); 2.14 (s, 3H, CH3); 1.46 (s, 9H, 3 x CH3). 
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Synthesis of 3-ethoxycarbonyl-[5I-(imidazol-1II-yl)-2I-(tert-
butoxycarbonyl)aminophenyl]benzamide  
 
 
 
Compound 89 was obtained starting from mono-ethyl isophtalate (62 mg, 0.3 
mmol) and 4-(imidazol-1I-yl)-2-amino-(tert-butoxycarbonyl)aniline (0.1 g, 0.4 
mmol) with the general condensation method A (TLC: CHCl3/MeOH 9/1), (0.1 g, 
75% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.15 (s, 1H, NH); 8.91 (s, 1H, NH); 8.56 (s, 1H, 
2II-H); 7.49 (s, 1H, 2-H); 8.25 (d, J=7.8, 1H, 4-H); 8.19 (d, J=8.4, 1H, 3I-H); 7.84 (d, 
J=2.5, 1H, 6I-H); 7.83-7.64 (m, 3H, 5-H, 6-H, 5II-H); 7.54 (dd, J=8.4, J=2.5, 1H, 4I-H); 
7.27 (s, 1H, 4II-H); 4.38 (q, J=7.0, 2H, CH2CH3); 1.45 (s, 9H, 3 x CH3), 1.36 (t, 3H, 
J=7.0, CH2CH3). 
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Synthesis of 3-ethoxycarbonyl-[5I-(4II-methylimidazol-1II-yl)-2I-(tert-
butoxycarbonyl)aminophenyl]benzamide  
 
 
 
Compound 90 was obtained starting from mono-ethyl isophtalate (74 mg, 0.4 
mmol) and 4-(4I-methylimidazol-1I-yl)-2-amino-(tert-butoxycarbonyl)aniline (0.1 
g, 0.4 mmol) with the general condensation method A (TLC: CHCl3/MeOH 9/1), 
(0.1 g, 50% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.12 (s, 1H, NH); 8.84 (s, 1H, NH); 8.55 (t, J=1.7, 
1H, 2-H); 8.24 (dt, J=7.8, J=1.7, 1H, 4-H); 8.18 (dt, J=7.8, J=1.7, 1H, 6-H); 8.07 (d, 
J=1.2, 1H, 2II-H); 7.76 (d, J=2.6, 1H, 6I-H); 7.72 (t, J=8.0, 1H, 5-H); 7.68 (d, J=8.9, 
1H, 3I-H); 7.46 (dd, J=8.9, J=2.6, 1H, 4I-H); 7.39 (d, J=1.2, 1H, 5II-H); 4.38 (q, J=7.3, 
2H, CH2CH3); 2.16 (s, 3H, CH3); 1.45 (s, 9H, 3 x CH3); 1.36 (t, J=7.3, 3H, CH2CH3). 
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Synthesis of 3-hydroxycarbonyl-[5I-(imidazol-1II-yl)-2I-(tert-
butoxycarbonyl)aminophenyl]benzamide  
 
 
 
Compound 91 was obtained starting from 3-ethoxycarbonyl-[5I-(imidazol-1II-yl)-
2I-(tert-butoxycarbonyl)aminophenyl]benzamide (0.1 g, 0.3 mmol) in THF 
accordingly to the general method B (TLC: CHCl3/MeOH 9/1), (34 mg, 31% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H, NH); 8.82 (s, 1H, NH); 8.55 (s, 1H, 2-
H); 8.19 (t, J=1.1, 1H, 2II-H); 8.11 (d, J=7.9, 1H, 4-H); 7.94 (d, J=7.9, 1H, 6-H); 7.82 
(d, J=2.6, 1H, 6I-H); 7.73-7.68 (m, 2H, 3I-H and 5II-H); 7.51-7.46 (m, 2H, 5-H and 4I-
H); 7.10 (t, J=1.1, 1H, 4II-H); 1.45 (s, 9H, 3 x CH3). 
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Synthesis of 3-hydroxycarbonyl-[5I-(4II-methylimidazol-1II-yl)-2I-(tert-
butoxycarbonyl)aminophenyl]benzamide  
 
 
 
Compound 92 was obtained starting from 3-ethoxycarbonyl-[5I-(4II-
methylimidazol-1II-yl)-2I-(tert-butoxycarbonyl)aminophenyl]benzamide (80 mg, 
0.2 mmol) in THF accordingly to the general method B (TLC: CHCl3/MeOH 9/1), 
(18 mg, 22% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.09 (s, 1H, NH); 8.82 (s, 1H, NH); 8.56 (t, J=1.6, 
1H, 2-H); 8.21-8.14 (m, 2H, 4-H and 6-H); 8.07 (d, J=1.5, 1H, 2II-H); 7.76 (d, J=2.5, 
1H, 6I-H); 7.71-7.74 (m, 2H, 5-H and 3I-H); 7.45 (dd, J=8.8, J=2.7, 1H, 4I-H); 7.39 
(d, J=1.5, 1H, 5II-H); 2.16 (s, 3H, CH3); 1.45 (s, 9H, 3 x CH3). 
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Synthesis of NI-[5IV-(imidazol-1V-yl)-2IV-(tert-butoxycarbonyl)aminophenyl]-N-
{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}isophtalamide  
 
 
 
Compound 93 was obtained starting from 3-hydroxycarbonyl-[5I-(imidazol-1II-yl)-
2I-(tert-butoxycarbonyl)aminophenyl]benzamide (35 mg, 80 µmol) and NI-(2-
methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-yl]amine (24 mg, 88 
µmol) with general method A (TLC: CHCl3/MeOH 9/1), (31 mg, 56% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H, NH); 10.08 (s, 1H, NH); 9.27 (dd, 
J=2.2, J=0.7, 1H, 2III-H); 8.98 (s, 1H, NH); 8.84 (broad s, 1H, NH); 8.67 (dd, J=4.7, 
J=1.6, 1H, 6III-H); 8.55 (t, J=1.7, 1H, 2-H); 8.51 (d, J=5.4, 1H, 6II-H); 8.47 (ddd, 
J=8.0, J=2.2, J=1.6, 1H, 4III-H); 8.21-8.14 (m, 3H, 4-H, 6-H and 2v-H); 8.09 (d, J=2.0, 
1H, 2I-H); 7.84 (d, J=2.7, 1H, 6Iv-H); 7.75-7.68 (m, 3H, 5-H, 3Iv-H and 5v-H); 7.54-
7.49 (m, 3H, 6I-H, 5III-H and 4Iv-H); 7.43 (d, J=5.4, 1H, 5II-H); 7.23 (d, J=8.2, 1H, 5I-
H); 7.11 (t, J=1.0, 1H, 4v-H) 2.24 (s, 3H, CH3); 1.43 (s, 9H, 3 x CH3). 
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Synthesis of NI-[5IV-(4V-methylimidazol-1V-yl)-2IV-(tert-
butoxycarbonyl)aminophenyl]-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}isophtalamide  
 
 
 
Compound 94 was obtained starting from 3-hydroxycarbonyl-[5I-(4II-
methylimidazol-1II-yl)-2I-(tert-butoxycarbonyl)aminophenyl]benzamide (34 mg, 
80 µmol) and NI-(2-methyl-5-aminophenyl)-N-[4I-(pyridin-3II-yl)pyrimidin-2I-
yl]amine (24 mg, 88 µmol) with general method A (TLC: CHCl3/MeOH 9/1), (36 
mg, 65% yield). 
 
 
1H-NMR (300 MHz, DMSO-d6): δ 10.41 (s, 1H, NH); 10.09 (s, 1H, NH); 9.27 (d, 
J=2.3, 1H, 2III-H); 9.00 (s, 1H, NH); 8.86 (s, 1H, NH); 8.67 (dd, J=4.8, J=2.3, 1H, 6III-
H); 8.55 (t, J=1.7, 1H, 2-H); 8.51 (d, J=5.0, 1H, 6II-H); 8.48 (dt, J=8.0, J=2.3, 1H, 4III-
H); 8.21-8.13 (m, 2H, 4-H and 6-H); 8.09 (d, J=1.9, 1H, 2I-H); 7.81 (d, J=2.6, 1H, 6IV-
H); 7.72 (t, J=7.8, 1H, 5-H); 7.70 (d, J=9.0, 1H, 3IV-H); 7.57-7.47 (m, 5H, 5 x Ar-H); 
7.23 (d, J=8.5, 1H, 5I-H); 2.23 (s, 3H, CH3); 2.18 (s, 3H, CH3); 1.43 (s, 9H, 3 x CH3). 
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Synthesis of NI-[5IV-(imidazol-1V-yl)-2IV-aminophenyl]-N-{4I-methyl-3I-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}isophtalamide  
 
 
 
Compound 12 was obtained starting from NI-[5Iv-(imidazol-1v-yl)-2Iv-(tert-
butoxycarbonyl)aminophenyl]-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-2II-
yl]aminophenyl}isophtalamide (31 mg, 45 µmol) accordingly to the deprotection 
method C (TLC: CHCl3/MeOH 9/1), (26 mg, 94% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H, NH); 10.92 (s, 1H, NH); 9.27 (dd, 
J=2.1, 1H, 2III-H); 8.97 (s, 1H, NH); 8.67 (dd, J=4.8, J=1.5, 1H, 6III-H); 8.58 (t, J=1.7, 
1H, 2-H); 8.51 (d, J=5.2, 1H, 6II-H); 8.48 (ddd, J=7.8, J=2.1, J=1.5, 1H, 4III-H); 8.20-
8.13 (m, 2H, 4-H and 6-H); 8.10 (d, J=2.1, 1H, 2I-H); 7.69 (t, J=7.7, 1H, 5-H); 7.59-
7.47 (m, 4H, 6I-H, 5III-H, 2v-H and 5v-H); 7.43 (d, J=5.2, 1H, 5II-H); 7.27-7.20 (m, 2H, 
5I-H and 4Iv-H); 7.09 (broad s, 1H, 4v-H); 7.97 (broad s, 1H, 6Iv-H); 6.90 (d, J=8.7, 
1H, 3Iv-H); 5.22 (broad s, 2H, NH2); 2.23 (s, 3H, CH3); 
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Synthesis of NI-[5IV-(4V-methylimidazol-1V-yl)-2IV-aminophenyl]-N-{4I-methyl-3I-
N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}isophtalamide  
 
 
 
Compound 13 was obtained starting from NI-[5Iv-(4v-methylimidazol-1v-yl)-2Iv-
(tert-butoxycarbonyl)aminophenyl]-N-{4I-methyl-3I-[4II-(pyridin-3III-yl)pyrimidin-
2II-yl]aminophenyl}isophtalamide (36 mg, 52 µmol) with the general method C 
(TLC: CHCl3/MeOH 9/1), (19 mg, 63% yield). 
 
 
1H-NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H, NH); 9.89 (s, 1H, NH); 9.27 (d, J=2.2, 
1H, 2III-H); 8.97 (s, 1H, NH); 8.67 (dd, J=4.8, J=2.2, 1H, 6III-H); 8.56 (t, J=1.6, 1H, 2-
H); 8.51 (d, J=5.1, 1H, 6II-H); 8.48 (dt, J=7.9, J=2.2, 1H, 4III-H); 8.19-8.13 (m, 2H, 4-
H and 6-H); 8.10 (d, J=2.0, 1H, 2I-H); 7.86 (d, J=2.6, 1H, 6IV-H); 7.69 (t, J=7.9, 1H, 5-
H); 7.54-7.49 (m, 2H, 6I-H and 5III-H); 7.45-7.42 (m, 2H, 5II-H and 2V-H); 7.25-7.21 
(m, 2H, 5I-H and 5V-H); 7.19 (dd, J=8.5, J=2.6, 1H, 4IV-H); 6.87 (d, J=8.5, 1H, 3IV-H); 
5.16 (broad s, 2H, NH2); 2.24 (s, 3H, CH3); 2.14 (s, 3H, CH3). 
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5.3.2 SYNTHESIS OF DUAL TYROSINE KINASES-HDAC INHIBITORS 
FUNCTIONALIZED WITH METALS 
 
5.3.2.1 GENERAL METHOD 
 
General method for the metal coordination 
A solution of metal salt in MeOH (4 ml) was added to a solution of hydroxamic 
derivative, 4 or 9 (0.1 mmol) in MeOH (30 ml) neutralized to pH = 7 with aqueous 
KOH 10%. The mixture was stirred overnight at room temperature (TLC: 
CHCl3/MeOH 9/1 + vanillin), the solvent was partially evaporated under vacuum 
and water (20 ml) was added to the residue. The solid precipitate was collected 
by filtration to afford the functionalized product. 
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide zinc complex 
 
 
 
Starting from compound 4 and Zinc(II)acetate dehydrate (11 mg, 50 µmol) with 
the coordination general method was obtained compound 14 (36 mg, 72% yield). 
 
 
1H-NMR (500 MHz, DMSO-d6): δ 10.29 (s, 1H, NH); 9.28 (dd, J=2.0, J=0.7, 1H, 2III-
H); 8.97 (s, 1H, NH); 8.70 (dd, J= 4.8, J=1.6, 1H, 6III-H); 8.51 (d, J=5.2, 1H, 6II-H); 
8.47 (ddd, J=8.0, J=2.0, J=1.6, 1H, 4III-H); 8.11 (broad s, 1H, 2-H); 8.09 (d, J=1.8, 
1H, 2I-H); 7.90 (d, J=7.8, 1H, 4-H); 7.74 (d, J=7.8, 1H, 6-H); 7.56 (t, J=7.8, 1H, 5-H); 
7.52 (ddd, J=8.0, J=4.8, J=0.7, 1H, 5III-H); 7.50 (dd, J=8.3, J=1.8, 1H, 6I-H); 7.45 (d, 
J=16.0, 1H, 1IV-H); 7.43 (d, J=5.2, 1H, 5II-H); 7.22 (d, J=8.3, 1H, 5I-H); 6.60 (d, 
J=16.0, 1H, 2IV-H); 2.23 (s, 3H, CH3). 
 
13C-NMR (500 MHz, DMSO-d6): δ 165.17; 161.20; 159.35; 151.22; 148.10; 137.82; 
137.49; 137.03; 136.46; 135.78; 134.42; 132.41; 132.19; 130.10; 129.93; 128.56; 
127.48; 126.25; 123.79; 123.10; 122.70; 117.10; 116.66; 116.38; 107.63; 17.63. 
 
IR νmax/cm-1: 3414 (hydroxamate N-H); 1649 (benzamide C=O); 1581 
(hydroxamate C=O); 1552 (hydroxamate C-N).  
 
Elemental analysis for C52H42N12O6Zn: 
Calcd: C 62.68%; H 4.25%; N 16.87%. Found: C 63.00%; H 4.87%; N 17.50%.  
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-5-trifluoromethyl-N-{4I-
methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide zinc 
complex  
 
 
 
Starting from compound 9 and Zinc(II)acetate dehydrate (11 mg, 50 µmol) with 
the coordination general method was obtained compound 15 (50 mg, 88% yield). 
 
1H-NMR (500 MHz, DMSO-d6): δ 10.50 (s, 1H, NH); 9.29 (d, J=1.7, 1H, 2III-H); 9.00 
(s, 1H, NH); 8.70 (dd, J=5.0, J=1.3, 1H, 6III-H); 8.52 (d, J=5.2, 1H, 6II-H); 8.48 (dt, 
J=8.1, J=1.7, 1H, 4III-H); 8.41 (broad s, 1H, 2-H); 8.22 (broad s, 1H, 6-H); 8.13 
(broad s, 1H, 4-H); 8.08 (d, J=1.5, 1H, 2I-H); 7.59 (d, J=16.0, 1H, 2IV-H); 7.52 (dd, 
J=8.1, J=5.0, 1H, 5III-H); 7.50 (dd, J=8.3, J=1.5, 1H, 6I-H); 7.44 (d, J=5.2, 1H, 5II-H); 
7.25 (d, J=8.3, 1H, 5I-H); 6.73 (d, J=16.0, 1H, 1IV-H); 2.24 (s, 3H, CH3). 
 
13C-NMR (500 MHz, DMSO-d6): δ 163.59; 161.67; 161.16; 159.58; 151.46; 151.20; 
148.31; 148.23; 146.25; 137.95; 136.87; 135.95; 134.37; 132.26; 130.22; 129.97; 
129.57; 128.12; 126.83; 123.86; 123.79; 122.41; 117.84; 116.64; 107.69; 90.36; 
17.50. 
 
IR νmax/cm-1: 3436 (hydroxamate N-H); 1662 (benzamide C=O); 1582 
(hydroxamate C=O); 1555 (hydroxamate C-N).  
 
Elemental analysis for C54H40F6N12O6Zn:  
Calcd: C 57.28%; H 3.56%; N 14.84%.Found: C 58.31%; H 4.35%; N 14.87%. 
Experimental Procedures  
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide copper complex  
 
 
 
Starting from compound 4 and copper(II) chloride dihydrate (8 mg, 50 µmol) with 
the coordination general method was obtained compound 16 (37 mg, 74% yield).  
 
IR νmax/cm-1: 3416 (hydroxamate N-H); 1655 (benzamide C=O); 1581 
(hydroxamate C=O); 1552 (hydroxamate C-N).  
 
Elemental analysis for C54H42CuN12O6:  
Calcd: C 62.80%; H 4.26%; N 16.90%. Found: C 61.90%; H 4.35%; N 16.30%. 
 
 
 
  
Experimental Procedures  
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-5-trifluoromethyl-N-{4I-
methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide copper 
complex  
 
 
 
Starting from compound 9 and copper(II) chloride dihydrate (8 mg, 50 µmol) with 
the coordination general method was obtained compound 17 (55 mg, 97% yield).  
 
IR νmax/cm-1: 3438 (hydroxamate N-H); 1650 (benzamide C=O); 1581 
(hydroxamate C=O); 1552 (hydroxamate C-N).  
 
Elemental analysis for C54H40CuF6N12O6: 
Calcd: C 57.37%; H 3.57%; N 14.87%. Found: C 57.15%; H 3.89%; N 14.76%. 
 
  
Experimental Procedures  
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide iron complex  
 
 
 
Starting from compound 4 and iron(III) chloride hexahydrate (9 mg, 35 µmol) 
with the coordination general method was obtained compound 18 (44 mg, 86% 
yield).  
 
IR νmax/cm-1: 3422 (hydroxamate N-H); 1648 (benzamide C=O); 1581 
(hydroxamate C=O); 1555 (hydroxamate C-N).  
 
Elemental analysis for C78H63FeN18O9:  
Calcd: C 64.51%; H 4.37%; N 17.36%. Found: C 63.89%; H 3.93%; N 16.18%. 
 
 
  
Experimental Procedures  
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Synthesis of 3-[(2IV-hydroxylamino)carbonyl-vinyl]-5-trifluoromethyl-N-{4I-
methyl-3I-N-[4II-(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide iron 
complex 
 
 
 
Starting from compound 9 and iron(III) chloride hexahydrate (9 mg, 35 µmol) 
with the coordination general method was obtained compound 19 (51 mg, 90% 
yield). 
 
IR νmax/cm-1: 3435 (hydroxamate N-H); 1664 (benzamide C=O); 1581 
(hydroxamate C=O); 1550 (hydroxamate C-N).  
 
Elemental analysis for C81H60F9FeN18O9:  
Calcd: C 58.74%; H 3.65%; N 15.22%. Found: C 59.78%; H 4.49%; N 15.24%. 
  
Experimental Procedures  
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6. CONCLUSIONS 
 
 
Starting from previously identified hit compounds (4-anilinoquinazolines EGFR 
inhibitors; N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide topoisomerases I 
and II inhibitor; 4-anilinopyrimidines as multi kinases inhibitors; N-phenyl-N’-[4-
(pyrimidin-4-ylami-no)phenyl]urea derivatives as class III TKs inhibitors; pyrido-
pyrimidines as Abl inhibitors), we synthesized and tested several novel analogues 
with the aim of identifying novel promising multi-target inhibitors. Together, our 
data indicated: 
 Quinazolinone derivatives as novel promising anti-fibrotic compounds 
with multiple kinases inhibitory properties. The synthesis of novel 
compounds and more exhaustive biological investigation on this novel 
class of multi-kinase inhibitors is in progress.  
 Benzoquinoline moiety decorated with protonatable side chains could be 
a promising scaffold for the development of intercalating 
antitopoisomerase I and II agents. 
 N-phenyl-N’-[4-(6-phenylpyrimidin-4-ylamino)phenyl]urea derivatives 
constitute a promising class of subfamily selective inhibitors of class III 
RTKs. To further develop these class of compounds novel analogues will 
be synthesized and biologically evaluated. 
 N-(2-fluoro-5-trifluoromethylphenyl)-N’-{4’-[(2’’-benzamido)pyridin-4’’-
ylamino] phenyl}urea will be soon in vivo tested to evaluate its efficacy 
and toxicity. 
 3-[(2IV-hydroxylamino)carbonyl-vinyl]-N-{4I-methyl-3I-N-[4II-(pyridin-3III-
yl)pyrimidin-2II-yl]aminophenyl}benzamide (Compound 4) and 3-[(2IV-
hydroxylamino)carbonyl-vinyl]-5-trifluoromethyl-N-{4I-methyl-3I-N-[4II-
(pyridin-3III-yl)pyrimidin-2II-yl]aminophenyl}benzamide (Compound 9) will 
be soon in vivo tested to better investigate their pharmacokinetic, toxicity 
and efficacy.  
Conclusions 
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 The metal complexes (14-19) will be submitted to in vitro tests as soon as 
possible. In particular, besides determining the ability of compounds to 
impair the redox homeostasis, we will evaluate the effect of the metal in 
the modulation of the pharmacokinetic properties. Indeed whether 
compounds 14-19 will possess anti-proliferative activity this will be due to 
the influence of the metal in the cell uptake. In fact the original ligand (4 
not bearing the CF3 function) showed very low activity in MTT test due to 
poor cell permeation.  
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Discovery of wtRET and V804MRET Inhibitors: From Hit to
Lead
Luca Mologni+,[a] Martina Dalla Via+,[b] Adriana Chilin,[b] Manlio Palumbo,[b] and
Giovanni Marzaro*[b]
Introduction
Protein kinases (PKs) are among the most investigated targets
for cancer therapy.[1] This class of enzymes regulates almost all
cellular events by transferring a phosphate group from ATP to
the target protein substrate.[2, 3] The human kinome comprises
518 members, grouped in families, subfamilies, and classes, ac-
cording to structural and functional similarities.[3] Of particular
interest is the family of tyrosine kinases (TKs); their deregula-
tion, through mutation or overexpression of TKs, is often relat-
ed to cancer onset and progression,[4] and in the last two de-
cades, a number of ATP-mimic TK inhibitors (TKIs) have been
developed.[5] TKIs share some common pharmacophore fea-
tures, like a nitrogen-containing heterocycle (for interaction
with the kinase hinge region), a lipophilic moiety (for interac-
tion with a hydrophobic region not exploited by ATP) and a
bridge connecting the two.[1, 6] According to the bound kinase
conformation, TKIs are classified as type I, I1=2, II, III, and IV in-
hibitors. In particular, type II inhibitors bind the inactive kinase
conformation, which bears a larger lipophilic cleft than the
active conformation. Accordingly, type II inhibitors have a
larger lipophilic moiety than type I inhibitors.[7]
As part of our kinase inhibitors discovery project,[8, 9] we re-
cently reported that some N-phenyl-N’-[4-(pyrimidin-4-ylami-
no)phenyl]urea derivatives behave as subfamily-selective
class III multitarget kinase inhibitors.[9] To further investigate
the usefulness of these compounds in developing novel TKIs,
we tested compound 1 (selected as a hit compound in our
previous study) against some kinases phylogenetically related
to the class III receptor TKs, that is, the FGFR family and the
kinase RET. From this very preliminary screening, we found
that 1 possessed a low but not negligible inhibitory activity
against RET (IC50=11.9 mm).
The RET proto-oncogene has been recognized as an impor-
tant therapeutic target in thyroid neoplasia and in a small
subset of non-small-cell lung cancer (NSCLC) patients.[10,11] On-
cogenic activation of RET occurs through one of two mecha-
nisms: point mutations in the extracellular or the kinase
domain of RET are frequently found in medullary thyroid carci-
noma (MTC) and in multiple endocrine neoplasia, while chro-
mosomal rearrangements involving the catalytic domain of
RET are predominant in papillary thyroid carcinoma (PTC) and
in NSCLC.[10] In both cases, aberrant RET-driven signaling
ensues, leading to increased cell proliferation and survival.
Thus, actual inhibition of RET kinase is paramount for effective
treatment of these diseases. Four drugs (vandetanib, cabozan-
Oncogenic activation of RET kinase has been found in several
neoplastic diseases, like medullary thyroid carcinoma, multiple
endocrine neoplasia, papillary thyroid carcinoma, and non-
small-cell lung cancer. Currently approved RET inhibitors were
not originally designed to be RET inhibitors, and their potency
against RET kinase has not been optimized. Hence, novel com-
pounds able to inhibit both wild-type RET (wtRET) and its mu-
tants (e.g. , V804MRET) are needed. Herein we present the devel-
opment and the preliminary evaluation of a new sub-micromo-
lar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphen-
yl)-N’-{4’-[(2’’-benzamido)pyridin-4’’-ylamino]phenyl}urea (69),
endowed with a 4-anilinopyridine structure, starting from our
previously identified 4-anilinopyrimidine hit compound. Profil-
ing against a panel of kinases indicated 69 as a multi cKIT/
wtRET/V804MRET inhibitor.
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tinib, sorafenib, and lenvatinib) have been recently approved
for the treatment of thyroid cancer.[12] However, these com-
pounds were not originally designed as RET inhibitors. A few
more compounds are under investigation,[12] including a
potent inhibitor of the V804M mutant.[13] Different strategies
have been pursued for the identification of novel RET inhibi-
tors, such as drug repurposing,[14] kinase profiling,[15] and use
of multicomponent reaction libraries.[16] In this work, we report
our efforts in the development of novel analogues of com-
pound 1 endowed with sub-micromolar RET inhibitory poten-
cy. According to our previous results,[9] we hypothesized that 1
would bind the inactive kinase conformation. As no crystallo-
graphic structure has been deposited in the Protein Data Bank
(PDB) to date for the inactive RET conformation, we decided to
use a classical medicinal chemistry approach rather than a
structure-based approach. However, to suggest a plausible
binding mode supported by experimental evidence, a molecu-
lar docking study based on homology modeling is also pre-
sented.
Results and Discussion
Optimization of urea moiety
The first optimization step for hit compound 1 regarded the
evaluation of different substituents on both phenyl rings on
the urea functionality (Table 1). The diphenyl urea motif is pres-
ent in several known type II kinase inhibitors and commonly
interacts with the lipophilic cleft typical of TKs.[6] Hence, we de-
cided to functionalize the terminal phenyl ring with lipophilic
substituents, differing from the steric and electronic features.
In particular, we focused our attention on substituents already
evaluated for the development of kinase inhibitors, such as 2-
fluoro-5-methyl,[17] 2-fluoro-5-trifluoromethyl,[18] 4-chloro-3-tri-
fluoromethyl,[19] or 2,5-difluoro[20] substituents. The central ani-
line ring was functionalized with bulky moieties to obtain indi-
rect information about the size of the hydrophobic cleft in the
inactive RET conformation. Inhibitory potency against recombi-
nant wild-type RET (wtRET kinase), expressed as IC50 values
(mm), allowed the derivation of useful SARs. Functionalization
of the terminal ring was mandatory for enhancing activity. In
particular, the presence of a methyl or trifluoromethyl function-
ality at the 5(3) position led to the most potent compounds in
the series (2, 3, and 5). A 2-fluoro functionality was useful in
the absence of any other substituent (compare 4 with 1), or
when a 5-trifluoromethyl functionality was also present (com-
pare 5 with 3). Conversely, when a 5-methyl functionality was
present, the 2-fluoro substituent did not improve the activity
(compare 7 with 3). Bulky substituents were not well tolerated
(8). The presence of a 4-chloro-3-trifluoromethyl functionality
led to a completely inactive compound, and functionalization
of the central aniline ring was detrimental for activity (see 10–
12). On the basis of inhibitory data and synthetic accessibility,
compound 5 (bearing the 2-fluoro-5-trifluoromethyl pattern on
the terminal phenyl group) was chosen as a model for further
improvement. The compounds listed in Table 1 were synthe-
sized according to Scheme 1.
Briefly, 4,6-dichloropyrimidine was first condensed with phe-
nylboronic acid and then with a slight excess of the appropri-
ately substituted aniline. Compounds 16 and 17 were submit-
ted to alkaline hydrolysis, whereas compound 20 was reduced
with elemental iron in an aqueous ethanol solution, slightly
acidified with acetic acid. All amino derivatives were finally
condensed with the appropriate isocyanate derivatives in di-
chloromethane at room temperature, affording the desired
ureas in moderate to good yields.
Optimization of nitrogen heterocycle
The second optimization step regarded the evaluation of dif-
ferent substituents at the 6’’ position of the pyrimidine ring
(Table 2). At this position, we mainly chose to replace the
phenyl ring with simple heterocycles (i.e. , furan and thiophene,
to verify the effect of electron density in this part of the
moiety) or to insert a spacer (to potentially establish hydrogen
bonds) between the aryl and the pyrimidine moiety. Substitu-
tion of the 6’’-phenyl ring with heteroaryls resulted in similar
potencies (compare 22 and 23 with 5). Conversely to what
was previously observed for inhibition of class III receptor TK
members,[9] the introduction of a polar functionality at the 6’’-
phenyl ring decreased compound potency (see 24). The great-
est effect was observed when a spacer was introduced be-
tween the pyrimidine and the aryl ; the NH functionality led to
a totally inactive compound (25), whereas a carboxamido func-
tionality (26) furnished the most active compound overall.
The compounds listed in Table 2 were synthesized according
to Scheme 2. Compounds 22 and 23 were synthesized accord-
ing to the same synthetic strategy as 5 (see Scheme 1), with
the only difference being the nature of arylboronic acid used
in the first step. Compounds 24 and 25 were synthesized fol-
lowing our previously reported strategy.[9] For the synthesis of
Table 1. Structure and IC50 values (isolated
wtRET) of compounds 1–12.
ID R1 R2 IC50 [mm]
[a]
1 H H 11.9:0.7
2 H 3-Me 3.3:0.5
3 H 3-CF3 4.8:0.2
4 H 2-F 6.1:0.7
5 H 2-F,5-CF3 4.1:0.1
6 H 2,5-diF 6.2:0.5
7 H 2-F,5-Me 7.1:0.7
8 H 3-OMe 19.8:0.8
9 H 4-Cl,3-CF3 >100
10 2’-OMe 2-F,5-CF3 10.7:0.7
11 2’-Br 2-F,5-CF3 42.3:5.5
12 3’-OMe 2-F,5-CF3 >100
[a] Values are the mean:SEM of three determinations.
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compound 26, the starting dichloropyrimidine was first con-
verted into the 6-amino-4-chloropyrimdine. Intermediate 38
was then condensed with benzoyl chloride in presence of
DMAP, taking advantage of a microwave-assisted organic syn-
thesis technique. Compound 39 was then submitted to the
usual synthetic steps to obtain the desired urea derivative.
In parallel to the evaluation of different substituents at the
6’’ position of the pyrimidine ring, we also evaluated different
pyrimidines, in terms of both the relative position of nitrogen
atoms with respect to the phenyl ring and the presence of
substituents (Table 3). As mentioned above, we decided to
hinder the pyrimidine nucleus with different substituents (i.e. ,
CN, Me, SMe) to explore the steric features of the ATP binding
pocket of RET. In addition, we modified the number and rela-
tive position of the nitrogen atoms in the heterocycle to inves-
tigate the importance the of the hydrogen bond acceptor fea-
tures of the scaffold. The addition of another substituent in
Scheme 1. Synthesis of compounds 2–12. Reagents and conditions: a) phenylboronic acid, Pd(PPh3)4, Na2CO3, H2O, DME, reflux, 16 h; b) aniline derivative,
iPrOH, MW 80 8C, 3V20 min; c) phenylisocyanate derivative, CH2Cl2, RT, 16 h; d) NaOH, H2O, RT, 16 h; e) Fe
0, acetic acid, EtOH, H2O, reflux, 2 h.
Table 2. Structure and IC50 values (isolated
wtRET) of compounds 22–26.
ID R IC50 [mm]
[a]
5 4.1:0.1
22 3.8:0.2
23 5.2:0.1
24 36.0:2.4
25 >100
26 1.2:0.3
[a] Values are the mean:SEM of three determinations.
Table 3. Structure and IC50 values (isolated
wtRET) of compounds 41–45.
ID X Y R IC50 [mm]
[a]
5 CH N H 4.1:0.1
41 C@CN N H >100
42 CH N Me >100
43 CH N S@Me >100
44 N CH H 1.5:0.1
45 N C@CN H >100
[a] Values are the mean:SEM of three determinations.
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the pyrimidine ring led to fully inactive compounds (41–43
and 45). Conversely, a change in the pyrimidine ring geometry
from a 4-anilino-6-phenyl to a 4-anilino-2-phenyl led to an in-
teresting improvement in activity (compare 44 with 5). At this
stage, a preliminary cytotoxicity test was run on RET+ thyroid
carcinoma cells at a fixed compound concentration (10 mm),
using the molecules that showed activity toward the recombi-
nant enzyme. The analysis confirmed 22, 26, and 44 as the
most active compounds, showing, on average, >75% cell
growth inhibition (Figure S2, Supporting Information). Com-
pounds listed in Table 3 were synthesized according to
Schemes 3–5.
Compound 41 was synthesized starting from benzaldehyde,
which was condensed in a single-pot reaction with ethyl cya-
noacetate and formamidine to yield hydroxypyrimidine 47
(Scheme 3). Standard chlorination and condensation with p-
phenylenediamine and the isocyanate furnished the desired
final product. The 2-substituted pyrimidine derivatives were
prepared in two different ways. Compound 42 (Scheme 4A)
was prepared starting from dichloropyrimidine 50, which was
Scheme 2. Synthesis of compounds 22–26. Reagents and conditions: a) arylboronic acid derivative, Pd(PPh3)4, Na2CO3, H2O, DME, reflux, 16 h; b) p-phenylene-
diamine, iPrOH, MW, 80 8C, 3V20 min; c) 2-fluoro-5-trifluoromethylphenylisocyanate, CH2Cl2, RT, 16 h; d) Fe
0, AcOH, EtOH, H2O, reflux, 2 h; e) chloroacetyl chlo-
ride, TEA, DME, RT, 16 h; f) N-methylpiperazine, KI, TEA, DMF, RT, 48 h; g) aniline, TEA, iPrOH, MW, 150 8C, 30 min; h) NH4OH, iPrOH, 80 8C (sealed tube), 16 h;
i) benzoyl chloride, DMAP, MW, 100 8C, 5 min.
Scheme 3. Synthesis of compound 41. Reagents and conditions: a) ethyl cyanoacetate, formamidine acetate, K2CO3, EtOH, reflux, 16 h; b) POCl3, reflux, 2 h;
c) p-phenylenediamine, iPrOH, 80 8C, 20 min; d) 2-fluoro-5-trifluoromethylphenylisocyanate, CH2Cl2, RT, 16 h.
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selectively monohydrolyzed to compound 51 before being
submitted to Suzuki reaction and subsequent chlorination. Un-
fortunately, all attempts to perform the Suzuki reaction on 50
to directly obtain compound 53 was unsuccessful. For com-
pound 43 (Scheme 4B), the thiopyrimidine ring was obtained
by treating ethyl benzoylacetate with thiourea. Compounds 44
and 45 were synthesized starting from benzamidine 60, which
was condensed with either ethyl propiolate or with 2-cyano-3-
ethoxyacrylate (Scheme 5). In all the cases, the hydroxypyrimi-
dine intermediates (i.e. , 52, 57, 61, and 64) were chlorinated
and submitted to condensation with p-phenylenediamine and
then with the isocyanate.
Development of lead compound
The acquired biological data were then used to design three
novel compounds bearing the features of the most active de-
rivatives (Table 4). The optimization steps previously described
suggested the importance of a benzamido substituent on the
pyrimidine ring (26) and the nitrogen heterocycle geometry
(44). Starting from these observations, two novel compounds
were designed and synthesized that shared two common fea-
tures: the presence of the benzamido functionality and the ab-
sence of a nitrogen atom at the Y position of the nitrogen het-
erocycle (see Table 4 for structure clarification). Compound 68
was a 4-anilino-2-substituted pyrimidine, whereas compound
69 was a 4-anilinopyridine. Surprisingly, compound 68 showed
poor activity, despite bearing the structural features of the two
most active compounds identified during our work. On the
contrary, replacement of the pyrimidine ring with a pyridine
furnished the first sub-micromolar RET inhibitor in our series
(69). Compound 69 was profiled against a panel of kinases se-
lected from the ScanEDGE subset of DiscoverX (http://
www.discoverx.com/services/drug-discovery-development-serv-
ices/kinase-profiling/kinomescan/scanedge). In particular, we
tested our lead compound at a single concentration (1 mm)
against the target kinases of starting hit compound 1 (i.e. ,
FLT3, cKIT, and PDGFRb) and against the most common targets
of other RET inhibitors (i.e. , Abl1, BRAF, ERK1, MET, Src, and
VEGFR2) using the KinomeScan platform. The KinomeScan
technology measures the ability of the tested compound to
displace the target kinase from a high affinity ATP mimic
probe. The result of the assay is expressed as a percent of con-
trol (POC) value that is statistically correlated with the dissocia-
tion constant. The lower the POC, the higher the affinity of the
test compound for the target kinase. For a more exhaustive
Scheme 4. Synthesis of compounds A) 42 and B) 43. Reagents and conditions: (A) a) HCl 3m, nBuOH, MW, 125 8C, 10 min; b) phenylboronic acid, Pd(PPh3)4,
K2CO3, DME, H2O, MW, 130 8C, 5 min; c) POCl3, 80 8C, 4 h; d) p-phenylenediamine, iPrOH, MW, 150 8C, 20 min; e) 2-fluoro-5-trifluoromethylphenylisocyanate,
CH2Cl2, RT, 16 h. (B) a) NaOEt 20% in EtOH, RT, 20 min, then thiourea, reflux, 24 h; b) MeI, NaOH, H2O, RT, 16 h; c) POCl3, 80 8C, 4 h; d) p-phenylenediamine,
iPrOH, MW, 150 8C, 20 min; e) 2-fluoro-5-trifluoromethylphenylisocyanate, CH2Cl2, RT, 16 h.
Scheme 5. Synthesis of compounds 44 and 45. Reagents and conditions: a) ethyl propiolate, K2CO3, EtOH, reflux, 16 h; b) POCl3, 80 8C, 4 h; c) p-phenylenedia-
mine, iPrOH, MW, 80 8C, 40 min; d) 2-fluoro-5-trifluoromethylphenylisocyanate, CH2Cl2, RT, 16 h; e) ethyl (ethoxymethylene)cyanoacetate, DMF, reflux, 96 h.
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description of POC and of KinomeScan technology, see https://
www.discoverx.com/tools-resources/leadhunter-study-reports-
data-analysis. Results are listed in Table 5.
Together, our results identified 69 as a multi cKIT/wtRET/
V804MRET inhibitor. Notably, hit compound 1 was previously
identified as a dual cKIT/PDGFRb inhibitor (POC values <0.5
against both kinases under the same experimental condi-
tions).[9] Hence, our efforts to improve activity against RET kin-
ases also led to a slightly lower potency against PDGFRb. Com-
pounds listed in Table 4 were synthesized according to
Scheme 6, starting from the commercially available 2-amino-4-
chloro-pyrimidine and -pyridine.
Compound 70 was condensed with p-phenylenediamine
and with the substituted isocyanate. The last synthetic step
was the PyBOP-mediated condensation of the free amino func-
tionality with benzoic acid. For the synthesis of compound 69,
conversely, formation of the benzamido functionality was per-
formed as the first synthetic step.
In vitro testing
The most active compounds (22, 26, 44, and 69) were then
tested against the recombinant V804MRET mutant and in cellular
assays against selected RET+ and RET@ cell lines (Table 6). Van-
detanib, a kinase inhibitor clinically used to treat thyroid
cancer, was used for comparison purposes. All compounds
(with the only exception of 22, which bears a 6’’-furyl substitu-
ent) were more potent against the mutant than the wild-type
RET kinase. The novel RET inhibitors showed promising cyto-
toxic effects on RET+ cancer cell lines of both thyroid and
lung origin. Interestingly, three of four tested compounds
showed selective cytotoxicity in RET+ versus RET@ thyroid car-
cinoma cells. In particular, the activity and selectivity of com-
pound 69 were similar to that of vandetanib. We then ana-
lyzed RET autophosphorylation in the presence of 69 in TPC-1
cells harboring the CCDC6/RET fusion and in HEK293 ectopical-
ly expressing the V804M mutation.[13] Compound 69 was able
to inhibit RET activation at low micromolar concentrations, in
line with cell growth data (Figure 1). The inhibition of RET auto-
Table 4. Structure and IC50 values (isolated
wtRET) of compounds 67–69.
ID X Y R IC50 [mm]
[a]
5 CH N 4.1:0.1
26 CH N 1.2:0.3
44 N CH 1.5:0.1
68 N CH 31.8:1.3
69 CH CH 0.24:0.01
[a] Values are the mean:SEM of three determinations.
Table 5. Selectivity profile of compound 69.
Kinase POC [1 mm]
Abl1 12
BRAF 67
ERK1 100
FLT3 1.5
cKIT <0.5
MET 76
PDGFRb 0.95
RET <0.5
Src 28
VEGFR2 8
Scheme 6. Synthesis of compounds A) 67–68 and B) 69. Reagents and con-
ditions: a) p-phenylenediamine, iPrOH, MW, 80 8C, 40 min; b) 2-fluoro-5-tri-
fluoromethylphenylisocyanate, CH2Cl2, RT, 16 h; c) benzoic acid, PyBOP, TEA,
DMF, RT, 30 min; d) benzoyl chloride, DMAP, MeCN, MW, 100 8C, 5 min.
Figure 1.Western blot analysis of RET phosphorylation inhibition by com-
pound 69 at the indicated micromolar concentrations in A) TPC-1 and
B) HEK-RETV804M cells. Total RET is shown for loading control.
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phosphorylation was also determined in NIH3T3-PTC2 (see Fig-
ure S3).
Molecular docking
Preliminary molecular modeling studies were used to propose
the binding mode for compound 69 in both wild-type and
mutant RET. As mentioned above, no crystallographic structure
has been deposited to date in the PDB for the inactive RET
conformation. Hence, homology models for both wtRET and
V804MRET kinases were computed using SwissModel.[21] The co-
ordinates for VEGFR2 in complex with sorafenib (PDB ID:
3WZE)[22] were used as a template. The comparison between
the active and inactive conformations for RET is reported in
Figure S4.
AutoDock Vina was used to predict the binding modes for
compound 69 with wtRET (Figure 2A–C) and V804MRET (Fig-
ure 2D–F). Compound 69 was predicted to establish two hy-
drogen bonds with the Ala807 in the hinge region. In particu-
lar, the hydrogen bond between the carboxamide NH of 69
Table 6. Biological evaluation of selected compounds.
ID IC50 [mm]
[a] SI[b]
wtRET V804MRET TPC-1
[CCDC6/RET]
TT
[C634WRET]
MZ-CRC-1
[M918TRET]
Lc2/ad
[CCDC6/RET]
ARO
[V600EBRAF]
NPA
[V600EBRAF]
22 3.8:0.2 60.4 8.5:0.8 6.3:0.8 15.8:1.4 2.6:0.02 6.3:0.4 7.8:0.02 1
26 1.2:0.3 0.65:0.04 3.6:0.3 0.46:0.01 4.6:0.5 0.62:0.01 8.6:2.8 7.9:2.3 4
44 1.5:0.1 0.74:0.19 5.2:0.03 3.7:0.1 12.1:0.2 4.1:0.1 37.8:13.7 20.5:3.9 5
69 0.24:0.01 0.11:0.02 1.9:0.3 0.26:0.01 1.3:0.06 0.16:0.01 7.0:0.6 7.2:0.02 8
Van[c] 0.10:0.01 >10 0.41:0.04 0.86:0.03 1.2:0.3 0.22:0.02 2.6:0.1 7.0:0.9 7
[a] Values are the mean:SEM of three determinations. [b] Selectivity index: IC50 value ratio of non-target (RET@, ARO, and NPA) to target cell. [c] Vandeta-
nib.
Figure 2. A) Predicted binding mode for 69 and wtRET. B) Details of the wtRET residues surrounding compound 69. C) Schematic representation of the interac-
tions between 69 and wtRET. Hydrogen bonds are shown as dashed red lines; the arene–arene interaction is shown as a dashed green line; hydrophobic inter-
actions are represented by black solid curved lines. D) Predicted binding mode for 69 and V804MRET. E) Details of the V804MRET residues surrounding 69. F) Sche-
matic representation of the interactions between 69 and V804MRET. Hydrogen bonds are shown as dashed red lines; the arene–arene interaction is shown as a
dashed green line; hydrophobic interactions are represented by black solid curved lines; the sulfur–arene interaction is shown as a dashed blue line.
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with the carboxylic functionality of Ala807 could justify the im-
portance of an amide substituent. The urea moiety was hy-
pothesized to interact with both the carboxylate of the con-
served Glu775 from the aC helix and with the backbone
amide of Asp892 (which belongs to the DFG motif). The termi-
nally substituted ring fits well in the hydrophobic pocket, es-
tablishing lipophilic interactions with several amino acids. In
the case of RET, the hinge region and the gatekeeper residue
are highly hydrophobic. Hence, we concluded that 69 was
more active than 26 due to the presence of a less hydrophilic
moiety (pyridine in place of a pyrimidine). Finally, as hypothe-
sized in our previous work with ponatinib, the observed activi-
ty of 69 against the V804M mutant may be due to the ability
to induce the DFG-out conformation of the kinase; in this case,
the compound would fit in the active site without clashing
with the bulky mutant gatekeeper.[13] Moreover, the slightly im-
proved activity of the compound against the V804M mutant
relative to wild-type enzyme was possibly due to the ability of
69 to establish a sulfur–arene interaction with the mutated
gatekeeper. With respect to the nitrogen heterocycle, molecu-
lar docking simulations failed in suggesting a reason for the
higher activity of pyridine derivative 69 with respect to pyrimi-
dine analogue 68. Docking simulations of 68 in RET furnished
results similar to those of 69, in terms of either binding pose
or Vina Score (data not shown). Hence, our findings constitute
an example of how a classical medicinal chemistry approach
can still offer new (and less predictable) insight into protein–
ligand binding.
Conclusions
Starting from our previously identified hit compound 1 (dual
cKIT/PDGFRb inhibitor), we synthesized and tested several
novel analogues with the aim of identifying novel promising
RET inhibitors. Together, our data suggest that the 4-anilinopyr-
idine scaffold rather than the 4-anilinopyrimidine scaffold can
be used for the development of RET inhibitors. Molecular mod-
eling simulations were not useful in justifying this observation,
suggesting the importance of using a classical medicinal
chemistry approach in hit-to-lead and lead optimization pro-
cesses. The compounds reported herein showed a slight pref-
erence toward the V804MRET mutant, making them attractive
lead compounds. In particular, compound 69 (multi cKIT/wtRET/
V804MRET inhibitor) was considered the most promising lead in
the series for further derivatization to obtain new potent inhib-
itors of RET tyrosine kinase for the specific treatment of RET+
cancer. Future work addressing the efficacy and toxicity of 69
in vivo is needed.
Experimental Section
See the Supporting Information for the synthesis and characteriza-
tion of compounds.
Biochemical and cellular assays : The recombinant RET catalytic
domain (WT and V804M mutant, aa 700–1020) was expressed as a
His-tagged protein in baculovirus and purified by affinity chroma-
tography as described.[23] Inhibitors were tested for activity using
an ELISA-based kinase assay as described previously.[24] All cell lines
were purchased from the American Type Culture Collection (ATCC)
and maintained in DMEM medium (except Lc2/ad, which grow in
Ham’s F12 medium) supplemented with 10% fetal bovine serum,
l-glutamine (2 mm), penicillin–streptomycin (100 UmL@1), and gen-
tamicin (100 UmL@1). TT, TPC-1, and MZ-CRC-1 are thyroid carcino-
ma cell lines expressing oncogenic RET;[13] ARO and NPA thyroid
cancer cells are not dependent on RET activity, rather they express
the V600EBRAF oncogene;[25] Lc2/ad is an NSCLC cell line harboring
the CCDC6/RET fusion.[26] Cell growth assays were performed using
MTS assays (CellTiter 96 Aqueous One Solution Cell Proliferation
Assay, Promega) after 72 h incubation of cells (10000 per well)
with increasing compounds concentrations in 96-well plates.
Dose–response curves were generated by GraphPad Prism soft-
ware by plotting log inhibitor concentration versus normalized
kinase activity, and IC50 values were calculated as the concentra-
tions causing half-maximal responses relative to control. Data were
generated in triplicate and repeated in at least two independent
experiments. Ponatinib and vandetanib were purchased from Sell-
eck Chemicals, dissolved in DMSO, aliquoted, and stored at @20 8C.
Computational methods : Computational studies were carried out
on a 4 CPU (Intel Core2 Quad CPU Q9550, 2.83 GHz) ACPI V64
Linux workstation with Ubuntu 16.10 operating system. The tridi-
mensional structure of the template for homology modeling was
downloaded from the PDB (PDB ID: 3WZE). The sequences of the
kinase domain of wtRET and of V804MRET were downloaded from
PubMed Protein (https://www.ncbi.nlm.nih.gov/protein). The wtRET
and V804MRET homology models were prepared with SwissModel
Automatic Modelling Mode (swissmodel.expasy.org)[21] as previous-
ly reported.[16] The structure of compound 69 was prepared with
MarvinSketch 5.5.0.1 software (www.chemaxon.com/products). The
lowest-energy conformations and the degree of protonation at
pH 7.4 were determined with OpenBabel software[27] using the
MMFF94s force field. For all molecules, the appropriate.pdbqt files
were prepared with the AutoDockTools graphical interface of Auto-
Dock 4 software.[28] All docking studies were performed with Auto-
Dock Vina[29] using a docking box of 22.5V16.5V20.25 a dimen-
sions and exhaustiveness=20. Finally, the lowest energy conforma-
tion for both 69/wtRET and 69/V804MRET was analyzed.
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 2016 Elsevier Ltd. All rights reserved.Topoisomerases are still a major target in the field of anticancer
agents. Topoisomerase inhibitors, as anthracyclines, mitoxantrone,
amsacrine, camptothecin,1,2 impair DNA replication and transcrip-
tion by blocking the DNA relaxation process, thus exerting antipro-
liferative activity.3
Due to our interest in designing DNA-intercalating topoiso-
merase inhibitors,4–6 we planned to synthesize and study novel
nitrogen-containing polycyclic aromatic compounds decorated
with cationic side chain, taking N-[2-(dimethylamino)-ethyl]
acridine-4-carboxamide (DACA, 1) and N-[2-(dimethyl-amino)
ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-
4-carboxamide (SN 28049, 2) (Fig. 1) as model compounds.
DACA, in which the acridine moiety allows DNA intercalation
and the carboxamide side chain provides GC-selectivity,7 demon-
strated so good antitopoisomerase activity to enter phase I and II
clinical trials,8,9 also proving to overcome multidrug resistance,10
but low dose potency and an unusual form of toxicity prevented
further development.11 SN28049 was developed as DACA ana-
logue,12 with a benzonaphthyridine rather than an acridine chro-
mophore,13 and demonstrated 20-fold higher dose potency and
lower toxicity.11At the beginning, we planned to prepare benzo[f]quinolin-3-
one derivatives (3) as angular isoster of 1 and 2. Thus 2-naphthy-
lamine (4) and ethyl propiolate (5) were condensed in
dichloromethane at reflux in the presence of palladium acetate
and trifluoroacetic acid (TFA), as described for oxygenated ana-
logues (coumarin derivatives).14 However in these conditions no
reaction product was formed, probably due to the difference in
reactivity between amino and hydroxyl group.
Since we had previously experienced that the Microwave
Assisted Organic Synthesis (MAOS) can dramatically affect the
reaction course,15,16 we performed the planned synthesis under
microwave irradiation in TFA. Surprisingly, we found that, dou-
bling the stoichiometric quantity of propiolate in the absence of
palladium acetate, a novel product was formed, identified by
means of 1H NMR and HRMS as ethyl benzo[f]quinoline-2-carboxy-
late (6), instead of the expected benzo[f]quinolin-3-one (3)
(Scheme 1).
The reaction mechanism probably involves the initial formation
of a 3-(naphthalene-2-ylamino)acrylate intermediate through the
addition of arylamine to a protonated propiolate molecule, a reac-
tion extensively described.17,18 The b-enamino ester intermediate
undergoes to a Stork-like enamine addition19 to another proto-
nated propiolate molecule, enabling the next acid catalyzed
intramolecular cyclization. Finally, the elimination of an ethyl acet-
ate molecule allows to obtain a fully aromatic system, yielding
compound 6 (Scheme 2).
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Figure 1. Structure of DACA (1) and SN 28049 (2).
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4876 G. Marzaro et al. / Bioorg. Med. Chem. Lett. 26 (2016) 4875–4878The condensation of two molecules of b-enamino ester to
1,2-dihydroquinoline in acid medium (i.e. HI) has already been
described,20,21 but the final aromatization did not take place in that
condition. In those reactions the arylamine:propiolate ratio was
1:1, affording at most 0.5 equivalents of quinoline (hence
yield could be at most 50%). Conversely, in our method theN
a
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Scheme 3. Synthesis of compounds 7a–c and 10a–c. Reaction conditions: (a) 5, TFA, MW
9–45%.stoichiometry is 1:2, affording up to 1 equivalent of quinoline (as
confirmed by our reported yields higher than 50%).
The reaction of propiolate and arylamines to afford quinoline
derivatives has also been reported, but besides these two reagents,
a further reactant is needed for the completion of the nitrogen
nucleus. A carbonyl compound (aldehyde or ketone)22–25 or a car-
boxyl compound (formic acid)26 is required, whose carbonyl will
represent the carbon in 4 position of the final quinoline nucleus.
In our reaction the carbon in 4 position is the omega carbon of
the second propiolate molecule, thus the further carbonyl com-
pound is no longer needed to obtain the quinoline nucleus.
Since the elimination of ethyl acetate is not a common event in
organic reaction, our hypothesis was assessed by means of GC
analysis of the reaction mixture. Indeed, the experiments con-
firmed the EtOAc elimination (see Supplementary Material for
details).
Several reaction conditions were then tested (see Table 1S in
Supplementary Material). The best experimental conditions
involves the use of toluene as solvent, TFA as acid and microwave
irradiation at 150 C (50W) for 7 min and furnished the title com-
pound with the easiest work-up: by simply cooling the reaction
mixture with vigorous stirring, the benzoquinoline slowly crystal-
lized in high purity.
The reaction protocol was applied also to 1-naphthylamine,
obtaining the corresponding benzo[h]quinoline in good yields (9;
Scheme 3B). Compounds 6 and 9 are already known, even if syn-
thesized by different synthetic pathway.26–31 As the compounds
bear the carboxylic function as DACA and SN28049, we took ben-
zoquinolines 6 and 9 as starting nitrogen-containing polycyclic
aromatic compounds and we synthesized some carboxamide
derivatives with cationic side chain as potential DNA-intercalating
topoisomerase inhibitors.
The carbethoxybenzoquinolines 6 and 9were coupled with N,N-
diethylethylenediamine, 2-morpholinoethylamine or 1-(2-ami-
noethyl)piperazine in DMSO and catalytic amount of copper iodide
under microwave irradiation to provide compounds 7a–c and 10a–
c (Scheme 3A and B).
To increase the hydrophilicity of carboxamide derivatives and
to determine the role of another condensed ring on biological
activity, the 8,9-ethylendioxybenzo[h]quinoline analogues 14a–c
were synthesized (Scheme 4).
Compound 1131 was reduced to 12 by catalytic hydrogenation
over Pd/C, then condensed with ethyl propiolate as above
described and functionalized with the cationic side chains to the
desired carboxamide 14a–c (Scheme 4).
The cytotoxic activity of benzoquinolines 6, 7a–c, 9, 10a–c, 13
and 14a–c was assayed by means of an in vitro assay32 on threeN
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Table 1
Cell growth inhibition in the presence of benzoquinolines 6, 7a–c, 9, 10a–c, 13 and
14a–c
Compound Cell line GI50 (lM)a
HL-60 Hep-G2 HeLa
6 P50 P50 >50
7a 24.1 ± 2.3 27.8 ± 1.4 >50
7b >50 >50 >50
7c >50 >50 >50
9 >50 P50 >50
10a 29.8 ± 3.3 32.2 ± 2.6 >50
10b >50 >50 >50
10c >50 >50 >50
13 >50 >50 >50
14a 30.0 ± 3.3 >50 >50
14b 32.5 ± 2.8 >50 >50
14c 33.8 ± 4.3 39.4 ± 2.5 >50
m-AMSAb 0.012 ± 0.002 0.0060 ± 0.0011 0.17 ± 0.02
a Values are the mean ± SD of at least three independent experiments.
b See Ref. 5.
Figure 2. Linear flow dichroism spectra for compound 7a at [drug]/[DNA] ratios: 0
(dotted line) and 0.08 (continuous line). [DNA] = 1.9  103 M.
Figure 3. Effect of the benzoquinoline 7a on the relaxation of supercoiled plasmid
DNA mediated by human recombinant topoisomerase II. Supercoiled DNA (DNA)
was incubated with topoisomerase II in the absence (topo II) and presence of test
compound at indicated concentrations (lM). 8 lM m-AMSA was used as reference
drug.
G. Marzaro et al. / Bioorg. Med. Chem. Lett. 26 (2016) 4875–4878 4877human tumor cell lines: HL-60 (human acute promyelocytic leuke-
mia cells), HepG2 (human hepatocellular carcinoma cells) and
HeLa (human cervix adenocarcinoma cells). The results, expressed
as GI50 values, that is the concentration of the test agent inducing
50% reduction in cell number compared with control cultures, are
shown in Table 1.
The obtained values indicate for 7a and 10a the capacity to
induce the most significant cytotoxic effect on both HL-60 and
Hep-G2 cell lines, with GI50 values ranging from 24.1 to 32.2 lM.
Otherwise, on HeLa cells they appear inactive at the concentrations
taken into account. As regard the others benzoquinolines belong-
ing to these series (7b, 7c, 10b and 10c), they are ineffective on
all cell lines taken into consideration, like the unsubstituted 6
and 9. These results suggest an important role in the antiprolifera-
tive activity for the dimethylamino substituent and this assump-
tion could be valid also for the dioxolane derivatives 13 and
14a–c. Also in this latter series indeed, the lower GI50 value is
shown by the dimethylamino derivative 14a. Nevertheless, by con-
sidering 14a–c, also the fourth dioxolane ring seems to participate
in the cytotoxicity, because they are all active on HL-60 cells that
appear as the most sensitive cell line.
Due to the presence of the planar benzoquinoline moiety, it was
hypothesized that the antiproliferative activity of the most active
7a could be related to the formation of a molecular complex with
DNA following an intercalative mode of binding. To verify this
hypothesis, flow linear dichroism (LD) experiments were per-
formed as previously described33 and the spectra of DNA solution
alone and in the presence of 7a at [drug]/[DNA] ratios = 0.08 are
reported in Figure 2. The DNA spectrum (dotted line) shows thetypical negative dichroic signal at 260 nm, due to the purine and
pyrimidine chromophores. The addition of 7a (continuous line)
induces the appearance of a further negative signal at higher wave-
lengths (310–380 nm). The presence of a LD signal in this spectral
region, where only the added benzoquinoline chromophore can
absorb, indicates the occurrence of a complexation with the
macromolecule. Moreover, the negative sign of this latter LD signal,
as that due to the DNA bases, highlighted an intercalative mode of
binding, i.e. an orientation of the molecular plane of the benzo-
quinoline chromophore parallel to the plane of the purine and
pyrimidine bases.
The ability of 7a to form a molecular intercalative complex with
DNA suggested the possibility that the benzoquinoline derivative
could interfere with the catalytic activity of nuclear enzymes, like
topoisomerase II. Indeed, for a number of antiproliferative inter-
calative agents the ability to inhibit topoisomerase II was demon-
strated.34 In this connection, we investigated the effect of 7a on the
relaxation of supercoiled pBR322 plasmid DNA mediated by
human recombinant topoisomerase II,35 and the results are shown
in Figure 3. The well-known antitopoisomerase II drug m-AMSA
was taken as reference compound and used at 8 lM.
In the presence of topoisomerase II the supercoiled plasmid
DNA (lane ‘DNA’) relaxes and indeed, the disappearance of the
supercoiled form, along with the concurrent formation of a number
of topoisomers can be observed (lane ‘topo II’). The addition of
increasing concentrations of 7a induces a dose-dependent inhibi-
tion of the enzyme activity. Indeed, at 50 lM the appearance of
the supercoiled form can already be detected, and at 100 lM the
complete absence of topoisomers along with an amount of super-
coiled form higher to that obtained with the reference drug, can be
observed.
Figure 4. Effect of 7a on the stabilization of covalent-DNA-topoisomerase II
complex. Supercoiled DNA (DNA) was incubated with topoisomerase II in the
absence (topo II) and presence of 7a at indicated concentrations (lM). 8 lM
m-AMSA was used as reference.
4878 G. Marzaro et al. / Bioorg. Med. Chem. Lett. 26 (2016) 4875–4878Many intercalative agents, such as adriamycin, m-AMSA and
mitoxantrone, are able to inhibit topoisomerase II catalytic cycle
by stabilizing an intermediate, known as cleavable complex, into
a lethal condition for the cell. The drugs that exert this ability are
named topoisomerase II poisons.34,36,37 The poisoning effect can
be experimentally demonstrated by a cleavable complex assay
which allows the detection of the topoisomerase II-dependent for-
mation of linear from supercoiled DNA.38 Figure 4 shows the
results obtained from the cleavage complex assay carried out in
the presence of two concentrations of 7a, i.e. 100 and 200 lM,
and of m-AMSA at 8 lM, as reference.
The relaxation activity of topoisomerase II (lane ‘topo II’) pro-
vokes the relaxation of supercoiled pBR322 DNA and the reference
drug induces, as expected, the formation of a detectable amount of
linear DNA (lane ‘m-AMSA’). In the presence of 7a, even at the
highest concentration taken into consideration (200 lM), the for-
mation of linear DNA does not occur, indicating the inability of
the benzoquinoline derivative to act as topoisomerase II poison.
In conclusion we have developed a novel single step strategy to
access to carbethoxy benzoquinoline starting from both 1- and 2-
naphtyhlamines with good yields, short reaction times, very easy
work-up procedures and absence of any metal catalyst.
The derivatives carrying a dimethylamino side chain induce an
antiproliferative effect on leukemic cells and interestingly, the
most active 7a demonstrates the ability to form a molecular inter-
calative complex with DNA. Moreover, 7a shows a significant inhi-
bition of the relaxation activity mediated by the nuclear enzyme
topoisomerase II.
Overall, these results suggest that benzoquinoline moiety deco-
rated with protonatable side chains could be a promising scaffold
for the development of intercalating antitopoisomerase II agents.
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Some new 3-substituted quinazolinones were synthesized and evaluated as inhibitors of kinases
involved in ﬁbrogenic process. The compounds were tested against a panel of both tyrosine and serine
ethreonine kinases. The proﬁle of selectivity of some representative compounds was investigated
through molecular docking studies. The most interesting compounds were also evaluated in vitro as
potential agents for the treatment of ﬁbrotic diseases. Quinazolinone derivatives reduced proliferation
and expression of genes involved in the ﬁbrogenic process in hepatic stellate cells (HSCs) and intestinal
subepithelial myoﬁbroblasts (ISEMFs). Furthermore some compounds downregulated phosphorylation
of p38MAPK. Our ﬁndings provide evidences that 3-substituted quinazolinones target multiple essential
pathways of the ﬁbrogenic process.
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Protein kinases are ubiquitous enzymes devoted to the regula-
tion of almost all cellular events. The kinases catalyze the transfer of
a phosphate group from the ATP to speciﬁc substrate eventually
leading to transduction and propagation of cellular signal [1].
Deregulated activity, mutation or over-expression of these enzymes
have been correlated to cancer [2], chronic inﬂammatory disorders
[3], diabetes [4], cardiovascular diseases [5] and hypertension [6].
According to the targeted amino acids, kinases are commonly
grouped in two major families: the tyrosine kinases (TKs) and the
serineethreonine kinases (STKs). Among the TKs, the epidermal
growth factor receptor (EGFR), the type 2 vascular endothelial re-
ceptor (VEGFR2 or KDR), the type 1 ﬁbroblast growth factorD, Crohn's Desease; COL1A1,
; ECM, extracellular matrix;
e 1 ﬁbroblast growth factor
cells; ISEMF, intestinal sub-
ndothelial receptor; mTOR,
rived growth factor receptor;
hreonine kinases; TFA, tri-
roteinase 1; TK, tyrosine ki-
rzaro).
served.receptor (FGFR1), and the cytoplasmic enzymes Abl1 and Src play
crucial roles in cell proliferation as well as in cancer onset and
progression [7]. On the other hand, the phosphatidylinositol-3 ki-
nase (PI3K) is mainly a lipid kinase that, along with the mammalian
target of rapamycin (mTOR), is included in the STK family. Indeed,
by phosphorylation of serine or threonine containing proteins the
mTOR/AKT/PI3K pathway controls several cellular functions
including inﬂammatory responses and cancer development [8].
Remarkably, TKs and STKs -induced intracellular signals are
important modulators of ﬁbrogenic process in lung, liver, pancreas,
heart, and gut. Fibrosis can occur during tissue repair or inﬂam-
mation as a result of persistent activation of ﬁbrogenic cells, which
leads to aberrant extracellular matrix (ECM) deposition and pro-
gressive substitution of the normal parenchyma by scar tissue [9].
For instance, persistent liver injury and unrestrained inﬂammatory
cascade lead to EGFR-mediated proliferation and migration of he-
patic stellate cells (HSCs), the cellular population involved in the
deposition of ECM in the liver [10]. In addition, release of speciﬁc
growth factors triggers the synergistic activation of a number of
protein kinase pathways that serve different biological roles related
to ﬁbrogenesis [11]. Inhibition of KDR by neutralizing monoclonal
antibody ameliorated carbon tetrachloride induced hepatic ﬁbrosis
in mice not only by suppressing the neovascularisation but also by
reducing the a1(I)-procollagen mRNA expression in HSCs [12].
Likewise, preliminary randomized double-blind clinical trials
G. Marzaro et al. / European Journal of Medicinal Chemistry 115 (2016) 416e425 417indicate that sirolimus and everolimus, two mTOR inhibitors,
induce remission in refractory Crohn's Disease (CD) by decreasing
the number of intestinal subepithelial myoﬁbroblasts (ISEMFs) and
the expression of pro-ﬁbrotic cytokines [13e15]. Currently, the
pharmacological care in patients with tissue ﬁbrosis relies on cor-
ticosteroids and immunosuppressant drugs but ﬁbrosis-related
consequences remain a major causes of morbidity and mortality
[16].
The pivotal role of kinases as targets for novel drugs is clearly
demonstrated by the huge amount of ATP-mimic kinase inhibitors,
mainly TK inhibitors, developed in the last two decades [17]. The
ATP-mimic kinase inhibitors belong to different chemical classes of
compounds. However they share a common pharmacophore [17]
that is generally composed by: i) a scaffold (mainly a nitrogen
containing heterocycle) able to interact through an H-bond with
the kinase hinge region; ii) a lipophilic moiety (mainly an aromatic
or an heteroaromatic system) that occupy a pocket opened by the
so called gatekeeper residue; iii) a spacer between the heterocycle
and the hydrophobic moiety; iv) solvent exposed residues. As part
of our novel bioactive compounds discovery projects [18e20] and
due to our experience in quinazoline compounds [18,19,21], we
decided to investigate whether it was possible to develop novel
quinazolinone-based kinase inhibitors able to restrain the activa-
tion of ﬁbrogenic cells. Quinazolinone compounds are endowed
with a number of biological activities comprising antiviral [22],
antitubercular [23], antimicrobial [24], antitubulin [25], antifolate
[26], anticonvulsivant [27], anti-inﬂammatory [28], antiﬁbrotic [29]
and anticancer [30e32] properties. Their kinase inhibitory activity
however has not been extensively explored.
Herein we report the synthesis and the preliminary evaluation
of several 3-substituted quinazolinones against a panel of kinases
mainly involved in the ﬁbrogenic process. The binding mode of
several compounds with the target kinases was investigated by
means of molecular docking studies. The anti-ﬁbrotic activity of the
compounds was assessed in vitro.
2. Results and discussion
2.1. Chemistry
The general structure of the novel compounds is reported in
Fig. 1A.
The 3-substituted quinazoline compounds are structurally
related to another well known class of kinases inhibitors, the 4-
anilinoquinazolines [34,35] (Fig. 1B), as demonstrated by the su-
perimpositionwith erlotinib in its binding conformationwith EGFR
(Fig. 1C and D). According to our previous studies [19], the 6 and 7
positions of the quinazolinone scaffold were functionalized with
dimethoxy functions or with fused dialkoxy rings, namely a
dioxane and a dioxolane ring. The 3 position of the quinazolinoneFig. 1. (A) General structure of quinazolinone derivatives. (B) General structure of 4-anilin
scaffold (green carbon sticks) and erlotinib (cyan carbon sticks). (D) Superimposition of
(cyan carbon sticks). The tridimensional structure of erlotinib was extracted by the crystallog
colour in this ﬁgure legend, the reader is referred to the web version of this article.)was substituted with several lipophilic moieties (2-bromopyridine,
biphenyl, halophenyl) linked to the quinazolinone nitrogen with a
bridge of variable sizes and chemical properties (methylene, 2-
hydroxyethylene, 2-oxoethylene). According to the type of substi-
tution at the positions 6 and 7, the newly synthesized compounds
were grouped in three classes (Table 1). All the compounds have
been synthesized starting from the appropriate aniline derivatives
through quinazoline intermediates, taking advantage of an already
reported synthetic strategy [36] (Scheme 1).
Brieﬂy, anilines 16a-c were protected as carbamates, submitted
to condensation with hexametylenetetramine in TFA under mi-
crowave irradiation and then to aromatization with potassium
ferricyanide in hydroalcoholic KOH at reﬂux. The obtained quina-
zoline 18a-c were oxidized with CAN in acetic acid to quinazoli-
nones 19a-c [18], which were ﬁnally condensed with the suitable
halobenzyl derivatives, aryloxyrane or haloacetophenones and NaH
in DMF under microwave irradiation give the ﬁnal products 1e15.
2.2. Kinase screening
To outline the proﬁle of activity/selectivity, all the synthesized
compounds were preliminarily screened for their ability to coun-
teract the kinase activity of a selected panel of kinases (both TKs
and STKs) involved in ﬁbrosis [37e43]. Thus, in this study the
synthesized compounds have been tested at 1 mMagainst a panel of
six tyrosine kinases and two serineethreonine kinases. Vatalanib
(PTK787/ZK-22258, a poly-tyrosine kinase inhibitor endowed with
anti-ﬁbrotic and anti-neoplastic activities) [44,45] has been used as
positive control. The results of the screening are summarized in
Table 2.
Many compounds inhibited the activity of KDR or EGFR, though
to a lower extent than vatalanib. The majority of these compounds
(6, 10, 11, and 14) were dual KDR and EGFR inhibitors, whereas
compound 1 was a dual EGFR/PDGFRb (Platelet-Derived Growth
Factor Receptor b-isoform) inhibitor. Moreover compounds 7 and
11 were also active against one of the tested STKs. All the com-
pounds were inactive against the cytoplasmic kinases Abl1 and Src
and the receptor kinase FGFR1.
2.3. Molecular docking
To rationalize the activity proﬁle of some representative com-
pounds, molecular modelling studies were performed. In particular
we focused on compounds 1 (active against EGFR; inactive against
KDR), 11 (active against KDR, EGFR and PI3K; inactive against
mTOR) and 7 (active against mTOR; moderately active against
PI3K).
As depicted in Fig. 2A, compound 1 was expected to interact
through the N1-quinazoline nitrogen and the pyridine nitrogen
with the hinge region residue M793 and with the gatekeeper T790oquinazoline kinase inhibitors. (C) Superimposition of the 3-benzylquinazolin-4-one
the 3-(benzoylmethyl)quinazolin-4-one scaffold (yellow carbon sticks) and erlotinib
raphic complex with EGFR (PDB ID: 1M17) [33]. (For interpretation of the references to
Table 1
Structures of the synthesized compounds.
Compd Series X Ar
1 A -CH2-
2 A -CH2-
3 A -CH2-
4 A -CH2-
5 A -CH2CO-
6 A -CH2CH(OH)-
7 B -CH2-
8 B -CH2-
9 B -CH2-
10 B -CH2CO-
11 B -CH2CO-
12 B -CH2CH(OH)-
13 C -CH2-
14 C -CH2-
15 C -CH2-
aReagents and conditions: (i) ClCOOEt, TEA, T
°C, 10 min. 2. K3Fe(CN)6, KOH 10%, EtOH/H2O
min; (iv) 2-bromo-3-bromethylpyridine (1) o
bromobenzylbromide (3, 8) or 4-bromobenzylbro
15) or 2,4’-dibromoaceto-phenone (5, 10) or
bromophenyl)oxirane (6) or 2-(3-chlorophenyl)ox
°C, 5 min.
Scheme 1. General strategy for the synthesis of qu
G. Marzaro et al. / European Journal of Medicinal Chemistry 115 (2016) 416e425418of EGFR respectively. No consistent binding mode for compound 1
in KDR was obtained. Probably, the presence of the V916 as gate-
keeper in KDR was detrimental for the activity: when the pose
obtained for compound 1 in EGFR was inserted in KDR a clash
between the valine and the lipophilic moiety was observed
(Fig. 2B).
The presence of a longer bridge with H-bond acceptor feature in
compound 11 was probably the key to achieve dual EGFR/KDR in-
hibition (Fig. 3). Again, theN1-quinazoline nitrogenwas expected to
form an H-bond with the hinge residues (M790 in EGFR, Fig. 3A;
C918 in KDR, Fig. 3B). In the case of EGFR, an additional H-bond
between the alcoholic function of T790 and the carbonyl of 11 was
suggested by molecular docking, whereas in KDR the bromophenyl
function probably established lipophilic interaction with the gate-
keeper (V916).
Notably, a similar behaviour was found also for compound 5 and
10, bearing the same CH2C]O bridge (data not shown).
Besides being a dual EGFR/KDR inhibitor, compound 11was also
able to inhibit PI3K while it was inactive against the other tested
STK, mTOR. On the contrary, the shorter bridge in compounds 7 and
8 led to compounds endowed with moderate dual mTOR/PI3K
inhibitory activity. As depicted in Fig. 4, 7 (Fig. 4A) and 11 (Fig. 4B)
showed comparable binding modes in PI3K. Docking studies sug-
gested that the dioxane oxygens could establish H-bonds with the
hinge residue V848, the N1-quinazoline nitrogen atoms could
interact with the K799 and the lipophilic moieties may be involved
in T-shaped areneearene interactions with theW781 aromatic side
chains.
Conversely, in mTOR kinase, compound 7 was expected to
interact with the hinge residue V2240 through an H-bond, with the
W2239 through a T-shaped areneearene interaction and with the
DFG-motif (Fig. 5A). A similar pose was not obtained for compound
11. Indeed, the alignment of compound 11 on the pose obtained for
compound 7 in mTOR revealed two clashes between the carbonyl
in the bridge and the W2239 and between the bromine atom and
the I2163 side chain (Fig. 5B).
Finally, we used molecular docking studies also to investigate
the differences in potencies of compounds 1, 3 and 4 against EGFR.
Indeed, very small variation in structures (compounds mainly
differed for the relative position of the bromine atom and for the
presence of a pyrimidine in place of a phenyl function at position 3)
caused quite high differences. As shown in Fig. 6A, there were
probably no differences in binding modes for compounds 1 and 3.
Hence, the lower activity of 3 could be ascribed to the lack of
interaction with the T790 (due to the absence of the nitrogen atom
in the benzyl portion) rather than to the bromine atom position. OnHF, rt, 30 min; (ii) 1. HMTA, TFA, MW, 110 
 1/1, reflux, 4 h; (iii) CAN, AcOH, H2O, rt, 5 
r 3-phenyl-benzylbromide (2, 14) or 3-
mide (4, 9, 13) or 4-phenylbenzylchloride (7, 
 2,3’-dibromo-acetophenone (11), or 2-(4-
irane (12), NaH, anhydrous DMF, MW, 120 
inazolinone derivatives as kinase inhibitorsa.
Table 2
Kinase inhibition proﬁle.
Fig. 2. (A) Binding mode proposed for 1 in EGFR. (B) Clash (black arrow) between 1 and V916
on the left side of the pictures, while the kinase solvent accessible region is on the right si
Fig. 3. (A) Binding mode proposed for 11 in EGFR. (B)Binding mode proposed for 11 in KDR (V
side of the pictures, while the kinase solvent accessible region is on the right side.
G. Marzaro et al. / European Journal of Medicinal Chemistry 115 (2016) 416e425 419the contrary, docking studies suggested a worse complementarity
with the ATP pocket for compound 4 (Fig. 6B), probably caused by
the hindrance of the para-bromine atom.2.4. In vitro anti-ﬁbrotic activity
As many substituted quinazolinones are endowed with good/
strong inhibition activity towards kinases involved in the ﬁbrogenic
process (Table 2), we decided to assess the biological effect of the
active compounds in modulating the activation of ﬁbrogenic cells,
namely HSCs and ISEMFs. Primary cells were isolated from human
liver or gut specimens and cultured in plastic support to induce
in vitro ﬁbrogenic activation. As reported in Fig. 7, at 1 mM com-
pounds 6, 7, 10, 11, and 14 were the most effective in reducing the
mRNA levels speciﬁc for COL1A1 in HSCs and ISEMFs. The mRNA
transcript levels speciﬁc for FN1 and TIMP1 were decreased also by
compounds 1 and 5. Noteworthy, compounds 6, 7, 10, 11, and 14
showed a unique proﬁle of activity in the series since they were
able to inhibit KDR with strong/good potency and at least another
kinase (Table 2). Compounds 1 and 5 effectively reduced the mRNA
expression levels of TIMP1 and FN1 in pathological samples (i.e.
ISEMFs cultured from patients suffering from Crohn's disease) with
poor effect on myoﬁbroblasts obtained from healthy subjects in
which the ﬁbrogenic activation is probably less important. For all
the tested genes, the reduction in the mRNA expression was com-
parable to one reported for vatalanib. Finally, compounds endowedin KDR (V916 is represented as mesh surface). In both cases, the kinase hinge region is
de.
916 is represented as mesh surface). In both cases, the kinase hinge region is on the left
Fig. 4. (A) Binding modes proposed for 7 in PI3K. (B) Binding mode proposed for 11 in PI3K. In both cases, the kinase hinge region is on the left side of the pictures, while the kinase
solvent accessible region is on the right side.
Fig. 5. (A) Binding proposed for 7 in mTOR. (B) Clashes (black arrows) between 11 and W2239 and I2163 in mTOR (11, W2239 and I2163 are depicted as mesh surfaces). In both
cases, the kinase hinge region is on the left side of the pictures, while the kinase solvent accessible region is on the right side.
Fig. 6. (A) Comparison between the binding modes suggested by docking studies for 1 (yellow carbon sticks) and 3 (cyan carbon sticks) in EGFR. (B) Comparison between binding
modes of 1 (yellow carbon sticks) and 4 (pink carbon sticks) in EGFR. In both cases, the kinase hinge region is on the left side of the pictures, while the kinase solvent accessible
region is on the right side. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the expression of genes involved in the ﬁbrogenic process.
Compounds 1, 6, and 13 also inhibited proliferation in HSCs and
ISEMFs. Consistent with previous reports, VEGF induces prolifera-
tion in HSCs [46]. As reported in Fig. 8, treatment of cells with 1 mM
for 72 h signiﬁcantly decreased VEGF-induced proliferation. The
effect was more evident in cells treated with compounds 1 and 13,the only quinazolinone derivatives endowed with good inhibition
of PDGFR.
Most important, the treatment for 72 hwith compounds at 1 mM
did not compromise cell viability (Fig. 9). On the contrary, under the
same conditions vatalanib reduced cell viability, as previously re-
ported [47].
The anti-ﬁbrogenic and anti-proliferative effects of compounds
Fig. 7. Expression levels of mRNA transcripts speciﬁc for prepro-alpha 1 collagen (COL1A1), ﬁbronectin (FN1), and tissue inhibitor of metalloproteinase 1 (TIMP1) assessed by
quantitative RT-PCR on hepatic stellate cells (HSCs) and intestinal subepithelial myoﬁbroblasts (ISEMFs) cultured from specimens obtained by healthy subjects and patients
suffering from Crohn's disease (CD). Data are reported as mean ± SE. * denotes P < 0.05 vs untreated, control cells (CTR). Vat: vatalanib.
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MAPK. Thus, phosphorylation of p38MAPK is augmented in acti-
vated HSCs mediating the upregulation of COL1A1 mRNA levels
[48]. Indeed, phospho-p38MAPK levels mainly decreased in HSCs
treated for 4 h with compounds 1, 6 and 11 at 1 mM as compare to
untreated cells (Fig. 10). Similar results were obtained in ISEMFs
cultured from patients suffering from Crohn's disease (data not
shown).
3. Conclusions
The evaluation of kinase inhibitors bearing the quinazolinone
core has not yet been extensively studied, although this scaffold is
present in a number of biologically active compounds. In this work
the synthesis and the preliminary biological evaluation of quina-
zolinone derivatives as kinase inhibitors have been described. The
synthesized compounds have been tested towards a panel of six
tyrosine kinases and two serineethreonine kinases. The proﬁle of
selectivity of some representative compounds has been rational-
ized through molecular docking studies, furnishing useful sugges-
tions for further development of this class of compounds.
The kinase inhibition proﬁle evaluated by in vitro assay (Table 2)
prompted us to investigate the anti-ﬁbrotic properties ofquinazolinone derivatives. Our data revealed that the synergistic
inhibition of EGFR and KDR efﬁcaciously reduced the levels of
mRNA transcripts involved in the ﬁbrogenic activation of both HSCs
and ISEMFs, the cell populations mainly involved in the ﬁbrosis of
liver and gut, respectively. Indeed, compounds 6, 10, 11 and 14,
showing the dual EGFR/KDR inhibitory activity, signiﬁcantly
reduced COL1A1 mRNA expression as compare to non-treated
in vitro activated cells to an extent comparable to or even greater
than vatalanib. Previous studies reported the involvement of EGFR
and KDR in the regulation of HSCs [10,12] but to our knowledge this
is the ﬁrst time that dual inhibitors of TKs efﬁcaciously control
expression of ﬁbrogenic genes. The simultaneous inhibition of KDR
and EGFR however is not mandatory for the anti-ﬁbrotic effect.
Indeed, compounds 1, 5, and 7 revealed different gene-related and
cellular speciﬁc effects. In particular, compound 7 endowed with
dual KDR/mTOR inhibitory activity, signiﬁcantly downregulated the
expression of pro-ﬁbrogenic genes. Thus, several soluble factors
and signalling pathways are central to the ﬁbrotic process. Besides
EGFR and KDR, PDGFR has been reported as the most potent pro-
liferative factor toward HSCs and myoﬁbroblasts [49]. Because of
their combined role in ﬁbrosis, inhibition of both proliferation and
ﬁbrogenesis is an attractive target for antiﬁbrotic therapy. Among
our synthetized quinazolinone derivatives only compound 1
Fig. 8. Cell proliferation assessed as carboxyﬂuorescein diacetate succinimidyl ester
(CFSE) positive cells (percentage). HSCs and ISEMFs were treated with 1 ng/ml VEGF
and compounds for 72 h. Fluorescence was then evaluated by FACS analysis. Data are
reported as mean ± SE.  denotes P < 0.05 vs untreated, control cells (CTR). * denotes
P < 0.05 vs VEGF-treated cells. Vat: vatalanib.
Fig. 9. Percentage of vital HSCs and ISEMFs following treatment with compounds for
72 h. Data are reported as mean ± SE. * denotes P < 0.05 vs untreated, control cells
(CTR). Vat: vatalanib.
Fig. 10. Inhibition of p38MAPK phosphorylation assessed by western blot analysis in
HSCs untreated (CTR) or treated for 4 h with compounds 1 mM.
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reported good anti-ﬁbrotic activity, reducing FN1 and TIMP1mRNA
transcript levels and also inhibited VEGF-induced cell proliferation.
However, even if at lower extent compound 6 reported anti-
proliferative activity, too, proving that quinazolinone derivatives
inhibit activated ﬁbrogenic cells by complex mechanisms. Indeed,
compounds 1, 6, and 11 exert their anti-ﬁbrotic and anti-
proliferative effects on p38MAPK pathway although we can not
exclude other intracellular signaling cascades.
On the basis of the acquired data and of the docking studies,
novel compounds with improved inhibitory activity against STKs
will be synthesized, with the aim to strengthen the anti-ﬁbroticproperties of quinazolinone derivatives. Fully exhaustive relation-
ship between kinases inhibition proﬁle and biological activity is
however not derivable mainly because i) the expression of the
G. Marzaro et al. / European Journal of Medicinal Chemistry 115 (2016) 416e425 423different ECM proteins is driven by several intracellular pathways
and ii) different kinases are speciﬁcally elicited in distinct cell
populations (i.e. HSCs and ISEMFs) as well as at different step of the
ﬁbrogenic process (compare effects on ISEMFs from healthy sub-
jects and patients suffering for Crohn's disease). Indeed, a complex
network of extracellular factors (e.g. endocrine system,metabolism,
growth factor and metalloproteinase secretion) characterizes
ﬁbroblast activation and ECM deposition in every tissue-related
ﬁbrogenic process [50,51]. The acquired data indicate compounds
1, 6, and 11 as novel promising anti-ﬁbrotic compounds endowed
with multiple kinases inhibitory properties. The synthesis of novel
compounds as well as amore exhaustive biological investigation on
this novel class of multi-kinase inhibitors is in progress. Overall, our
data suggest that the quinazolinone is an attractive scaffold for the
development of novel inhibitors of kinases involved in the ﬁbro-
genic process.
4. Experimental
4.1. Chemistry
See Supplementary Data for general synthetic methods, for the
synthesis of 2-bromo-3-bromethylpyridine and for the analytical
details (mp, NMR, HRMS, elemental analyses) of all compounds.
Purity of all tested compounds was determined by elemental ana-
lyses and was found equal or more than 95%. Compounds 19a [21]
and 19b-c [18] were synthesized as previously reported.
General procedure for quinazolinones 1e15. A mixture of quina-
zolinone 19a [21] or 19b-c [18] (1.0 mmol) and NaH in DMF was
maintained under N2 for 5 min. The appropriate haloderivative or
aryloxirane was added (1.0 mmol) and the mixture was microwave
irradiated at 120 C (power 250 W; hold time 5 min). After cooling,
the mixture was poured in sat. NH4Cl solution (30 mL) and the
obtained precipitate were collected by ﬁltration. The solid was
puriﬁed by crystallization to give the title compounds (yields
10e52%).
4.2. Computational methodologies
The computational experiments were performed on a 4 CPUs
(Intel Core2 Quad CPU Q9550 @ 2.83 GHz) ACPI 64 Linux work-
station (operating system: Ubuntu ver. 12.04). Protein structures
were handled with Chimera 1.5.3 software [52]. The structures of
the quinazolinone compounds were prepared using MarvinSketch
5.5.0.1 software [53] and OpenBabel 2.2.3 softwares [54]. The
docking studies were conducted with AutoDock 4.2 software [55]
as previously reported [19]. Further details are given in
Supplementary Data.
4.3. Biology
4.3.1. In vitro kinase assays
Synthesized compounds were tested in vitro for inhibition of a
panel of TKs and STKs, as previously reported [19]. See
Supplementary Data for a detailed description.
4.3.2. Cell isolation and culture
Human hepatic stellate cells (HSCs) were freshly isolated from
non-pathological fragments of liver tissue collected during surgical
procedures. Samples were processed separately and HSCs were
cultured as previously described [56]. Brieﬂy, following digestion
with collagenase and pronase, HSCs were isolated by centrifugation
over a gradient of Percoll (Amersham Biosciences, Sweden) and
cultured in DMEM containing 10% vol/vol fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, (allprovided by Gibco, Milan, Italy). Purity of cultured HSCs was
assessed by immunocytochemistry using anti-aSMA antibody
(Sigma).
Human intestinal subepithelial myoﬁbroblasts (ISEMFs) were
isolated from non-pathological colonic biopsies collected during
colonoscopy for cancer screening and from patients with Crohn's
disease collected during routine follow-up endoscopy program.
Tissue samples were processed separately. Biopsies were diced and
digested for 30 min at 37 C in collagenase (0.25 mg/ml, Sigma).
Recovered cells were suspended in DMEM with 20% vol/vol FBS,
2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 ng/
mL fungizone (Gibco). Purity of cultured ISEMFs was ascertained by
ﬂuorescence-activated cell sorting (FACS) analysis using anti-CD90
antibody (ImmunoTools, Germany). HSCs and ISEMFs were
cultured at 37 C in a 5% CO2 humidiﬁed incubator. At conﬂuence,
cells were detached using 0.05% Trypsin-EDTA (Gibco). The study
protocol followed the principles expressed in the Declaration of
Helsinki and was approved by the Ethical Committee of the Uni-
versity Hospital of Padova. Each patient was provided with detailed
information about the study aims and protocols, and gave their
written, informed consent.
4.3.3. RNA isolation and quantitative polymerase chain reaction
HSCs and ISEMFs were cultured in 6 well plates and treated for
24 h with 1 mM of test compounds or vatalanib. Total RNA was
extracted using the SV total RNA isolation system (Promega, Italy)
according to the manufacturer's instructions. Contaminating DNA
was removed by DNase I treatment (Promega). cDNA was synthe-
sized using 2 mg RNA as template, random hexamer primers and
MuLV Reverse Transcriptase (Applied Biosystems, Milan, Italy).
Gene expression was evaluated by quantitative polymerase chain
reactions (qPCR) using ABI Prism 7700 Sequence Detection System
(Applied Biosystems), TaqMan qPCR Master Mix (Applied Bio-
systems), and speciﬁc oligonucleotides and probes (Universal Probe
Library system, UPL, Roche Applied Science, Monza, Italy) for
prepro-alpha 1 collagen (COL1A1), ﬁbronectin 1 (FN1), and tissue
inhibitor of metalloproteinase 1 (TIMP1). The expression of the
target gene was normalized to the level of the housekeeping gene
18S ribosomal RNA (18SrRNA). Experiments were performed in
triplicate for each isolated cell batch. The relative changes in gene
expression were analyzed using the DDCT method. Oligonucleo-
tides and probes are reported in Supplementary Data.
4.3.4. Proliferation assay
HSCs and ISEMFs were incubated at 37 C for 10 min in pre-
warmed PBS containing 0.1% vol/vol BSA (Sigma) and 25 mM car-
boxyﬂuorescein diacetate succinimidyl ester (CFSE, Molecular
Probe, Invitrogen). Staining was quenched by adding 5 volumes of
ice-cold culture media. Sixteen hrs later the cells were washed and
treated with 1 mM compounds or vatalanib for 72 h. Cell prolifer-
ation was evaluated by the partitioning of ﬂuorescent dye between
daughter cells using BD FACS-Calibur ﬂow cytometer. Experiments
were performed in duplicate for each isolated cell batch. Results
were analyzed using the WinMDI 2.9 (Windows Multiple Docu-
ment Interface for Flow Cytometry) program.
4.3.5. Cell viability assay
To evaluate cell viability, HSCs and ISEMFs were seeded into 96-
well plates at 2  103 cells/well. Cells were then exposed for 72 h to
1 mM tested compounds or vatalanib and ﬁnally added with 3-(4,5-
dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT,
0.50mg/ml, Sigma) for 4 h. Formazan crystals were dissolved in 10%
w/vol SDS containing 0.01 M HCl. Optical densities were measured
at 450 nm using a microplate reader (Sunrise, Tecan; Switzerland).
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batch and cell viability was expressed as a percentage relative to
respective untreated cells.
4.3.6. Western blotting
HSCs and ISEMFS isolated from gut specimens of patients
suffering from Crohn's disease were treated for 4 h with com-
pounds at 1 mM. For Western blot analysis total proteins from
cultured cells were extracted in RIPA buffer (150 mM NaCl, 50 mM
TriseHCl, 0.25% wt/vol sodium deoxycholate, 0.1% Nonidet P-40,
100 mM NaVO4, 1 mM NaF, 1 mM phenylmethylsulfonyl ﬂuoride,
10 mg/ml aprotinin, 10 mg/ml leupeptin). Particulate material was
removed by centrifugation. Proteins were separated with 10% SDS
PAGE and then transferred to nitrocellulose membranes (BioRad,
Italy). Membranes were probed with phospho-p38 MAP Kinase
antibody (Cell Signaling) and then incubated with anti-rabbit HRP-
conjugated secondary antibodies. Immune complexes were visu-
alized using enhanced chemiluminescence (Millipore). Membranes
were then re-probed with p-38 MAP Kinase antibody as loading
control. Experiments were performed in duplicate. Images were
captured using Hyper Film MP (GE Healthcare).
4.3.7. Statistical analysis
Statistical analysis was performed using GraphPad Prism 3.03
software (San Diego, California, USA). One-way analysis of variance
followed by the Bonferroni post-hoc test was used to compare
multiple experimental groups. P values < 0.05 were considered
statistically signiﬁcant.
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Kinase inhibitors are attractive drugs/drug candidates for the treatment of cancer. The most recent 
literature has highlighted the importance of multi target kinase inhibitors, although a correct 
balance between specificity and non-specificity is required. In this view, the discovery of multi-
tyrosine kinase inhibitors with subfamily selectivity is a challenging goal. Herein we present the 
synthesis and the preliminary kinase profiling of a set of novel 4-anilinopyrimidines. Among the 
synthesized compounds, the N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives selectively 
targeted some members of class III receptor tyrosine kinase family. Starting from the structure of 
hit compound 19 we synthesized a further compound with an improved affinity toward the class III 
receptor tyrosine kinase members and endowed with a promising antitumor activity both in vitro 
and in vivo in a murine solid tumor model. Molecular modeling simulations were used in order to 
rationalize the behavior of the title compounds.
Protein kinases (PKs) are key enzymes that regulate almost all cell processes. PKs transfer a phosphate 
group from ATP (or GTP) to specific residues (mainly tyrosine, threonine or serine) located in the 
target proteins, thus promoting specific pathways1,2. The human kinome contains 518 different protein 
kinases grouped into eight major families on the basis of structural similarity2,3. The overexpression or 
deregulation of kinases (in particular tyrosine kinases, TKs) are often linked to cancer onset and progres-
sion4. Hence, TKs are among the major classes of biological targets for modern cancer therapy5. The TK 
family contains both receptor (RTK) and cytoplasmic enzymes3. Among the RTKs, of particular interest 
are the ErbB family6 (or class I RKT, comprising the four receptors ErbB1-4) and the platelet-derived 
growth factor family7 (PDGF; or class III RTK). Activating mutations of ErbB1 (also known as epidermal 
growth factor receptor, EGFR) are correlated with onset and progression of different solid cancers8 and 
in particular with lung cancer9. Mutations in class III RTK members (i.e. Fms-like TK-3, FLT3; colony 
stimulating factor-1 receptor, CSF1R; KIT; PDGFRα ; PDGFRβ ) are associated with hyper-proliferative 
pathologies as hematologic neoplasms10,11, lung cancer12 and pancreatic cancer13,14.
The high number of FDA approved drugs in the last 15 years reveals the growing interest in TK inhib-
itors (TKIs)15,16. In most cases, TKIs act as ATP-mimic compounds, although several allosteric inhibitors 
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are under investigations17. Cancer is a multi factorial disease and recent findings have highlighted the 
importance of multi targeting compounds, i.e. compounds able to inhibit, with comparable potencies, 
more than one TK18. However, both selective (e.g. erlotinib and gefitinib) and unselective (e.g. sunitinib 
and dasatinib) kinase inhibitors are useful anticancer drugs. Hence, whether multi-kinase inhibitors have 
significant advantages than single kinase inhibitors is still debated19. Only some specific kinases should 
be targeted by multi-inhibitors to guarantee high efficacy while maintaining an acceptable safety: in 2010 
Morphy used the term “selectively nonselective” TKIs to describe compounds with an ideal profile of 
kinase inhibition20.
Currently, a number of multi kinase inhibitors have been discovered, both by chance and by design19. 
The rational design of “selectively nonselective” TKIs is a challenging and fascinating goal: the ATP 
binding pocket is quite conserved in the entire kinome, and it is particularly conserved inside each PKs 
subfamily. In this view, an achievable and promising aim could be the design/development of subfamily 
selective kinase inhibitors. However, as recently reported, the inhibition of all the members of a single 
subfamily can lead to substantial toxicity21.
The ATP pocket is delimited by the hinge region (containing also the gatekeeper residue), the P-loop, 
the C-helix and the activation loop (containing the highly conserved DFG motif; Fig.  1a). The ATP 
binding pocket is constituted by the adenine pocket, the hydrophilic ribose pocket and two hydrophobic 
regions (Fig.  1b,c). Accordingly, TKIs are commonly constituted by i) a nitrogen containing hetero-
cycle able to form an H-bond with the hinge region; ii) an hydrophobic moiety interacting with the 
hydrophobic region I of the kinase; iii) a spacer between the heterocycle and the hydrophobic moiety 
(Fig. 1d,e)15,22.
Figure 1. Structure of kinases and of designed compounds. (a) Main element in kinase structure. (b) 
Binding of AMP-ANP (PDB ID: 2GS7). (c) Schematic representation of binding of ATP and features of the 
ATP binding pocket. (d) Detail of binding of a kinase inhibitor (erlotinib; PDB ID: 1M17). (e) Schematic 
representation of binding of inhibitor (erlotinib) with respect to the features of the ATP binding pocket. 
Image partially readapted from ref. 22. (f) General structures of designed compounds and their structural 
relationship with 4-anilinoquinazolines. (g) Supposed binding mode of designed compounds in the ATP 
binding pocket.
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A recurring motif in kinase inhibitors is the pyrimidine nucleus. Some symmetric 
4,6-dianilinopyrimidines were reported as selective EGFR inhibitors23. However, the selectivity profile 
was reported only for few compounds23. Similar compounds were also patented by Avila therapeutics 
(WO2009/051822), but few kinases were considered as targets. A number of 4-anilino-6-phenylpyrimidines 
were patented as cyclin-dependent kinase (CDK) inhibitors (see for example WO2008/129080 and 
WO2011/077171). Phosphorous containing pyrimidines as CDK inhibitors were recently published24. 
Examples of FDA approved pyrimidine based TKIs are imatinib25 (Abl/KIT/PDGFRβ inhibitor) and 
dasatinib26 (dual Abl/Src inhibitor). Examples of compounds involved in clinical trials are BAY100039427 
and the fused pyrimidine PHA-84812528 (pan CDK inhibitors). Nevertheless, in most cases the pyrimi-
dine nucleus is not the main “nitrogen containing heterocycle”, since it does not interact with the hinge 
region, as shown by X-ray crystallography29.
Another interesting class of TKIs is constituted by the 4-anilinoquinazolines30. These compounds 
are mainly known as high selective EGFR31, dual EGFR/ErbB232 or dual EGFR/VEGFR233 (vascular 
endothelial growth factor receptor-2). We have recently reported that the m-biphenylamine as aniline 
moiety led to multi kinase inhibitors targeting EGFR, fibroblast growth factor receptor-1 (FGFR1), 
VEGFR2, PDGFRβ , Src and Abl at nanomolar concentrations34,35. Indeed, 4-anilinoquinazolines could 
be considered as fused pyrimidine (i.e. 4-anilinobenzopyrimidine).
On these basis, we planned the synthesis of novel potential TKIs bearing the 4-anilinopyrimidine core 
as the nitrogen containing heterocycle (Fig. 1f). The compounds were further characterized by 5-phenyl, 
6-phenyl or 6-phenylamino moieties designed to interact with the hydrophobic region II of the ATP 
pocket, the ribose pocket or the DFG motif (Fig. 1g). The 4-anilino portion of the compounds was sup-
posed to interact with the hydrophobic pocket I (HP-I) of the kinase, in analogy to 4-anilinoquinazolines. 
The interactions with HP-I have often been used to obtain selectivity in kinase inhibitions36–38. For exam-
ple, very small differences in position or nature of 4-anilinosubstituent in quinazoline compounds led to 
selective EGFR39, VEGFR240 or janus kinase (JAK)41 inhibitors. Hence, we functionalized the 4-anilino 
moiety with substituent differing in the hydrophobicity/hydrophilicity, in the ability to act as H-bond 
donor or acceptor, in the position and in the size. Since our purpose was to determine how the function-
alization of the pyrimidine nucleus at 4 and 5 or at 4 and 6 positions could modulate the kinase selec-
tivity profile, at this stage, we considered only simple commercially available or easily accessible anilines. 
Several papers and patents describing very similar compounds as kinase inhibitors are present in liter-
ature (a selection of representative bibliography is reported in Table S2). The novelty of our work relies 
in the evaluation of a library of simple 4-anilinopyrimidines against a wide panel of kinases and human 
cancer cell lines to discover novel “selective unselective” hit compounds. Indeed, through this approach 
we identified the 6-phenyl-4-anilinopyrimidine derivative 19 as a selective dual KIT/PDGFRβ inhibi-
tor. Compound 19 was further improved, leading to a novel and more potent KIT/PDGFRα /PDGFRβ 
inhibitor (27) endowed with a promising anticancer potential. Molecular modeling studies were used to 
clarify the structure activity relationships emerged by Kd determination. Since both 19 and 27 targeted 
only few specific members of a TK family, they can be considered as novel “selectively nonselective” TKIs.
Results
Compounds synthesis. The structures of synthesized compounds are reported in Fig.  2 (see also 
Table S1).
Compounds 1–7 and 8–12 were obtained starting from 4,6-dichloropyrimidine 28 (Fig. 3a). In case 
of unsymmetrical compounds (1–7), compound 28 was first condensed with a slight excess of aniline 
in i-PrOH in the presence of triethylamine (TEA) and then with the appropriate aniline derivatives 
in i-PrOH, in both cases taking advantage from the Microwave Assisted Organic Synthesis (MAOS). 
Diarylurea derivative 7 was obtained by the reaction of aminoderivative 6 with phenyl isocyanate in 
dichloromethane.
In case of symmetrical compounds (8–12), compound 28 was reacted with a double amount of the 
appropriate aniline derivatives, but in this case, the nucleophilic aromatic substitutions were performed 
in i-PrOH at reflux without the presence of TEA.
Compounds 13–19 were synthesized starting from ethyl benzoylacetate (30; Fig.  3b) which was 
reacted with thiourea in anhydrous alkaline medium obtaining the corresponding thiopyrimidinol 31. 
The thiol function was removed through Ni-Raney reduction. Compound 32 was then activated toward 
nucleophilic substitution by reaction with POCl3/TEA. Finally, the chloropyrimidine 33 was condensed 
with the appropriate aniline derivatives in i-PrOH, under microwave irradiation. Compound 19 was 
obtained from aminoderivative 18 as above described for compound 7.
Compounds 20–26 were synthesized adapting a previously reported synthetic strategy42 (Fig.  3c). 
Thiourea 34 was firstly condensed with N,N-dimethylformamide dimethyl acetal and then treated with 
iodomethane in order to elicit the nucleophilic properties of the sulfur atom. Intermediate 36 was then 
reacted with phenylacetyl chloride in the presence of TEA. In this case we did not remove the sul-
fur function at this stage. In fact, the process worked better first activating compound 37 toward the 
nucleophilic aromatic substitution, then reacting compound 38 with the appropriate anilines and finally 
removing the sulfur function with the Ni-Raney system. Compound 26 was obtained from aminoderiv-
ative 25 as above described for compound 7.
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Among all the synthesized compounds, only two were previously reported: compound 5 was cited as 
synthetic intermediate43, whereas 8 was patented by Zeneca (US5880130). However, the two compounds 
were not previously screened against a panel of kinases. Compound 19 was commercially available in 
the Ambinter screening library. However, as reported in the Ambinter web site, it might be available only 
under re-synthesis with an extended delay, thus we synthesized it by ourselves. Besides, the compound 
was not present in academic accessible databases (e.g. PubChem, Reaxys).
Tyrosine kinases screening. Synthesized compounds were screened against a panel of 48 
kinases selected within the ScanEDGE subset of DiscoverX (http://www.discoverx.com/services/
drug-discovery-development-services/kinase-profiling/kinomescan/scanedge). The ScanEDGE includes 
97 kinases and is an economical approach to assess compounds selectivity throughout the human kinome. 
All the wt-TKs along with some relevant mutants of Abl1 (T315I) and of EGFR (L858R and L858R/
T790M) were chosen. The remaining 18 targets (3 Tyrosine Kinases-Like, TKLs; 15 Serine-Threonine 
Kinases, STKs) were selected among the remaining kinases in the ScanEDGE subset on the basis of 
their well established role in cancer (see Fig. S2 for a graphical representation of the selected kinases 
with reference to the kinome tree. Some references highlighting the role of each kinase in cancer are 
also reported in Table S3).
The compounds were evaluated using the KinomeScan™ platform (http://www.discoverx.com/ser-
vices/drug-discovery-development-services/kinase-profiling/kinomescan), that measures the ability of the 
test compound to disrupt the complex between a high affinity ATP-mimic probe immobilized on a solid 
support and the kinase of interest. The KinomeScan is a very helpful technology for the fast and reliable 
screening of a number of compounds against a wide and customizable panel of kinases. Besides, it is not 
based on the use of hazardous radioactive 32P-ATP and has a very low rate of false positive (< 1%)44. The 
screening platform outputs a “Percent of Control” (POC) value, statistically correlated to the dissociation 
constant (Kd) value (http://www.discoverx.com/tools-resources/leadhunter-study-reports-data-analysis), 
for each pair of kinase/ligand. The POC is calculated as reported in equation (1):
Figure 2. Structures of synthesized compounds. 
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=
−
−
×
( )
POC
test compound signal positive control signal
negative control signal positive control signal
100
1
Where: test compound signal = amount of kinase still binding the probe after treatment with test com-
pound; negative control signal = amount of kinase still binding the probe after treatment with DMSO 
(100% control); positive control signal = amount of kinase still binding the probe after treatment with 
control compound (0% control). Hence, low POC values indicate high affinity.
The compounds were tested at high concentration (10 μ M), in order to highlight not only the main 
target but also the off-targets. The results of the preliminary screening are reported as heat map (Fig. 4; 
see also Table S4 for all the measured values), in which the compounds are grouped on the basis of the 
6 or 5 substituent at the pyrimidine ring.
All the tested compounds were almost inactive against both TKL and STK members. The 
6-phenylamino compounds targeted the ErbB family (comprising the wt-EGFR, ErbB2 and the two 
EGFR mutants L858R and L858R/T790M). Similarly to what previously reported23, these derivatives were 
mainly active against wt-EGFR, although with different potencies. Some 6-phenylamino compounds and 
the three phenylurea derivatives (7, 19 and 26) were active against the members of the class III RTKs 
family.
Structure activity relationship. Overall, 4-anilinopyrimidines targeted mainly the ErbB and the 
class III RTKs subfamilies.
With respect of targeting EGFR, the presence of a 5-phenyl or a 6-phenyl ring was detrimental (com-
pare 1 with 13 and 20; Fig.  5a). Hence, only 6-phenylamino-4-anilinopyrimidines were active against 
Figure 3. Synthesis of compounds 1–26. See Fig. 2 for R specification.
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EGFR. For these compounds, the substitution of the 4-aniline moiety with small meta lipophilic substit-
uents was preferred (e.g. potencies: 1m−Me > 4p−Me; 8m−Me = 1m−Me = 9m−Br > 11p−Cl). Conversely to what 
previously reported for 4-anilinoquinazolines34, a biphenylamino moiety was detrimental (see 2 and 
10). The L858R mutation (that causes an enhancement of the kinase activity without directly modifying 
the ATP site45) did not affect the ligand binding, whereas the T790M gatekeeper mutation dramatically 
impaired the interaction. Despite the high degree of similarity between wt-EGFR and ErbB2, compounds 
were not active against the latter kinase. The presence of small meta hydrophilic function (i.e. 3m−OH) was 
well tolerated, still leading to selective EGFR inhibitors. Interestingly, small para hydrophilic substituents 
(OH, NH2) led to less selective compounds: derivatives 5 and 6 targeted EGFR, some members of the 
class III RTKs and AXL. The lowest selectivity was obtained when the pyrimidine core was functionalized 
at both 4 and 6 position with para-hydroxyaniline moieties: indeed compound 12 targeted a number 
of kinases, comprising also the T790M mutant of EGFR. We are planning further investigation on this 
compound. When the 4-anilino was functionalized with bulky hydrophilic function (i.e. a phenylurea, 
see compound 7), very poor activity against EGFR was observed.
With respect of targeting class III RTKs, as above mentioned, the presence of a para H-bonding 
substituent in the 4-aniline moiety was required (see compounds 5 and 6). When the 4-aniline moiety 
was functionalized with a para-phenylurea substituent, selective class III RTK members inhibition was 
obtained. Indeed, in the case of phenylurea compounds (7, 19 and 26), the functionalization at 5 or 
6 position of the pyrimidine nucleus played a key role in determining the degree of selectivity within 
the subfamily. The inhibition of KIT and PDGFRβ was not affected by pyrimidine substitution at 5 
or 6 position (potencies: 76−Phenylamino = 196−Phenyl = 265−Phenyl). Conversely, the inhibition of PDGFRα 
strongly depended on both the nature and the position of the pyrimidine substituent (potencies: 265−
Phenyl > 196−Phenyl > 76−Phenylamino). The absence of a substituent at the 6 position led to the inhibition of all 
the members of the subfamily (see 265−Phenyl). On the other end, the presence of the 6-phenyl gave the 
highest selectivity (potencies for 196−Phenyl: KIT = PDGFRβ > PDGFRα > CSF1R > FLT3). Finally, the 
introduction of a linker between the phenyl and the pyrimidine nuclei gave an intermediate selectivity 
degree (potencies for 76−Phenylamino: KIT = PDGFRβ = FLT3 > CSF1R > PDGFRα ).
The main structure activity relationships are resumed in Fig. 5b.
Cytotoxicity. Compounds active against at least one kinase among EGFR and class III RTKs were 
evaluated for their cytotoxic properties against two different human cancer cell lines, namely non small 
cells A549 lung cancer cells (sensitive to EGFR inhibitors)46 and pancreatic BxPC3 adenocarcinoma 
(sensitive to both PDGFRβ and EGFR inhibitors)47,48 cells. For comparison purposes, sunitinib (SU), a 
multi-kinase inhibitor49, was evaluated under the same experimental conditions. The results, expressed 
as IC50 values (μ M) calculated from the dose-survival curves obtained after 72 h of drug treatment from 
the MTT test, are reported in Table 1.
The newly synthesized compounds (excluding 8, 9 and 12) showed a cytotoxic potency in the micro-
molar range against both cancer cell lines. In particular, the two phenylurea derivatives 7 and 19 (see 
Fig.  5a for structures) were up to about 6 times more effective than the reference TKI against both 
A549 and BxPC3 cells (see potency relative to SU, calculated as the ratio between IC50 of sunitinib and 
Figure 4. Results of primary screening of compounds against kinases. The heat map displays the results 
of the primary screening in terms of POC values for each pair of kinase/ligand. The lower the POC (white 
to red boxes), the tighter the binding. Compounds are listed according to Fig. 2.
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IC50 of tested compounds in Table 1). Tested against non-tumor cells in rapid proliferation, the human 
embryonic kidney HEK293 cells, 19 elicited selectivity index values (SI = quotient of the IC50 toward non 
cancerous cells divided by the average IC50 for the malignant cells) approximately 1.5-folds higher than 
that calculated with SU, thus attesting a preferential cytotoxicity versus neoplastic cells. On the contrary, 
compound 7 was more cytotoxic against non transformed cells (SI < 1).
Improvement of pharmacodynamic properties of hit compound 19. Based on the kinases 
screening results and on the IC50 and the SI values, we selected derivative 19 as our “hit compound”. As 
mentioned above, the 6-phenyl ring was designed to occupy the hydrophobic pocket II (Fig. 1g), which 
is next to the hydrophilic ribose binding region of the kinases (Fig. 1c). Hence, we tried to improve the 
ability of the hit compound to interact with class III RTK members through the insertion of a small 
hydrophilic moiety, intended to occupy the sugar pocket of the kinases, thus obtaining compound 27 
(Fig. 6; see also Supplementary Information for details on synthetic procedures).
The ability of compounds 19 and 27 to bind the class III RTK members was measured (Table 2; see 
also Figs S3 and S4 for dose/response curves).
As supposed, the further functionalization of the 6-phenyl ring with a polar moiety able to interact 
with the sugar pocket improved the binding affinity toward all the tested kinases. Nevertheless, for both 
compounds the main target remained KIT. The highest affinity improvement was observed for PDGFRα 
(nearly an order of magnitude), whereas the interaction with PDGFRβ was not substantially modified. 
Compound 19 was confirmed as a dual KIT/PDGFRβ inhibitor, while compound 27 should be consid-
ered as a KIT/PDGFRα /PDGFRβ inhibitor.
The cytotoxic profile of 19 and 27 was assessed on a wider panel of human tumor cell lines including 
also examples of breast (MCF-7), cervical (A431), colorectal (HCT-15), and ovarian (2008) cancers as 
Figure 5. Structure activity relationships for 4-anilino compounds. (a) Selectivity profile of some selected 
compounds highlights the features required for selective EGFR, dual EGFR/class III RTKs or selective class 
III RTKs inhibition. (b) Schematic representation of main structure activity relationships with respect to 
4-anilinopyrimidine core.
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well as melanoma (A375), besides lung (A549) and pancreatic (BxPC3) cancer cells. IC50 values, cal-
culated from the dose-survival curves obtained after 72 h of drug treatment from the MTT test, are 
reported in Table 2. Anilinopyrimidines 19 and 27 showed a quite similar pattern of cytotoxicity over the 
cancer cell lines panel. Both compounds were endowed with a cytotoxic potency higher than that of SU, 
eliciting IC50 values in the low micromolar range. Notably, IC50 values measured on pancreatic adenocar-
cinoma BxPC3 cells were in the sub-micromolar range, exceeding by a factor of 6 those detected with the 
reference TKI. When tested against non-cancer HEK293 cells, derivative 27 showed an antiproliferative 
activity even lower than that of the parental compound 19, eliciting an average IC50 value of 10 μ M, thus 
suggesting a preferential activity towards cancerous cells.
Preliminary in vivo evaluation of lead compound 27. Basing on in vitro screening, derivative 27 
emerged as the most interesting compound since it was more effective than 19 against target kinases. 
Besides, it was as cytotoxic as 19 towards cancer cells while showing a more favorable selectivity index. 
On these basis, compound 27 was chosen for in vivo experiments against a syngeneic murine solid 
ID
A549 IC50 
(μM) ± SD
Potency 
relative to 
SU
BxPC3 IC50 
(μM) ± SD
Potency 
relative to 
SU
HEK293 IC50 
(μM) ± SD
Selectivity 
Index
1 8.94 ± 2.18 0.70 6.43 ± 1.78 0.79 – –
2 26.52 ± 3.85 0.23 17.90 ± 2.46 0.28 – –
3 28.25 ± 5.46 0.22 8.19 ± 2.18 0.62 – –
4 14.17 ± 2.75 0.44 23.25 ± 4.29 0.22 – –
5 16.32 ± 4.24 0.38 6.51 ± 1.07 0.78 – –
6 33.98 ± 4.98 0.18 16.13 ± 4.85 0.31 – –
7 5.13 ± 0.94 1.21 4.60 ± 0.85 1.10 3.14 ± 0.57 0.64
8 > 50 < 0.12 > 50 < 0.10 – –
9 > 50 < 0.12 > 50 < 0.10 – –
12 > 50 < 0.12 > 50 < 0.10 – –
19 3.16 ± 1.12 1.97 0.77 ± 0.21 6.56 7.33 ± 1.75 3.84
24 12.08 ± 1.99 0.51 16.43 ± 4.22 0.31 – –
25 26.12 ± 4.55 0.24 27.85 ± 5.28 0.18 – –
26 28.95 ± 5.86 0.21 30.85 ± 4.18 0.16 – –
SU 6.22 ± 1.84 1.00 5.05 ± 1.34 1.00 12.19 ± 2.83 2.14
Table 1.  Cytotoxicity of selected compounds against A549, BxPC3 and HEK293 cell lines.
Figure 6. Synthesis of compound 27. 
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tumor model, the murine Lewis Lung Carcinoma (LLC). The tumor growth inhibition induced by 27 was 
compared with that promoted by cisplatin (CDDP), the most common chemotherapeutic drug used in 
the treatment of lung cancers. Nine days after tumor inoculation, tumor-bearing mice were randomized 
into vehicle control and treatment groups (8 mice per group). Control mice received the vehicle (0.2%v/v 
EtOH and 99.8%v/v of a saline solution), whereas treated groups received daily doses of 27 (7.5 mg · kg−1 
in the vehicle solution composed of 0.2%v/v EtOH and 99.8%v/v of saline solution) or CDDP (1.5 mg · kg−1 
in saline solution). Tumor growth was estimated at day 20 (Fig. 7a). As an indication of the adverse side 
effects, changes in the body weights of tumor-bearing mice were monitored at day 1 and daily from day 
9. The intraperitoneal administration of 27 reduced by 84.7% the tumor mass compared to that of the 
control group (Fig. 7b, Table S5), promoting an in vivo antitumor activity even better than that exerted 
by CDDP which reduced the tumor mass of 71.6%.
Remarkably, even though 27 was administered at higher doses than CDDP, the time course of body 
weight changes indicated a more safety profile for our compound. Indeed, treatment with 27 resulted 
in a moderate body weight loss (< 10%) whereas, as well documented, CDDP provoked elevated body 
weight loss (Fig. 7c).
The molecular basis for class III RTKs subfamily selectivity. To rationalize the selectivity pro-
file showed by compounds 19 and 27, we firstly analyzed some key residues of the ATP-pocket usually 
involved in the binding of TKIs (Fig. 8a).
The class III RTK members mainly differ in:
– the gatekeeper residue (threonine for CSF1R, KIT, PDGFRα and PDGFRβ ; phenylalanine for FLT3). 
Threonine and phenylalanine don’t have similar steric requirements (blocks substitution matrix, BLO-
SUM50, scoreF−T = − 2);
– one amino acid in the DFG region sequence (cysteine for KIT, FLT3, PDGFRα and PDGFRβ ; glycine 
for CSF1R). Cysteine and glycine don’t have similar steric requirements (BLOSUM scoreC−G = − 3);
– the composition of the deeper part of hydrophobic pocket I, accessible only in the inactive kinase 
conformation (usually targeted by type II inhibitors), that was reported to account for the selectivity of 
certain type II kinase inhibitors51. Considering only the amino acids placing the side chains inside the 
binding pocket, the hydrophobic pockets differed only for one amino acid (leucine in KIT; methionine 
in the other kinases). However, leucine and methionine have similar steric requirements (BLOSUM 
scoreM−L = + 2). Remarkably, the sequences xExxxLxxL or xExxxMxxL are quite conserved in the TK 
family (see for example Src, Syk, ZAP70, TRKA, TIE2 and TYK2), thus the composition of the deeper 
part of hydrophobic pocket I could not mainly account for the overall observed selectivity of the 
compounds.
Kinase profiling
Kinase
19 27
Potency 
improvement
Kd (nM) KdRTK/KdKIT Kd (nM) KdRTK/KdKIT Kd19/Kd27
CSF1R 2900 132 1100 110 2.6
KIT 22 1 10 1 2.2
FLT3 4600 209 1300 130 3.5
PDGFRα 960 44 110 11 8.7
PDGFRβ 80 4 70 7 1.1
Cytotoxicity
 
19 27 Sunitinib
IC50 (μ M) ± SD IC50 (μ M) ± SD IC50 (μ M) ± SD
 A549 3.16 ± 1.12 3.11 ± 1.09 12.19 ± 2.83
 BxPC3 0.77 ± 0.21 0.81 ± 0.32 5.05 ± 1.34
 2008 1.98 ± 0.75 1.82 ± 0.73 3.52 ± 1.22
 MCF-7 1.23 ± 0.89 1.55 ± 0.75 2.58 ± 0.85
 A431 2.85 ± 1.03 1.96 ± 0.92 3.89 ± 1.15
 LoVo 7.45 ± 1.53 7.76 ± 1.28 8.18 ± 2.67
 A375 6.41 ± 2.02 5.56 ± 1.39 8.25 ± 2.88
Table 2.  Activities of compounds 19 and 27 on isolated kinases and on cell viability.
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Since both 19 and 27 targeted preferentially KIT, PDGFRα and PDGFRβ , we supposed that the 
simultaneous presence of the threonine as gatekeeper and of the cysteine just before the DFG motif was 
fundamental. Notably, no other TKs (among the tested ones) presented these two features. Hence, we 
concluded that the selectivity observed for some members of the class III RTK was mainly due to the 
presence of the two residues.
Molecular modeling studies were then conducted on both 19 and 27 in order to propose a plausible 
binding mode with the class III RTK members. From among the available crystal structures, we selected 
1T46 for KIT52, 1RJB for FLT353 and 4HW7 for CSF1R54. These structures were chosen on the basis of 
the similarity with 4ASD (VEGFR2 kinase domain in complex with sorafenib55) because of the high 
degree of similarity of sorafenib with our compounds. Remarkably, no structure for PDGFRα and β 
were available in the Protein Data Bank, thus these kinases were no further considered in computational 
simulations. The docking experiments were conducted using the AutoDock software56. The importance 
of the gatekeeper residue suggested the presence of a water molecule mediated H-bond between the N3 
of the pyrimidine and the threonine, as previously reported for the binding of quinazoline derivatives 
and EGFR (see for example the 1M17 PDB structure57). Remarkably, the supposed water molecule was 
not present in the 1T46 and 4HW7 protein structures. As recently reported, AutoDock software was 
Figure 7. In vivo testing of compound 27. Lewis lung carcinoma (LLC) was implanted i.m. (2 · 106 cells 
inoculum) into the right hind leg of 8-week old imbred C57BL mice. Nine days after tumor inoculation 
(palpable tumor), tumor-bearing mice were randomized into vehicle control and treatment groups (8 mice 
per group). Compound 27 was dosed daily at 7.5 mg/kg ip and CDDP was dosed daily at 1.5 mg/kg ip. At 
day 20, animals were sacrificed (i.e., before tumor can cause the animal discomfort), the legs were amputated 
at the proximal end of the femur, and the inhibition of tumor growth was determined according to the 
difference in weight of the tumor-bearing leg and the healthy leg of the animals expressed as % referred 
to the control animals. Control was constituted by vehicle (0.2%v/v EtOH and 99.8%v/v of saline solution). 
CDDP was used as positive reference. Both 27 and CDDP were administered at the highest not toxic doses 
(7.5 and 1.5 mg/kg, respectively), as determined by MTD studies. (a) Average tumor weight (g) after 20 
days of treatment with control or compounds. (b) Percentage of reduction in tumor growth after 20 days of 
treatment with respect to control mice. (c) Body weight changes. The body weight changes of LLC bearing 
C57BL mice treated with vehicle or tested compounds. Each drug was administered daily after 9 days from 
the tumor cell inoculum. Weights were measured at day 1 and daily from day 9. Error bars indicate the 
standard deviation.
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implemented with a specific force field with discrete displaceable waters in order to dock hydrated lig-
ands58. Following this approach, water molecules were added to compounds 19 and 27 and then docked 
in the protein structures (Fig. 8b–e; the full details of the binding mode for 19 and 27 are reported in 
Figures from S5 to S8).
As supposed, a water molecule classified as “strong” by the scoring protocol58 mediated the binding 
of both 19 and 27 with the threonine gatekeeper in KIT and CSF1R kinases, whereas it was displaced 
in FLT3. The lack of the water mediated H-bond in FLT3 was partially replaced by an edge-to-face 
arene-arene interaction between the aniline moiety and the F691, justifying the lower but not negligible 
binding. Beside the H-bonds, an additional edge-to-face arene-arene interaction was observed for the 
4-anilino moiety of both 19 and 27 and the F811 of the DFG domain of KIT (centroids distance: 5.5 Å 
in both cases). The binding mode predicted for 27 in KIT was consistent with the initial hypothesis since 
the hydrophilic moiety interacted with the residues in the ribose pocket (Fig. 8f).
We also investigated the role of cysteine of the DFG domain. The KITC809 (Fig.  8g) showed higher 
surface complementarity than the CSF1RG795 (Fig.  8h) with the urea moiety of the ligand. Moreover, 
the distances between the sulfur atom of C809 and the aniline moiety suggested the formation of a 
Figure 8. Binding mode study on compounds 19 and 27. (a) Sequences of hinge, DGF and hydrophobic 
pocket I regions of the ATP binding pocket for class III RTKs. Black (or red) characters indicate amino acids 
that place the side chain inside the ATP-pocket; grey characters indicate the amino acids that place the side 
chain outside the ATP-pocket. Amino acids that place the side chain inside the ATP-pocket and that differ 
between the five kinases are highlighted in red. The gatekeeper residue number is also reported. (b–f) Results 
of docking simulations: (b) Potential binding mode of 19 (gray stick) with KIT (green sticks); (c) Potential 
binding mode of 27 (blue stick) with KIT (green sticks); (d) Potential binding mode of 19 (yellow sticks) with 
CSF1R (pink sticks); (e) Potential binding mode of 19 (light pink sticks) with FLT3 (cyan sticks); (f) Potential 
binding mode of 27 (blue sticks) with KIT (green sticks and green cartoons), in context with the ATP 
binding site features. The 6-phenyl moiety of compound 27 is placed in the hydrophobic pocket II, whereas 
the hydrophilic function (i.e. the morpholine ring) is placed in the ribose pocket. (g,h) Details of docking 
simulations for compound 19 (yellow sticks) in KIT (blue sticks, panel (g)) and CSF1R (green sticks, panel 
(h)). Compound 19, KITC809 and CSF1RG795 are depicted as transparent surfaces. The gatekeeper residues 
(KITT670 and CSF1RT663) as well as other protein residues are depicted as sticks in order to allow a better 
comprehension of the compound binding modes.
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sulfur-arene interaction59. Furthermore, the higher steric hindrance of C809 constrained the urea moiety 
in a very favorable position to interact with the KITE640 carboxylic function.
Discussion
Tyrosine kinases inhibitors are among the most attractive and promising anti-cancer compounds. Both 
selective and unselective kinase inhibitors have been approved for cancer treatment. For multi-kinase 
inhibitors a correct balance between specificity and non-specificity is required20. In this view, the discov-
ery of compounds with subfamily selectivity is a challenging goal. The development of high-throughput 
screening technology to screen compounds against a number of kinases is having a high impact in the 
discovery of novel hit with interesting selectivity profile60. Due to our interest in discovering novel TKIs, 
we decided to explore the feasibility of obtaining novel multi-target TKIs bearing 4-anilinopyrimidine 
structure. Firstly we synthesized a small focused library of 26 different 4-anilinopyrimidine derivatives: 
the main scaffold was functionalized with different substituent at the 4-anilino moiety and at the 5 and 
6 positions of the pyrimidine nucleus to determine the molecular features required for kinases inhibi-
tion. Then, the library was screened against a panel of 48 different kinases (comprising TKs, TKLs and 
STKs). All the compounds were inactive against STKs and TK-like enzymes. Among TKs, the com-
pounds were able to target mainly EGFR and/or the member of the class III RTKs family (CSF1R, FLT3, 
KIT, PDGFRα and PDGFRβ ). The substitution of the pyrimidine nucleus at 5 or 6 positions was fun-
damental: compounds bearing a 5-phenyl or a 6-phenyl moiety resulted totally inactive against EGFR. 
Conversely, almost all the 6-phenylamino compounds bound both wt-EGFR and L858R-EGFR mutant.
In the case of 6-phenylamino compounds, the 4-anilino moiety could be functionalized with small 
lipophilic substituents (methyl, bromo, chloro) at meta or para positions, with a slight preference for the 
meta position. The functionalization with a small para hydrophilic function (5p−OH, 6p−NH2) extended 
the inhibitory spectrum, leading to EGFR/class III RTK/AXL inhibitors. The introduction of hydroxylic 
functions at both 4-anilino and 6-anilino moieties led to the wider spectrum of activity: compound 12 
was able to target also TRKA and JAK3. Besides, compound 12 retained a low but not negligible activity 
also against the T790M mutant of EGFR. When the 4-aniline was functionalized with a para-phenylurea 
moiety, we obtained a selective class III RTKs inhibitor (7). Compound 7 probably was a type II inhibitor, 
thus requiring an inactive kinase conformation. However, EGFR is known to adopt a Src-like inactive 
conformation61, which substantially differs from the KIT inactive conformation52: the DFG domain of 
inactive EGFR still remains close to the ATP binding pocket, thus limiting the dimension of the hydro-
phobic pocket I and impairing the binding with compound 7. Conversely, inactive KIT adopt a true 
DFG-out conformation with a larger hydrophobic pocket I.
Remarkably, all the compounds bearing the para-phenylurea moiety (7, 19 and 26) were selectively 
active against the class III RTK members. In this case, the substitution at 5 or 6 positions of the pyrim-
idine ring conferred selectivity inside the family: 5-phenyl compound (26) inhibited all the class III 
RTK members with comparable potencies; 6-phenyl compound (19) was a selective dual KIT/PDGFRβ 
inhibitor; 6-phenylamino compound (7) showed an intermediate selectivity degree between 19 and 26.
Compounds active against at least one of the main target kinases (EGFR and/or class III RTKs) were 
screened for their cytotoxic potential against lung and pancreatic cancer cell lines. Many of the studied 
compounds showed a marked in vitro antitumor activity, with IC50 values in the micromolar range. 
However, only 7 and 19 showed lower average IC50 values than the reference multi TKI, sunitinib. In 
addition, when tested against non-tumor cells in rapid proliferation, only compound 19 showed a pref-
erential antiproliferative activity toward neoplastic cells.
Dissociation constant determinations confirmed that compound 19 was a selective dual KIT/PDGFRβ 
inhibitor with nanomolar affinity. The structure of this hit compound was further modified in order to 
improve the pharmacodynamic properties. Hence, compound 27 (designed to interact also with the 
sugar pocket of the target kinases) showed overall lower Kd values against class III RTK members than 
19, resulting a multi KIT/PDGFRα /PDGFRβ inhibitor with nanomolar affinity (Kd against CSF1R and 
FLT3 were higher than 1 μ M).
Tested against a wide panel of cancer cell lines, including examples of breast, ovarian cancers along 
with melanoma, compounds 19 and 27 showed a comparable activity profile and were more effective 
than sunitinib in inhibiting cancer cell proliferation. Remarkably, compound 27 was more selective 
against cancer cells than the hit compound 19. Very preliminary in vivo studies were also conducted 
on compound 27. On LLC murine model of solid tumor, compound 27 promoted a reduction of tumor 
mass higher than CDDP, the most widely used drug in the management of lung neoplasms, coupling 
with a reduced host weight loss. Based on these promising results, we are now planning pharmacokinetic 
studies on compound 27 in order to determine its effective anti-cancer.
Molecular modeling studies were conducted on compounds 19 and 27 to investigate the molecular 
basis for the class III RTKs subfamily selectivity. The threonine as gatekeeper and the presence of a 
cysteine residue in the DFG domain played a key role in determining the selectivity profile. On the 
contrary, the hydrophobic pocket I composition was not fundamental for the selectivity profile. These 
findings suggest that in the design of “selectively unselective” TKIs the gatekeeper and the DFG domain 
compositions must be strongly considered. In particular, the presence of sulfur-arene interactions (for 
CDFG containing kinases) and the role of water mediated hydrogen bonds (for threonine gatekeeper 
containing kinases) may play critical roles. Furthermore, as supposed, docking studies suggested that 
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the 6-phenyl moiety of compound 27 interacted with both the hydrophobic pocket II and with the sugar 
pocket of the kinases.
Overall, our data suggested that the N-phenyl-N’-[4-(6-phenylpyrimidin-4-ylamino)phenyl]urea 
derivatives constitute a promising class of subfamily selective inhibitors of class III RTKs deserving fur-
ther development.
Methods
Computational Methodologies. All the computational studies were carried out on a 4 CPU (Intel 
Core2 Quad CPU Q9550, 2.83 GHz) ACPI × 64 Linux workstation with Ubuntu 12.04 operating system. 
The tridimensional structure of the kinases were downloaded from Protein Data Bank (PDB ID: 4HW7 
for CSF1R in complex with PLX647-OME; 1T46 for KIT in complex with imatinib; 1RJB for FLT3). 
The structures were superimposed using the UCSF Chimera software62 and the ligands, the ions and the 
water molecules were removed. The structure of compounds 19 and 27 were prepared with MarvinSketch 
5.5.0.1 software (www.chemaxon.com/products). The lowest energy conformations and the degree of pro-
tonation at pH 7.4 were determined with OpenBabel software63 using the MMFF94s force field. For all 
the molecules, the appropriate “.pdbqt” files were prepared with the AutoDockTools graphical interface 
of AutoDock 4 software56. Before docking simulations, the “.pdbqt” file of compounds 19 and 27 were 
solvated using the appropriate python script33 (more details are reported in Supplementary Information). 
All the docking studies have been performed with AutoDock4 using a docking box of 52 × 70 × 40 Å 
dimensions (centered on PLX647-OME coordinates) and 0.375 grid spacing. Each docking run con-
sisted of 50 independent searches with a maximum of 2,500,000 energy evaluations based on Lamarkian 
Genetic Algorithm searching engine. For each pair kinase/ligand the lowest energy pose was retained.
Experiments with Cultured Human Cells. All compounds, except derivative 27, were dissolved 
in DMSO just before the experiment, and a calculated amount of drug solution was added to the cell 
growth medium to a final solvent concentration of 0.5%, which had no discernible effect on cell killing. 
Compound 27 was dissolved in a 0.9% NaCl solution just before the experiment.
Sunitinib malate and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were 
obtained from Sigma Chemical Co, St.Louis, USA. Antibody for β -actin and ubiquitin were from Santa 
Cruz Biotechnology (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Cell cultures. Human lung (A549), breast (MCF-7), pancreas (BxPC3), and colon (LoVo) carcinoma 
cell lines along with melanoma (A375) were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). Human non-tumor embryonic kidney HEK293 cells were obtained from European 
Collection of Cell Cultures (ECACC, Salisbury, UK). Human cervical carcinoma A431cells were kindly 
provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto Nazionale dei Tumori, Milan, 
Italy). Human ovarian cancer 2008 cells were kindly provided by Prof. G. Marverti (Dept. of Biomedical 
Science of Modena University, Italy). Cell lines were maintained in the logarithmic phase at 37 °C in 
a 5% carbon dioxide atmosphere using the following culture media containing 10% fetal calf serum 
(Euroclone, Milan, Italy), antibiotics (50 units ∙ mL−1 penicillin and 50 μ g ∙ mL−1 streptomycin) and 2 mM 
l-glutamine: i) RPMI-1640 medium (Euroclone) for MCF-7, A431, BxPC3 and 2008 cells; ii) F-12 HAM’S 
(Sigma Chemical Co.) for A549 and LoVo cells; iii) D-MEM medium (Euroclone) for HEK293 cells.
Cytotoxicity MTT assay. The growth inhibitory effect towards human cell lines was evaluated by 
means of MTT (tetrazolium salt reduction) assay. Briefly, 3–8 ∙ 103 cells/well, dependent upon the growth 
characteristics of the cell line, were seeded in 96-well microplates in growth medium (100 μ L) and then 
incubated at 37 °C in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced 
with a fresh one containing the test compound at the appropriate concentration. Triplicate cultures 
were established for each treatment. After 72 h, each well was treated with 10 μ L of a 5 mg ∙ mL-1 MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) saline solution, and after 5 h additional 
incubation, 100 μ L of a sodium dodecylsulfate (SDS) solution in HCl 0.01 M were added. After overnight 
incubation, the inhibition of cell growth induced by the tested complexes was detected by measuring the 
absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader (Bio-Rad, Hercules, CA). Mean 
absorbance for each drug dose was expressed as a percentage of the control untreated well absorbance 
and plotted vs drug concentration. IC50 values represent the drug concentrations that reduced the mean 
absorbance at 570 nm to 50% of those in the untreated control wells.
In vivo anticancer activity toward Lewis Lung Carcinoma (LLC). All studies involving animal 
testing were carried out in accordance with the ethical guidelines for animal research adopted by the 
University of Padua, acknowledging the Italian regulation (D.L.G.S. 116/92) and European Directive 
86/609/EEC as to the animal welfare and protection and the related codes of practice. The experimental 
protocol was approved by the Italian Health Department according to the art. 7 of above mentioned 
D.L.G.S. 116/92. The mice were purchased from Charles River, Italy, housed in steel cages under con-
trolled environmental conditions (constant temperature, humidity, and 12 h dark/light cycle), and ali-
mented with commercial standard feed and tap water ad libitum. The LLC cell line was purchased from 
ECACC, United Kingdom. The LLC cell line was maintained in DMEM (Euroclone) supplemented with 
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10% heat inactivated fetal bovine serum (Euroclone), 10 mM L-glutamine, 100 U mL−1 penicillin, and 
100 μ g · mL−1 streptomycin in a 5% CO2 air incubator at 37 °C. The LLC was implanted intramuscularly 
(i.m.) as a 2 × 106 cell inoculum into the right hind leg of 8 week old male and female C57BL mice 
(24 ± 3 g body weight). After 9 days from tumor implantation (palpable tumor), mice were randomly 
divided into 3 groups (8 animals per group) and subjected to daily i.p. administration of 27 (7.5 mg · kg−1 
dissolved in a vehicle solution composed of 0.2%v/v EtOH and 99.8%v/v of saline solution), cisplatin 
(1.5 mg · kg−1 in saline solution), or the vehicle solution (0.2%v/v EtOH and 99.8%v/v of saline solution). 
At day 20, animals were sacrificed, the legs were amputated at the proximal end of the femur, and the 
inhibition of tumor growth was determined according to the difference in weight of the tumor-bearing 
leg and the healthy leg of the animals expressed as a percentage referring to the control animals. Body 
weight was daily measured and was taken as a parameter for systemic toxicity. All reported values are the 
means ± SD of no less than three measurements. Multiple comparisons were made by the Tukey− Kramer 
test (**p < 0.01; *or °p < 0.05).
Statistical analysis. All the values are the means ± S.D. of not less than three measurements. 
Multiple comparisons were made by ANOVA followed by Tukey–Kramer multiple comparison test, using 
GraphPad Software.
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